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ABSTRACT 
 
Mechanism of toxin activity and delivery in bacterial contact-dependent competition systems 
 
by 
 
Christina Marie Beck 
 
Bacteria live in complex microbial communities and must face the constant challenge of 
limited space and resources. These harsh conditions have driven the evolution of a variety of 
competition and communications systems that allow bacteria to interact with the surrounding 
microbes and eukaryotic organisms found in their respective niches. The research presented 
here focuses on two such systems that Gram-negative bacteria use to deliver toxic effector 
molecules into neighboring bacteria. The type VI secretion system (T6SS) is a dynamic 
syringe-like organelle that injects toxic effectors indiscriminately into both prokaryotic and 
eukaryotic cells. In contrast, CDI systems are restricted to a narrow target range. CDI 
involves a two-partner secretion system that presents a large exoprotein, CdiA, to the surface 
of cells. CdiA binds to receptors on target bacteria to facilitate delivery of a toxin derived 
from its C-terminus. 
In the introductory chapter, we will dissect what it known about each of these 
competition systems, including the toxin activities and delivery pathways of each system. 
Chapter 2 identifies a novel delivery process of a CDI toxin into Escherichia coli. In chapter 
3 we will learn that the CDI system found in uropathogenic E. coli 536 is restricted to intra-
strain delivery due to polymorphisms in the receptor proteins it utilizes for delivery. Chapter 
x 
 
4 will characterize novel CDI toxin activity while chapter 5 will explore the motive behind 
exploiting the metabolic enzyme, CysK, as a cofactor for a CDI toxin’s activity. Finally, 
chapter 6 will describe the mechanism of toxin delivery in the T6SS found in the 
opportunistic human pathogen Enterobacter cloacae.  
Ultimately, this thesis will explore the repertoire of toxins that are utilized by CDI and 
T6S systems. Chapters 3 and 5 will challenge the function of CDI as a competition system 
and suggests its role in kin selection. Lastly, we will examine the potential role of these 
competition systems in shaping microbial communities.  
xi 
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General Introduction  
Bacteria can be found in almost every ecological niche. Some environments, including 
the human intestinal tract and soil from croplands, harbor hundreds to thousands of different 
bacterial species
1,2
. In fact bacteria are rarely found in isolation, and evidence from a variety 
of habitats suggests the composition and diversity of bacterial species can have drastic effects 
on an ecosystem
3-6
. For example, human obesity was found to be associated with a high 
abundance of Firmicutes and low amount of Bacteroidetes phyla in the digestive tract while 
patients with inflammatory bowel disease (IBD) have a less diverse microbiota with a higher 
percentage of Escherichia coli species
7-10
. Given the challenge of limited space and resources 
in many of the environments bacteria colonize, they have developed a multitude of 
communication and competition systems to interact with other microbes or eukaryotic 
organisms. These systems can allow a simple unicellular bacterial cell to act like a 
multicellular organism by facilitating a sense of community and cooperation in their 
respective niches. Studying the mechanisms of these systems is vital if we hope to 
understand how they are used to shape microbial communities and thus their potential impact 
on an ecosystem.  
In the introductory chapter, we will cover some of the systems bacteria use in intra- and 
inter-species communication and competition.  First we will cover bacteriocins, small toxic 
proteins released upon cell lysis to kill neighboring bacteria. Then we will describe contact-
dependent growth inhibition (CDI), a two-partner secretion system that requires physical 
contact with target cells to deliver a toxin domain. Lastly we will discuss the type VI 
secretion system (T6SS), a membrane-spanning organelle that injects toxic effector 
molecules into both prokaryotic and eukaryotic cells. Throughout this thesis we will try to 
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identify both the similarities and differences between these systems to clarify the distinct 
function of each system. The research presented here will explore the activities of the toxin 
domains encoded by these systems, the narrow target range of CDI systems, and the 
mechanism of T6S assembly. Collectively, this work will hopefully help elucidate the roles 
of these competition systems in nature.   
 
Colicins 
Colicin Introduction 
Colicins are a well-studied example of intra-species competition in bacteria. They are 
soluble toxic proteins produced by certain strains of E. coli that get released into the 
environment during times of stress
11,12
. They specifically target E. coli, but producing strains 
do not kill their own population because they harbor an immunity protein that protects them 
from colicin activity
13
. Colicin-producing strains are abundant in nature and predominantly 
found in the gut of animals
14
. It is estimated that up to 50% of isolated strains of E. coli 
contain a colicin operon
14,15
. In crowded niches where resources are scarce, the stress 
response will induce colicin synthesis and release from a subset of the population. This will 
facilitate the clearing of susceptible E. coli strains in the area. Taken all together, colicin-
harboring strains of E. coli are thought to have a competitive advantage in nature. 
Colicins were first discovered in 1925 by Gratia, and named in 1946. They have since 
been discovered in many species of bacteria and are now collectively called bacteriocins.  
Even though they are homologous, colicins produced by other bacteria get their own label 
based on the name of the species producing the colicin. For example, bacteriocins produced 
by Enterobacter cloacae are called cloacins, Yersinia pestis produce pesticins, and so on
16
. 
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All bacteriocins behave similarly and thus the remainder of this introduction and thesis will 
describe and refer mostly to colicins.   
Colicins are 40-80 kDa and organized into three domains; each involved with a specific 
process of colicin activity
17-21
.  The middle domain is responsible for binding to a specific 
outer-membrane protein on the cell surface
22
.  This leads to a restricted target range where 
colicins are only able to kill other E. coli strains that have sensitive receptors.  The N-
terminal domain allows for translocation through the outer membrane by targeting either the 
Tol or TonB machinery
23
.  Colicins are organized into two groups based on the translocation 
machinery utilized by their N-terminal domain.  Group A colicins (A, E1-E9, K, L, N, S4, U, 
and Y) are translocated through the Tol system while Group B colicins (D, H, Ia, Ib, M, 5 
and 10) use the TonB system
24-26
.  The C-terminal domain contains either pore-forming or 
nuclease activity which ultimately causes cell death
27,28
.  All nucleases act in the cytoplasm 
targeting RNA or DNA except for colicin M which targets peptidoglycan precursors in the 
periplasm
29-32
.  
 
Colicin Synthesis and Release 
Colicins are found on a colicinogenic plasmid, pCol, of which there are two types
33
.  
Type I are small multicopy plasmids that contains a mobilization element expressing only 
colicin genes.  In contrast, type II are large single copy plasmids that carry other genes and 
are conjugative.  Group A colicins are usually found on type I plasmids, while type II 
plasmids typically contain Group B colicins
34
. With some exceptions, colicin producing 
strains only harbor one specific colicinogenic plasmid.  Colicins are expressed in one, two, or 
three gene operons under a LexA promoter
35-37
.  During times of stress, the SOS response 
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will be triggered and activate the LexA promoter, thus allowing expression of the colicin 
operon
38
. 
Group A colicins that contain a nuclease domain are found in three gene operons 
containing the colicin, followed by its immunity protein, and then a lysis protein
35,39-43
.  The 
lysis protein is responsible for release of the produced colicin-immunity pair into the 
environment and subsequent death of the producing cell
41-43
.  The immunity gene contains its 
own promoter in the open reading frame of the colicin that is constitutively on, thus 
protecting cells from autoinhibition or death by its siblings
11,44-46
.  Upon SOS induction, two 
mRNA transcripts are produced; one that allows translation of the colicin-immunity pair 
only, and the other that contains mRNA for all three genes.  This allows for more production 
of the colicin and limited amounts of the lysis protein
45,47
.  With high enough quantities of 
lysis protein, the cell will lyse and release multiple copies of the colicin-immunity pair
48-50
. 
Group A pore-forming colicins are found in two gene operons because the immunity gene is 
found on the negative strand of the colicin
51
. Consequently, group A colicin release is a self-
sacrificing system where some cells in the population will die to allow propagation of the 
remaining sibling cells.  
Nuclease and pore-forming colicins in group B have the same genetic layout as group A 
colicins; expect they do not contain a lysis gene. Therefore, the production of group B 
colicins does not kill the producing strain or allow release of the colicin into the environment. 
Interestingly, there are six secretion systems identified in Gram-negative bacteria that allow 
for transport of proteins into the environment without cell death. It is somewhat puzzling that 
colicins use this unique mechanism of export.  
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Colicin Import 
There are three distinct steps in colicin import. The first is binding to specific receptors 
on the outer membrane, the second is translocation across the cell envelope, and the third is 
transit through the inner membrane
52-54
. The first two steps are directed by the middle and N-
terminal domains, respectively. Each step will be dissected in this section.  
Both group A and B colicins utilize a variety of outer-membrane proteins including BtuB, 
OmpF, FepA, FhuA, Cir, Tsx, OmpA, and OmpW
25,55,56
. These receptor proteins are 
commonly monomeric β-barrels that contain extracellular loops.  Crystal structures of a few 
colicin-bound receptors have revealed that colicins are exploiting these extracellular loops to 
bind target cells
57,58
. This binding interaction is what restricts colicins to E. coli, since the 
extracellular loops of these β-barrel proteins vary amongst species. While the initial binding 
step is similar between group A and B colicins, the subsequent translocation events differ 
considerably between the two colicin groups. We will first discuss group A translocation.   
All group A colicins except for colicin N require another outer-membrane protein in 
order to initiate the translocation step. They all use OmpF with one exception. OmpF is a 
trimeric β-barrel protein that is thought to be recruited to the colicin-bound receptor protein. 
The interaction between the two outer-membrane proteins is predicted to form a translocon 
that the colicin can use to cross the membrane
59
. The immunity protein has been stripped off 
at this point so it does not enter the cell
60
.  There are a few models of how the colicin actually 
crosses the cell envelope.  One entails the colicin transporting through the pore of OmpF, 
another between the interface of OmpF and the lipid bilayer, and the last has it diffusing 
through the lipid bilayer itself.  Regardless, the colicin translocation domain must reach into 
the periplasm and make contact with a component of the Tol system for transit to start
61
.  
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The Tol system consists of three inner membrane proteins, TolA, TolQ, and TolR, and a 
periplasmic protein, TolB
62,63
.  Different group A colicins require distinct components of the 
Tol system for transport. Some colicins need every component of the Tol system, while 
others just need a subset
64
.  The N-terminal domain of some group A colicins have been 
shown to interact directly with TolA
65
. Regardless of which Tol components are needed, the 
basic mechanism consists of the N-terminal domain reaching into the periplasm to interact 
with the Tol system
61
.  Through an unknown mechanism, this allows the N-terminal and 
toxic domain of the colicin to enter the periplasm.  
Group B colicins do not require a separate outer-membrane protein for translocation, with 
the exception of colicins 5 and 10.  Therefore upon binding to its specific receptor protein, 
through an equally unknown mechanism, the N-terminal domain reaches down into the 
periplasm, but this time to interact with the TonB system
66,67
. The known components of this 
system are one outer-membrane protein and three inner-membrane proteins, TonB, ExbB, 
and ExbD
68
.  Outer-membrane proteins involved in nutrient uptake contain a five amino acid 
motif called the TonB box which permits direct contact with TonB
69
. This interaction is 
thought to trigger the release of the receptor’s substrate into the periplasm by harvesting 
energy from the proton-motive force through the TonB complex
70,71
.  Since the N-terminal 
domains of group B colicins contain a TonB box, a similar mechanism of import is proposed 
for colicin transit.   
Interestingly, the N-terminal domains of colicins can be swapped and they will still 
successfully enter the cell
51
.  This suggests that even though group A and B colicins 
parasitize different systems, the general mechanism of crossing the outer membrane is 
conserved. Once inside the periplasm, the pore-forming toxins just need to be inserted into 
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the inner membrane to perform their toxic activity. However the nucleases must enter the 
cytoplasm to perform their toxic action.  The mechanism of translocation across the inner 
membrane is even less understood than outer membrane transport. Overall, while the 
difference in translocation machinery is what distinguishes group A from B colicins, the 
general mechanism of transit into the cell is reasonably similar. 
 
Colicin Toxin Domain 
The toxic action of colicins is found in the C-terminal domain which will contain either 
pore-forming or nuclease activity
72
.  These domains can carry out their toxic function 
independent of the N-terminal and middle domains of the colicin. Immunity proteins bind to 
the toxic domain of its cognate colicin to prevent its lethal activity
51
. The structural biology 
of the ionophoric and nuclease colicins, as well as the mechanisms of immunity protection 
will be discussed in this section.  
Pore-formers 
There are ten pore-forming colicins. Surprisingly, they are water soluble and monomeric 
in producing cells which has permitted crystallization of five of them
73
.  Each has a similar 
structure consisting of 10 α-helices packed into a bundle74-78. In the structure of colicin A, 
two of the α-helices are hydrophobic and stay tucked inside the remaining 8 helices. It is 
unknown how this fold allows for insertion into the membrane upon entry into a target cell.  
Amazingly, is does not require the assistance of other cell proteins because in vitro studies 
have shown it can insert itself into pure lipid membranes
79
.   
Even though the fold of each crystalized pore-forming colicin is similar, the immunity 
proteins are only able to protect cells from their cognate toxin.  The immunity proteins 
9 
 
contain three or four transmembrane domains and sit in the inner membrane
80-84
. Swapping 
studies have shown that the specificity of colicin-immunity pairs comes from the ability of 
the immunity proteins to recognize the C-terminus of their cognate toxins
23,39,85,86
. The 
immunity protein does not prevent the toxin from inserting into the inner membrane. Rather, 
it is thought to prevent opening of the pore or block the pore if it does open
87,88
.  
Nucleases 
Nuclease activity is the other mechanism of killing for colicins. Colicin M targets 
peptidoglycan precursors in the periplasm which eventually causes cell lysis
29,30
. Its 
immunity protein has a signal sequence that anchors it to the periplasmic side of the 
cytoplasmic membrane to protect cells from colicin M activity
51
. The remaining nucleases 
target DNA, 16S rRNA, or tRNA in the cytoplasm
51
. As previously discussed, the 
translocation step through the inner membrane is nebulous. It is thought there is a cleavage 
event that allows the nuclease domain to release from the remainder of the colicin when 
delivered through the inner membrane
89,90
. In support of this model, the C-terminal domain is 
able to bind to and cleave its substrate independent of the translocation and receptor-binding 
domains. Furthermore, the immunity protein binds only to the C-terminal toxin domain of the 
colicin.  Nevertheless, the toxic domain is able to reach the cytoplasm to either bind its 
substrate and cause cell death in susceptible cells, or bind its immunity protein and deactivate 
in protected cells.  
DNases 
There are four known colicins that target DNA
35,91,92
. The structure of two colicin 
DNases have been solved to show they both have a similar V-shaped fold that allows binding 
to the minor groove of DNA
93,94
.  These are metal-dependent enzymes that contain an H-N-H 
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nuclease domain which is found in numerous nucleases in both prokaryotes and eukaryotes.  
This domain allows for the coordination of a divalent cation, activation of a water molecule 
to attack the phosphodiester backbone of DNA, and stabilization of the transition state
95-97
. 
Interestingly, the four DNase colicins are 67% identical by amino acid composition, but 
again the immunity proteins are specific for their cognate toxin. This is due to the sequence 
diversity seen at immunity binding sites. The immunities bind at an exosite to sterically 
hinder substrate binding, rather than directly binding to the active site cleft
98
. 
RNases 
The RNase colicins target either 16S rRNA or the anti-codon loops of specific tRNAs
99-
102
.  Both types are predicted to cleave their substrate by extracting a proton from the 2’ 
hydroxyl of the phosphodiester backbone which promotes auto-attack and cleavage. Active-
site residues help align the attack, stabilize the intermediate, and protonate the leaving group 
of the reaction
101-105
. While the mechanism of cleavage is similar between the two types of 
RNases, their structure and the function of their immunity proteins are distinct.  
The three 16S rRNases are 80% homologous and each cleaves the 3’ end of 16S rRNA in 
the context of 70S ribosome between nucleosides A1492 and A1493.  These residues are 
important for the stabilization of the mRNA and anti-codon loop of the corresponding 
tRNA
105,106
.  The cleavage event still allows for tRNA binding in the A-site; however the 
mechanism of translation inhibition and subsequent cell death is still disputed
107,108
.  Like the 
DNase immunities, the 16S rRNase immunities also bind at an exosite. In this case, the 
negatively charged immunity protein prevents the approach to the similarly charged RNA 
component of the ribosome
98
.  
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Colicin D and E5 each cleave the single-stranded anticodon loop of a subset of tRNAs. 
Colicin D targets all four arginine tRNAs while colicin E5 targets Asn, Asp, His, and 
Tyr
101,102
. Both colicins have positively charged active sites formed by β-sheets and α-helical 
bundles
109,110
. The tRNase immunity proteins differ from the DNase and 16S rRNase 
immunities in that they bind directly to the active site of their cognate toxin
109,111
.  This is a 
more straight-forward mechanism of inhibition where the immunity simply blocks the site of 
substrate binding.    
 
Colicin Conclusion 
Bacteriocins are just one of the many competition systems found in bacteria. Their 
synthesis and release in times of stress is an effective way to clear out sensitive strains when 
inhabiting a new niche, or stopping the invasion of susceptible strains in an established 
habitat.  It has proven difficult to study the in vivo relevance of bacteriocins. However the 
mere fact that bacteriocins are extensively represented in nature suggests they provide a 
competitive advantage for bacteria. Furthermore, the variety of toxins found in this system 
provides the potential for extensive competition between strains of bacteria.   
 
 
Contact-dependent growth inhibition (CDI) 
CDI Introduction  
Contact-dependent growth inhibition (CDI) is another competition system that deploys 
toxins into neighboring bacteria
112
. It was first discovered in 2005 in E. coli EC93, the 
dominant strain of E. coli isolated from a rat colony. As we just learned, enteric bacteria 
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commonly produce soluble toxins to inhibit the growth of nearby bacteria
51
. However, CDI is 
unique in that it requires direct physical contact with target cells
112
.  
The locus responsible for CDI activity is comprised of just three genes, cdiB, cdiA and 
cdiI. CdiB/CdiA is a two-partner secretion (TPS) system homologous to other TPS systems 
including FhaC/A. CdiB is a predicted β-barrel outer membrane protein that exports CdiA to 
the surface of the cell. CdiA is a large exoprotein ranging from 200-600 kDa that is predicted 
to form a β-helical structure that extends several hundred angstroms from the surface of the 
cell
113,114
. The extreme C-terminus of CdiA (CdiA-CT) encodes a toxic domain
115
.  When 
CdiA comes in contact with a receptor protein, CdiA-CT gets delivered into target cells and 
causes growth inhibition
116-119
. CdiI is an immunity protein that binds to and neutralizes 
CdiA-CT, thus preventing CDI
+
 cells from autoinhibition
112,115
.  
Bioinformatic analyses have led to the discovery of CDI systems in α, β, and γ-
proteobacteria. Its role in bacterial competition has since been demonstrated in multiple 
pathogenic species, including Burkholderia thailandensis, Erwinia chrysanthemi, and 
Enterobacter cloacae
115,117,120
. The prevalence of CDI systems in pathogenic bacteria, 
specifically its location in pathogenicity islands, suggests CDI might offer some unresolved 
aid to the ability of these strains to infect a host. Furthermore, given the specific target range 
of CDI systems, it seems plausible that these systems could also be involved in kin 
selection
118
. Insight into these speculations, as well as the mechanism of CDI will be covered 
in the rest of this section and throughout this thesis.  
 
CDI Toxin Domain 
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CdiA is conserved amongst E. coli until the last 200 amino acids where a conserved 
VENN peptide motif demarcates the toxic domain from the rest of CdiA
115
.  The C-terminal 
toxin domain will be referred to as CdiA-CT for the remainder of this thesis.  Consistent with 
this domain being polymorphic, there are numerous distinct toxic activities performed by 
CdiA-CTs
115,117,121
. Likewise, each CdiI protein is polymorphic, as only a cognate immunity 
protein will protect cells from CdiA-CT activity
115,121
. Thus far, CdiA-CTs have been 
identified as either pore-formers or nucleases. Interestingly, CdiA-CTs are not always found 
fused to CdiA.  They are also found downstream of CDI systems with no ATG or GTG start 
site. These are called “orphans” because of their displacement from full-length CdiA and 
inability to be translated
121
. This section will discuss the various toxic activities encoded by 
CdiA-CTs, the mechanism of immunity protection, and provide a comparison to the toxin-
immunity pairs encoded by colicins. Of note, there have been numerous publications on the 
predicted toxic functions of CdiA-CTs, but this section will only cover toxin activities that 
have been established in either in vitro and/or in vivo experiments.  
DNases 
The first crystal structure of a CDI DNase is from E. coli EC869. EC869 contains 11 
orphan CdiA-CT/CdiI pairs located downstream from its CDI locus. Orphan 11 encodes for 
DNase activity that requires a divalent cation for activity in vitro. It cuts both double- and 
single-stranded DNA in vitro and seems to degrade DNA in vivo based on target cells lacking 
DAPI staining after delivery of the toxin. It has a unique interaction with its immunity 
protein where the two proteins bind by β-augmentation to produce a six-stranded antiparallel 
β-sheet.  Other CDI DNases have been characterized, but not to the same extent as orphan 
11.  
14 
 
tRNases 
A cohort of CdiA-CTs cut tRNAs. However, unlike the two colicins that cut tRNA, there 
is a much wider variety of substrates and cut sites seen in CDI tRNases. CDI toxins from 
UPEC536 and Burkholderia pseudomallei 1026b act as general tRNases, but cleave at 
distinct sites in the anti-codon loop and T-loop, respectively
120
. In contract, a CDI toxin from 
B. pseudomallei E479 cleaves specifically Ala1B tRNA
120
. The crystal structures of a 
handful of CDI tRNases demonstrate that immunity proteins bind in the active site of the 
toxins to block substrate binding (Goulding, CW & Hayes, CS unpublished data)
122
. 
However, more structures will need to be resolved to conclude this is a general mechanism of 
toxin inhibition for CDI tRNases.  
Interestingly, CdiA-CT from uropathogenic E. coli 536 (CdiA-CT
UPEC536
) 
 
requires a 
cofactor protein, CysK, for both in vitro and in vivo activity
123
. CysK is a metabolic enzyme 
involved in cysteine biosynthesis. It normally binds to the enzyme involved in the previous 
step of cysteine synthesis, CysE, by interacting with its C-terminal tail
124
. Diner et al. found 
that CysK binds to the C-terminus of CdiA-CT
UPEC536 
in a similar manner. Furthermore, the 
immunity protein is still able to bind to the CT even in the presence of CysK
123
.  Chapter 5 
will explore the implications of this binding event. 
Pore-formers 
The first CDI system discovered contains a pore-forming toxin. Extensive analyses were 
performed to show that CdiA-CT from the CDI system in EC93 (CdiA-CT
EC93
) dissipates 
proton-motive force and steady-state ATP levels, suggesting it forms a hole in the inner 
membrane
125
. Interestingly, AcrB is necessary for its toxic activity
126
. It is thought that AcrB 
helps insert the toxin into the membrane. This is the only pore-forming CDI toxin whose 
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activity has been experimentally proven. Other pore-forming CDI toxins have been 
identified, but only by bioinformatic analysis.   
 
Delivery process of CDI 
We just learned that most CDI toxins are nucleases and must therefore enter the 
cytoplasm of cells to perform their toxic function.  The first step of the delivery process is a 
binding event between CdiA and a receptor protein on the surface of target cells. This was 
established in CDI
EC93
 which utilizes the monomeric β-barrel outer membrane protein, 
BamA
126
. Polymorphism in the extracellular loops of BamA between different species is 
what restricts CDI
EC93 
to target only E. coli strains
118
. The work done in chapter 3 identifies 
novel receptor proteins for CdiA
UPEC536
 which led to the identification of a 300 amino acid 
stretch about 2/3 the way through CdiA as the receptor-binding domain. This region of CdiA 
varies significantly between EC93 and other E. coli strains. Bioinformatic analyses have 
identified four different classes of CdiA in E. coli based on divergence specifically in the 
proposed receptor-binding domain region.  
The receptor-binding domain has been identified, but the remainder of the delivery 
process through both the outer and inner membrane remains speculative. The same three 
models for colicin transit through the outer membrane are considered: through the pore of the 
β-barrel, at the interface of the protein and lipid and through the lipid itself. CdiA is a large 
200-600 kDa protein that could itself aid in transit through the outer membrane. In contrast to 
colicins, CDI systems do not require TolA or TonB for delivery of CdiA-CT into the 
cytoplasm
119
. It is thought there is a cleavage event, possibly at the conserved VENN peptide 
motif that releases the toxic domain from the rest of CdiA. Interestingly, CDI systems are 
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modular. CdiA-CTs can be swapped between CDI systems and still function
115
. This suggests 
a general mechanism of delivery into the cytoplasm. Nevertheless, CdiA-CTs are able to 
enter the cytoplasm of susceptible cells where they can perform their toxic function or bind 
to their immunity protein and thus become neutralized. 
 
CDI Conclusion 
CDI systems contain a repertoire of distinct toxins that allows for potentially complex 
bacterial competition in the environment. Some CDI toxins are homologs to colicin toxin 
domains. While there are certainly many similarities between the two systems, there are 
significant differences in active-site structure, mechanism of cleavage, substrate specificity, 
and function of immunity protection. The overlap between colicin and CDI toxin activities is 
most likely reflective of the limited number of ways to kill a cell efficiently, and these toxins 
have evolved to do just that. It is important to keep studying and trying to identify new ways 
that bacteria are finding to effectively kill one another. The topic of chapter 4 will be the 
identification of novel CDI toxin activity.  
Colicins and CDI systems are both involved in intra-species competition. However, there 
are significant differences between colicin and CDI delivery that make the two systems 
distinct. First, colicin producing cells must sacrifice themselves whereas CDI
+
 cells are able 
to persist after toxin delivery.  Second, colicins get secreted into the environment in hopes of 
finding a susceptible target cell. This can potentially be a waste of self-sacrifice if there are 
no other E. coli strains to inhibit in the area. In contrast, CDI systems require direct physical 
contact with target cells, which will ensure delivery of the toxin being produced. However, 
the ability for colicins to diffuse into the environment gives them the potential to clear a large 
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area more efficiently, while CDI can only deliver into cells in the immediate area. Thus, CDI 
and colicins seem to offer distinct advantages and disadvantages for bacteria and therefore 
most likely have distinct roles in nature.  
CDI systems are prevalent throughout proteobacteria and specifically pathogens. Their 
role in nature has yet to be determined. The narrow target range of CDI systems suggest that 
it plays a role in intra-species competition. Therefore, the relevance of this system in 
complex microbial communities may be limiting. However, the presence of an intra-species 
CDI system in EC93 seemed to be beneficial, as EC93 was the dominant E. coli strain 
isolated from a rat colony. Chapter 3 will illuminate the role of CDI systems in nature with 
the discovery of receptor proteins that restrict some CDI systems to strain-specific delivery.   
 
 
Type VI Secretion (T6S) 
T6S Introduction 
Gram-negative bacteria have developed six secretion systems to translocate proteins into 
the extracellular space or into neighboring cells. The type VI secretion system (T6SS) is the 
most recent secretion system to be identified.  It is a membrane-spanning organelle that 
injects toxins into prokaryotic or eukaryotic cells in a contact-dependent manner
127
. The 
toxins delivered are called effectors and have a wide variety of activities that lead to cell 
death. Contrast to colicins or CDI toxins, T6 effectors mostly target substrates in the 
periplasm
128
.  Effectors contain an immunity protein located downstream to protect 
delivering cells from self-intoxication
129,130
. The first T6SS was initially found in a screen 
looking for a decrease in Vibrio cholera virulence towards Dictyostelium discoideum
131
. It 
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was later identified that this T6SS is able to deliver an effector into macrophages that cross-
links actin molecules to prevent mobility
132
.  Since its discovery in V. cholera, it seems the 
ability to inhibit prokaryotic cell function is rare and the main function of T6S is for bacterial 
competition
133
.  
Type 6 secretion systems are found in 25 % of sequenced strains and are more heavily 
represented in pathogenic species
131
. Some strains have more than one T6 loci encoded in 
their genome. Enterobacter cloacae has two, Pseudomonas aeruginosa contains 3, and 
Burkholderia thailandensis holds 6 T6SSs
134
. The implications of having more than one 
locus are unknown. T6S has been demonstrated to be functional in both intra- and inter-
species competition in many species including V. cholera, P. aeruginosa, B. thailandensis, 
Serratia marcescens, and E. cloacae. Additionally, functional T6S has been implicated to 
play a role in pathogenesis
135
. Cleary T6SSs are used in bacterial competition and can give 
strains an advantage in their respective environments.  
 
T6S Apparatus  
The constituents of the type VI apparatus are encoded in large gene clusters containing all 
the components required to build a functional T6SS
134
. There are examples of constitutive, 
tight, and induced expression of T6 loci
127
. While more genes can be present in the locus, 
assembly of a functional type VI organelle requires 13 “core components”136-138. These 
components make an envelope-spanning apparatus which is composed of a tube complex, 
membrane complex, and baseplate
139
. The tube complex contains an inner tube capped with a 
spike that is surrounded by an outer sheath. This structure assembles onto the baseplate 
which serves to connect the tube to the cell envelope via the membrane complex.   
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The baseplate and tube complex of the type VI organelle are structurally and functionally 
homologous to the tail proteins of T4 phage
140
. These are contractile phage that use their tail 
to inject DNA into cells
141
. The type VI organelle is doing the opposite by ejecting effectors 
out of the cell and into neighboring targets. T4 phage use tail fibers to secure its baseplate to 
the outer membrane, whereas T6SSs use the membrane complex to anchor on the opposite 
side of the membrane. Just like T4 phage, a contractile mechanism is used to deliver effectors 
into target cells
139
. In both cases, the outer sheath contracts to propel the inner tube outwards 
and into their respective targets. 
The nomenclature of type VI components has become complicated since its discovery. 
For this section and the remainder of the thesis, we will refer to the components as TssX for 
Type six secretion gene X. We will use the adapted names for Hcp, VgrG, ClpV, and VasK. 
Both adapted and conventional names of the type VI components, their homology to T4 
phage proteins, and their function are listed in Figure 3. 
Membrane Complex 
The membrane complex is composed of TssL, TssM, and TssJ, three proteins that 
associate with the membrane and one another to make the complex
142-146
. The complex spans 
from the cytoplasm all the way to the outer membrane. It is unclear how it is able to 
transverse through the peptidoglycan layer. The role of this complex is to anchor the 
remaining parts of the T6S apparatus to the cell envelope
147
.  
Tube Complex 
The T6SS tube complex is composed of an inner tube engulfed by an outer sheath. The 
inner tube is made up of hemolysin-coregulated protein (Hcp), a structural homolog to phage 
tail tube proteins
140,148
. Hcp assembles into homohexameric rings that stack head-to-tail with 
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a diameter of about 100Å
149,150
. This Hcp tube gets engulfed by an outer sheath made up of 
alternating TssB and TssC units that interact with one another to stabilize the sheath
151
. Hcp 
formation is essential for sheath assembly, suggesting the inner tube acts as a scaffold for 
TssB/C polymerization
150
.  
Baseplate 
The baseplate serves as the site of assembly for the inner tube and sheath so they are not 
free-floating in the cytoplasm. The baseplate associates with the membrane complex, 
connecting each component of the T6 apparatus together at the cell envelope
152
. The known 
components of the baseplate are valine-glycine repeat protein G (VgrG), TssE, and TssK. 
VgrG and TssE share homology with phage base plate proteins gp27-gp5 and gp25 
respectively
140,151,152
.   
VgrG trimers cap the Hcp inner tube and are thought to act like a spike and help penetrate 
the target-cell membrane
138
. VgrG proteins are further capped by PAAR (proline, alanine, 
alanine, arginine) motif-containing proteins
153
. PAAR motifs are able to coordinate a zinc ion 
to make a cone-like structure that is thought to further sharpen the tip of the T6 apparatus
153
. 
VgrG is required for the assembly of Hcp tubules and a PAAR-containing protein is required 
for functional T6 firing
150,153
. It is therefore thought that PAAR proteins help nucleate VgrG 
folding which is required for inner tube formation. Chapter 6 will reveal more about the role 
of PAAR proteins in T6S.  
Phage baseplate protein gp25 is involved with initiating the polymerization of the sheath 
proteins. Based on sequence homology and its ability to bind TssB/C complex, TssE likely 
performs the same role in T6S
139,154,155
.  
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TssK shows no similarity to phage proteins, but is required for sheath polymerization
156
. 
Furthermore, TssK binds to TssL, a component of the membrane complex
156
. Thus, TssK is 
likely the key intermediary between the baseplate/tube complex and the membrane complex. 
Its absence in T4 phage further validates its novel role in T6 assembly, as phage do not 
anchor to a membrane complex.  
Firing 
The triggering event for contraction and regulation of tube length during assembly 
remains unknown. It is known that upon contraction, which presumably happens only once 
everything is assembled properly, the inner tube is propelled outward
139
. This is supported by 
the presence of Hcp and VgrG proteins in the supernatant of T6
+
 but not T6
-
 cells
132
. 
Furthermore, the T6S apparatus has been captured in both the extended and contracted states, 
representing pre- and post-firing events, by electron cryo-tomography. In the extended state, 
the tube spans almost the entire length of the cell and has electron density inside while after 
contraction, it is hollow
139
. However, this does not elucidate how the tube spike is able to 
penetrate the target cell. Furthermore, how far the tubule penetrates the target cell, past the 
outer membrane, cell wall, or inner membrane, is unknown. 
Disassembly 
Once fired, the conformation of the sheath changes which allows ClpV to bind both TssB 
and TssC
139,157
. ClpV is an ATPase that uses ATP to disassemble the sheath proteins
136,149,157
. 
It is unclear whether these components can be recycled for another round of firing or if they 
are degraded.  
 
T6S Effectors 
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Just like colicin and CDI toxins, there are a wide variety of T6 effectors. Interestingly, 
unlike colicins and CDI, most type VI effectors act in the periplasm rather than the 
cytoplasm, and can be structural components of the T6SS
128,131,132,153
. Regardless, with the 
diversity of T6 effectors that continue to be identified, it is becoming more apparent that 
T6SSs have the potential to facilitate effective anti-bacterial activity in nature.  
VgrG effectors 
As previously described, VgrG is necessary for proper T6 assembly and forms the tube 
spike to help penetrate target cells. Interestingly, some VgrG proteins have extended C-
termini which encode for a toxic domain, and are thus named “evolved” or “extended” 
VgrGs
132,158
. Extended VgrGs have been demonstrated to show toxic activity in both 
bacterial and prokaryotic cells
132,159
. The evolved VgrGs that are predicted to act in anti-
bacterial activity have cognate immunity genes located immediately downstream
158
. The 
means of transport into recipient cells is clear for these effectors. Since VgrG is used to 
penetrate target cells, these toxins will clearly be delivered.  
PAAR-containing effectors  
PAAR-containing proteins are another example of a structural component of the T6 
apparatus acting as an effector. However, PAAR-containing effectors can have the toxin 
domain at their N- or C-terminus
153
. There are 5 classes of PAAR-containing proteins, 4 of 
which contain toxic domains
153
. Rearrangement hot spot (Rhs) proteins are large 200-400 
kDa proteins composed of a YD-repeat core and a C-terminal toxin domain demarcated by a 
conserved DPXGL peptide motif
121
. Many Rhs proteins have PAAR domains in their N-
terminus and have thus been characterized as PAAR proteins
153
. Delivery of the toxic 
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domains of PAAR-proteins is similar to the proposed delivery mechanism of evolved VgrGs; 
they are injected into target cells as part of the cell membrane-puncturing device.  
Peptidoglycan-targeting effectors 
Not surprisingly, numerous T6SS effectors have enzymatic activity towards 
peptidoglycan, the major structural component of the bacterial cell wall. Peptidoglycan is 
composed of alternating units of β1,4-linked N-acetylmuramic acid (MurNAc) and N-
acetylglucosamine (GlcNAc). Peptides of varying length attach to MurNAc and crosslink to 
one another, forming a mesh-like layer essential for cell structure. A type VI amidase effector 
(Tae) family containing 4 distinct classes has been characterized
130
. These enzymes are 
capable of cleaving the peptide crosslinks at distinct locations, thereby disrupting the 
meshwork and ultimately causing cell lysis
129,130,160-162
. Other T6 effectors target the sugar 
component of peptidoglycan. Muramidases and glucosaminidases can both be found in the 
T6SS glycoside hydrolase effector (Tge) family
130,163
. This family contains 3 distinct classes 
based on sequence-divergence and substrate specificity
128
. Consistent with these effectors 
targeting the cell wall, the cognate immunity protein of each effector contains a signal 
sequence that will direct it to the periplasm. Most peptidoglycan-targeting effectors are only 
10-20 kDa and have been proposed to bind inside Hcp monomers as they are building the 
inner tubule of the T6SS apparatus and will therefore be secreted into target cells upon 
contraction of the sheath
164
.  
Cell membrane-targeting effectors 
The lipid bilayer of bacterial cells is another essential component that T6S effectors 
target. Type VI lipase effector (Tle) proteins hydrolyze the lipids that make up the bacterial 
membrane, while pore-forming proteins dissipate the proton-motive force of cells
128,165
. 
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While there have only been two examples of pore-forming T6S effectors, there are 377 
predicted Tle proteins in T6SS
+
 bacteria
165
. Tle proteins have been broken up into 5 families 
based on bond specificity and phosphate head group preference. Tle families 1-4 contain a 
conserved GXSXG motif that is commonly found in lipases and esterases, while the Tle5 
family carries HXLXXXD motifs unique to phospholipase D enzymes
128
. Just like 
peptidoglycan-targeting T6SS effectors, the cognate immunity proteins for cell membrane-
targeting effectors are also predicted to function in the periplasm. The delivery process of 
these cell-membrane targeting effectors remains speculative. They are too large to fit inside 
the homohexameric ring formed by Hcp without unfolding
164
. Therefore, it is thought that 
they interact with an accessory protein to link it to the T6SS to be delivered into target cells.  
Cytoplasmic-acting effectors 
Not all T6 effectors target substrates in the periplasm. More recently, nuclease effectors 
have been identified. Most of these effectors are found in PAAR-containing proteins, and 
especially at the C-terminus of Rhs proteins (Rhs-CT)
121,153
. In fact to this date all Rhs-CTs 
are predicted to act in the cytoplasm. Of the effectors that are predicted to bind inside Hcp 
rings, only 5 have predicted cytoplasmic activity, although their toxic activity is unknown
128
. 
It is unclear if the delivery of these effectors differs from delivery of periplasmic-acting 
effectors, as cytoplasmic-acting toxins must cross both lipid bilayers of the recipient cell.  
 
T6S Conclusion 
T6SSs are prevalent in proteobacteria and deploy a diverse array of effector proteins that 
target essential and conserved cellular structures. Taken all together, this suggests these 
systems play a vital role in inter-species competition. There are many parallels between T6S 
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and CDI systems. Both require direct contact with target cells to deliver their respective toxic 
effector molecule to inhibit cell growth. While CDI systems mostly target substrates in the 
cytoplasm and T6S effectors are more commonly periplasmic-acting, each system 
demonstrates the ability to severely inhibit the growth of neighboring bacteria. It seems the 
function of these systems is redundant.  However, many strains of bacteria contain both 
systems, suggesting they provide their own distinct advantages. Understanding the 
mechanism of effector delivery, the toxins utilized and target-cell range of each of these 
systems will help clarify their distinct roles in nature. Chapter 6 will focus on the T6SS found 
in the opportunistic human pathogen, Enterobacter cloacae. 
 
 
Conclusion of the Introduction  
Bacteria are almost exclusively found in complex microbial communities, competing 
with a variety of species for limited resources and space. Therefore, bacteria have developed 
diverse competition systems to gain a fitness advantage in such harsh environments. We have 
discussed 3 such competition systems that are widespread in proteobacteria and specifically 
pathogenic species. The diversity of toxins found in bacteriocins, CDI systems, and T6SSs 
demonstrate the ability of these systems to mediate antagonistic effects to a wide range of 
species. However, we learned bacteriocins and CDI systems are restricted to intra-species 
delivery, while T6SSs participate in both intra- and inter-species competition. Understanding 
the role of each of these systems in the environment will help elucidate how complex 
microbial communities are established.  
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Figure 1. Model of colicin production and import. SOS promoter is induced upon stress 
leading to expression of the Colicin-Immunity pair and Lysis protein. Cell lysis allows for 
the release of Col-Imm. The receptor-binding domain binds its cognate outer-membrane 
protein which recruits a translocator to produce a translocon. The translocation domain 
interacts with TolA (Group A colicins) or TonB (Group B colicins) to facilitate transit 
through the outer membrane. Imm. is stripped away on the surface of cells. The toxin domain 
is delivered to the cytoplasm which causes cell death. Sibling cells will be protected by the 
production of cognate immunity protein. 
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Figure 2. Model of contact-dependent growth inhibition (CDI). CdiB exports CdiA onto 
the surface. Upon contact with a receptor protein on target cells, CdiA-CT transits into the 
cytoplasm where it can perform its toxic activity to cause cell death.  Sibling CDI
+ 
cells 
produce CdiI which binds to and inactivates CdiA-CT, thus allowing cell survival.  
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Figure 3. Model of the type VI secretion system (T6SS). Model arrangement of a T6S 
locus. The function of each protein in the apparatus and homology to phage proteins is listed. 
The inner tube comprised of Hcp homohexamers is assembled onto the baseplate and capped 
by PAAR-bound VgrG (spike). This is surrounded by an outer sheath made of TssBC 
subunits and anchored to the envelope by components of the membrane complex. Upon 
contraction of TssBC, the inner tube and spike are injected into recipient cells where toxic 
effectors are released. ClpV binds the sheath subunits for disassembly.  
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Chapter 2. F pili mediate import of a contact-dependent growth 
inhibition (CDI) toxin 
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Note: This research was originally published in Molecular Microbiology. I collaborated on 
this project with Elie Diner. Figure 1 is solely his work. Furthermore, Christopher Hayes and 
Elie Diner contributed to the writing in this chapter.  
 
Beck CM, Diner EJ, Kim JJ, Low DA, Hayes CS. “F pili mediate import of a contact-
dependent growth inhibition (CDI) toxin.” Molecular Microbiology. 2014 Jul;93(2):276-90. 
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Abstract 
 Contact-dependent growth inhibition (CDI) is a widespread form of inter-bacterial 
competition that requires direct cell-to-cell contact. CDI
+
 inhibitor cells express CdiA 
effector proteins on their surface. CdiA binds to specific receptors on susceptible target 
bacteria and delivers a toxin derived from its C-terminal region (CdiA-CT). Here, we show 
that purified CdiA-CT
536
 toxin from uropathogenic Escherichia coli 536 translocates into 
bacteria, thereby by-passing the requirement for cell-to-cell contact during toxin delivery. 
Genetic analyses demonstrate that the N-terminal domain of CdiA-CT
536
 is necessary and 
sufficient for toxin import. The CdiA receptor plays no role in this import pathway; nor do 
the Tol and Ton systems, which are exploited to internalize colicin toxins. Instead, CdiA-
CT
536
 import requires conjugative F pili. We provide evidence that the N-terminal domain of 
CdiA-CT
536
 interacts with F pilin, and that pilus retraction is critical for toxin import. This 
pathway is reminiscent of the strategy used by small RNA leviviruses to infect F
+
 cells. We 
propose that CdiA-CT
536
 mimics the pilin-binding maturation proteins of leviviruses, 
allowing the toxin to bind F pili and become internalized during pilus retraction. 
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Introduction 
Contact-dependent growth inhibition (CDI) systems are distributed throughout , 
 and proteobacteria, where they function in competition between closely related bacteria 
115,118,166,167
. CDI is mediated by the CdiB/CdiA family of two-partner secretion proteins. 
CdiB is an outer-membrane β-barrel protein required for secretion of the CdiA effector. CdiA 
proteins are filamentous and very large, ranging from ~180 kDa in Moraxella to over 600 
kDa in some Pseudomonas species 
115,166
. CdiA extends from the surface of CDI
+
 inhibitor 
cells and interacts with receptors on susceptible target bacteria. CDI has been characterized 
most extensively in Escherichia coli EC93, and its CdiA
EC93
 effector binds the highly 
conserved outer-membrane protein BamA as a receptor 
118,168
. Upon binding the receptor, 
CdiA
EC93
 appears to be cleaved to release a C-terminal toxin region (CdiA-CT
EC93
), which is 
subsequently translocated into the target cell through a poorly characterized pathway 
115,168,169
. E. coli EC93 inhibitor cells also deliver toxins to one another, but are protected 
from inhibition by a small CdiI
EC93
 immunity protein encoded immediately downstream of 
cdiA
EC93
 
112
. Thus, E. coli EC93 cells deploy CdiA-CT
EC93
 toxins to inhibit other non-
immune strains of E. coli. Because CDI confers a significant growth advantage to inhibitor 
cells, these systems are thought to mediate inter-strain competition for environmental niches. 
 CDI loci encode a diverse group of CdiA-CT/CdiI toxin/immunity sequences. There 
are at least 18 CdiA-CT/CdiI sequence types distributed throughout E. coli strains, and 
Burkholderia pseudomallei strains carry 10 distinct sequence types 
120,167
. Thus, CDI 
toxin/immunity pairs are highly variable, even between strains of the same species. In accord 
with this sequence diversity, CDI toxins exhibit a number of distinct activities. For example, 
CdiA-CT
EC93
 dissipates the proton-motive force and induces the phage-shock response 
170
, 
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suggesting that the toxin forms pores in the inner membrane of target cells. Many other CDI 
toxins have nuclease activities. CDI toxins from Dickeya dadantii 3937 and E. coli EC869 
are DNases that degrade target-cell genomic DNA 
115,169,171
. CDI
+
 bacteria also deploy 
RNases that preferentially cleave tRNA molecules. CdiA-CT
536
 from uropathogenic E. coli 
536 (UPEC 536) is a tRNA anticodon nuclease 
115,123
, and toxins from B. pseudomallei 
strains cleave tRNA in the anticodon loop, T-loop and aminoacyl-acceptor stem 
120
. Each 
CdiA-CT toxin is specifically neutralized by its cognate CdiI protein, but not the immunity 
proteins from other CDI systems 
115,120,171
. Therefore, CDI toxin/immunity complexity 
provides the basis for self/non-self discrimination during inter-strain competition. 
 The CdiA-CT toxin region is typically demarcated by a short, highly conserved 
peptide sequence. Most CdiA-CT regions are defined by the VENN peptide motif, but CdiA 
proteins from Burkholderia species contain an analogous (Q/E)LYN sequence 
115,120,172,173
. 
The function of this motif has not been explored, but it could play two important roles in 
CDI. First, the universally conserved Asn residue may catalyze auto-cleavage to release the 
CdiA-CT for subsequent translocation into target bacteria. Asn side-chains can undergo intra-
molecular attack on the peptide backbone, thereby cleaving the peptide chain and producing 
a cyclic succinimide. Asn residue cyclization is a well-characterized reaction that mediates 
auto-cleavage in several secreted proteins 
174,175
. Second, the nucleotide sequence encoding 
VENN may be important for recombination and subsequent expression of new cdiA-CT/cdiI 
gene pairs acquired by horizontal transfer. CDI toxins are modular and can be readily 
exchanged between systems. For example, E. coli CdiA proteins can deliver heterologous 
toxins from Yersinia pestis CO92 and Dickeya dadantii 3937, provided the CdiA-CTs are 
fused at the common VENN motif 
115,169
. Thus, bacteria might switch toxin/immunity types 
34 
 
by recombining a new cdiA-CT/cdiI sequence onto the 3´-end of the cdiA gene, thereby 
displacing the original toxin/immunity pair. Moreover, many species carry fragmented cdiA-
CT/cdiI gene pairs in tandem arrays downstream of the main cdiBAI gene cluster 
176
. These 
"orphan" toxin/immunity regions usually contain interspersed sequences that are homologous 
to transposases and integrases, implying recent acquisition through horizontal gene transfer 
167,176
. Taken together, these observations suggest that CdiA proteins have the intrinsic ability 
to auto-cleave and deliver diverse toxins across the target-cell envelope.   
 Although CDI toxins are hypothesized to translocate autonomously, CdiA
EC93
 
fragments released by E. coli EC93 cells do not inhibit the growth of other E. coli strains 
112
. 
One possible explanation is that only specific CdiA-CT fragments – presumably those 
released in response to receptor-binding – are able to enter target bacteria. This model 
suggests that purified toxin may be active against bacteria if it mimics the naturally cleaved 
CdiA-CT fragment. Therefore, we tested whether purified CdiA-CT toxins inhibit the growth 
of bacterial cultures. We find that purified CdiA-CT
536
 (from UPEC 536) inhibits E. coli cell 
growth, whereas CdiA-CT
3937
 (from D. dadantii 3937) has no effect. Structure-function 
analyses show that the N-terminal domain of CdiA-CT
536
 is necessary and sufficient for cell 
import, but surprisingly toxin translocation does not require BamA. Instead, conjugative F 
pili are required for the import of purified CdiA-CT
536
 toxin. We provide evidence that 
CdiA-CT
536
 binds to F pilin and hypothesize that this interaction allows the toxin to be 
internalized during pilus retraction. F-dependent RNA phages exploit a similar pathway to 
transport their genomes into cells, suggesting that CdiA-CT
536
 mimics RNA phage to enter 
F
+
 cells. 
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Materials and Methods 
Bacterial strains and plasmids used in this study 
Strains or plasmids Description
a
 Reference 
Strain   
X90 
F´ lacI
q
 lac´ pro´/ara∆(lac-pro) nal1 
argE(amb) rif
r
 thi-1, Rif
R
 
177
 
XL-1  
F´::Tn10 proA
+
B
+
 lacI
q
 
∆(lacZ)M15/recA1 endA1 gyrA96 thi 
hsdR17 (rK
-
 rK
+
) glnV44 relA1 lac. Tet
R
, 
Nal
R
 
Stratagene 
MC4100 
F
-
 araD139 ∆(argF-lac)U169 rpsL150 
relA1 deoC1 rbsR fthD5301 fruA25 λ–. StrR 
178
 
KW1070 X90 F
–
 
Kelly P. 
Williams 
CH2016 X90 (DE3) ∆rna ∆slyD::kan, KanR 179 
CH6479 X90 ∆tolA::kan, KanR This study 
CH6480 X90 ∆tonB::kan, KanR This study 
CH6680 X90 bamA101::kan, Kan
R
 
168
 & this 
study 
CH6866 KW1070 pOX38::gent, Gent
R
 This study 
CH6939 X90 ∆traA::cat, CmR This study 
CH7035 X90 ∆traT::cat, CmR This study 
CH9027 KW1070 F´::Tn10, Tet
R
 This study 
CH9354 X90 ∆tonB tolA::kan, KanR This study 
CH11476 X90 ∆trbI::cat, CmR This study 
CH11703 CH11717 ∆trbI::cat, TetR CmR This study 
CH11717 X90 Tn10, Tet
R
 This study 
CH11718 CH11717 ∆traA::cat, TetR CmR This study 
Plasmids   
pBR322 Cloning vector, Amp
R
 Tet
R
 
180
 
pACYC184 Cloning vector, Cm
R
, Tet
R
 
181
 
pTrc99A 
IPTG-inducible expression vector, 
Amp
R
 
GE 
Healthcare 
pCH450 
pACYC184 derivative containing E. 
coli araC and the L-arabinose-inducible 
ParaBAD promoter, Tet
R
 
182
 
pET21::cdiA-
CT/cdiI
3937
 
Over-produces CdiA-CT
3937
 and 
CdiI
3937
-His6, Amp
R
 
115
 
pET21::cdiA-
CT/cdiI
536
 
Over-produces CdiA-CT
536
 and CdiI
536
-
His6, Amp
R
 
115
 
pET21::DUF- Over-produces DUF638-CdiA-CT
536
 This study 
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CT/cdiI
536
  and CdiI
536
-His6, Amp
R
  
pET21::VENN-less-
CT/cdiI
536
 
Over-produces VENNless-CdiA-CT
536
 
and CdiI
536
-His6. Amp
R
 
This study 
pET21::Cys-less-
CT/cdiI
536
 
Over-produces CdiA-CT
536
 containing 
Cys13Ser and Cys19Ser mutations together 
with CdiI
536
-His6, Amp
R
 
This study 
pET21::tRNase/cdiI
536
 
Over-produces the C-terminal tRNase 
domain of CdiA-CT
536
 together with 
CdiI
536
-His6, Amp
R
 
123
 
pET21::cdiA-
CT(H178A)/cdiI
536
 
Over-produces catalytically inactive 
His178Ala variant of CdiA-CT
536
 toxin and 
CdiI
536
-His6, Amp
R
 
123
 
pET21K::cdiA-
CT/cdiI
ECL
 
Over-produces CdiA-CT
ECL
 and 
CdiI
ECL
-His6 from Enterobacter cloacae 
ATCC 13047, Amp
R
 
This study 
pCH450::cdiA-
CT
536
 
Expresses cdiA-CT
536
 under control of 
PBAD promoter, Tet
R
 
This study 
pCH450::DUF-
CT
536
 
Expresses DUF638-cdiA-CT
536
 under 
control of PBAD promoter, Tet
R
 
This study 
pCH450::VENN-
less-CT
536
 
Produces VENNless-CdiA-CT
536
, Tet
R
 This study 
pCH450::Cys-less-
CT
536
 
Produces CdiA-CT
536
 containing 
Cys13Ser and Cys19Ser mutations, Tet
R
 
This study 
pCH450::tRNase
536
 
C-terminal tRNase domain of CdiA-
CT
536
, Tet
R
 
This study 
pCH450::cdiA-
CT(H178A)
536
 
catalytically inactive His178Ala variant 
of CdiA-CT
536
, Tet
R
 
This study 
pDAL776 
pBR322 derivative that constitutively 
expresses cdiI
536
, Amp
R
 
115
 
pDAL852 
pBR322 derivative that constitutively 
expresses cdiI
3937
 from Dickeya dadantii 
3937, Amp
R
 
115
 
pOX38::gent 
pOX38 with integrated gentamicin-
resistance cassette, Gent
R
 
183
 
pTrc99A::cdiI
536
 
Expresses cdiI
536 
under control of the 
Ptrc promoter, Amp
R
 
This study 
pTrc99A::cdiI
ECL
 
Expresses cdiI
ECL
 from Enterobacter 
cloacae ATCC 13047
 
under control of the 
Ptrc promoter, Amp
R
 
This study 
pTrc99A::imE5 
Expresses imE5 under control of the Ptrc 
promoter, Amp
R
 
This study 
pET21::colE5-
CT/imE5 
Over-produces ColE5-CT (residues 
Met429 - Gln556) and together with ImE5-
His6, Amp
R
 
This study 
pET21::NT
536
-
colE5-CT/imE5 
Over-produces a protein containing 
residues Val1 – Tyr82 of CdiA-CT536 fused 
This study 
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to the nuclease domain of colicin E5 
(colE5-CT) together with ImE5-His6, Amp
R
 
pTrc99A::traA 
Expresses wild-type F-pilin under the 
control of the Ptrc promoter, Amp
R
 
This study 
pTrc99A::traA(D74
G) 
Expresses the Asp74Gly variant of F-
pilin under control of the Ptrc promoter, 
Amp
R
 
This study 
pTrc99A::traA(G12
0C) 
Expresses the Gly120Cys variant of F-
pilin under control of the Ptrc promoter, 
Amp
R
 
This study 
pTrc99A::trbI 
Expresses trbI under the control of the 
Ptrc promoter, Amp
R
 
This study 
pCH450::trbI 
Expresses trbI under the control of the 
PBAD promoter, Tet
R
 
This study 
a
Abbreviations: Amp
R
, ampicillin resistant; Cm
R
, chloramphenicol resistant; Gent
R
, 
gentamicin resistant; Kan
R
, kanamycin resistant; Nal
R
, nalidixic acid resistant; Rif
R
, 
rifampicin resistant; Str
R
, streptomycin resistant; Tet
R
, tetracycline resistant 
 
Oligonucleotides used in this study 
536-Nco-
for 
5´ - AGA CCA TGG TTG AGA ATA ATG CGC 
TGA G 
115
 
536-Xho-
rev 
5´ - GAT CTC GAG TAC AAT TAT CTG ATT 
GAT TTT T 
115
 
DUF-536-
Nco-for 
5´ - TCT CCA TGG GCG TAG ATC CGT CGA 
AAC TGA C 
This 
study 
VENN-
less-Nco-for 
5´ - AAT GCC ATG GGT CTG GTT GCC AGA 
GG 
This 
study 
tRNase-
Nco-for 
5´ - ATA CCA TGG GTT CCG GGG CTG CCT C This 
study 
536-
Cys(mut) 
5´ - CTT TAG TCC TGC TAG GTG CTG CGA 
CCG CAC TGC CTC TGG CAA C 
This 
study 
pET-
Sph/Pst 
5´ - CAA GGA ATG GTG CAT GCC TGC AGA 
TGG CGC CC 
179
 
pET-
Kpn/Nco 
5´ - AGT CCA TGG TAC CTC TCC TTC TTA 
AAG 
This 
study 
536-
H178A-for 
      5´ - GGA GGA TAT TGG GAT GCT ATG CAG 
GAA ATG C 
123
 
536-CT-
Xho-rev 
5´ - TTA CTC GAG GTA ATC ATA TTC CAT A This 
study 
536-cdiI-
Eco-for 
5´ - AGG GAA TTC CAT ATG ATT ACC TTA 
CGT AAA 
This 
study 
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536-cdiI-
Spe-rev 
5´ - GTG ACT AGT TAC AAT TAT CTG ATT 
GAT TT  
This 
study 
colE5-
M429-Nco 
5´ - CTG CCA TGG AAA GCA GGA AGA AG This 
study 
imE5-Spe 5´ - AAA ACT AGT CAT CTT TAA CGT GAT 
AAT GAA AGC 
This 
study 
immE5-
Eco-for 
5´ - GGA GAA TTC TCT ATG AAG TTA TCA 
CC 
This 
study 
pET-Pst-
rev 
5´ - CGG CTG CAG CAG CCA ACT CAG TGG This 
study 
colE5-Nco-
for 
5´ - GAG TTT CCA TGG GCG GTG GCG ATG G This 
study 
colE5-
Bam-rev 
5´ - AGC GGA TCC TTT ATT ATC CTC TTT 
CTT CTT C 
This 
study 
colE5-
Bam-for 
5´ - AAA GGA TCC AGA GAT GCT GAA GGC 
AAA C 
This 
study 
immE5-
Xho-rev 
5´ - CAC CTC GAG CAT CTT TAA CGT GAT 
AAT G 
This 
study 
536-Bam-
rev 
5´ - GCC CCG GAT CCG TAC TTA TC This 
study 
traA-Nco-
for 
5´ – TAA CCC ATG GTT GCT GTT TTA AGT 
GTT CAG G 
This 
study 
traA-Spe-
rev 
5´ – TTT ATA CTA GTT CAG AGG CCA ACG 
ACG GCC ATA CC 
This 
study 
traA-D74G 5´ - TTC GGT AAG GGC TCC AGT GTT GTT 
AAA TGG G 
This 
study 
traA-
G120C-Spe 
5´ - TAT ACT AGT TCA GAG GCA AAC GAC 
GGC C 
This 
study 
ECL-CT-
Kpn-for 
5´ - GGG GGT ACC ATG GCT GAG AAT AAC 
TCG CTG GC 
This 
study 
ECL-cdiI-
Nhe-rev 
5´ - CTC TGC TAG CGT TGT TAA GAC TAT 
GAT AAA AAT C 
This 
study 
ECL-cdiI-
Eco-for 
5´ - GAT TAA GGA ATT CTG GTA TGT TTG G This 
study 
ECL-cdiI-
Sac-rev 
5´ - AGT GAG CTC TGT TTC AGT TGT TAA 
GAC 
This 
study 
argQ probe 5´ -CCT CCG ACC GCT CGG TTC G 
179
 
tyrU probe 5´ - CTT CGA AGT CTG TGA CGG CAG 
120
 
traA-cat-
for 
5´ - ACA TTT AAT ACA CTC TAG TTT TAT 
TCA TTT ATC CGA AAT TGA GGT AAC TTA 
TGG AGA AAA AAA TCA CTG GAT ATA CC 
This 
study 
traA-cat-
rev 
5´ - GGA AAC GAT ATT TCT TAA GTT TAT 
TCT CGT CTC CCG ACA TCG TTT TAT TTC CTG 
TTA CGC CCC GCC CTG CCA CTC 
This 
study 
traT-cat-for 5´ - AAA ACA AGA AGT TAT CAA GAG TAA 
AAT AAA AGA TAT TAG AGA GTA AAT ATA 
This 
study 
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TGG AGA AAA AAA TCA CTG GAT ATA CC 
traT-cat-
rev 
5´ - CAA AGC GAG GCG TCA GTC AGG AGG 
CCG GTC AGA CCA GCC TCC GGA AGA TAA 
TTA CGC CCC GCC CTG CCA CTC 
This 
study 
trbI-cat-
for1 
5´ - GGA AGA ACA TGA GAA ATA CAG GAG 
TGT GGC ATG AGT GAG AAA AAA ATC ACT 
GGA TAT ACC 
This 
study 
trbI-cat-
for2 
5´ - AAG AAG TCA GGG CCG GAA ATG GCT 
TCG CTG GAA GCC TGG CTG GAA GAA CAT 
GAG AAA TAC 
This 
study 
trbI-cat-
rev1 
5´ - GCC CCC ATA TCA GCA GGG CAA TCA 
GCC CCC GGC ATC TCA TGC CCC TCC CTG 
CCA CTC ATC 
This 
study 
trbI-cat-
rev2 
5´ - CAC AGA TCG CCC CAG GTA CCA AGA 
TCG GCG GCG GCC ACA CTC TGC CCC CAT 
ATC AGC AGG 
This 
study 
trbI-Kpn-
for 
5´ - TTT GGT ACC ATG AGT TCA ACG CAG 
AAC 
This 
study 
trbI-Xho-
rev 
5´ - TTT CTC GAG TCT CAT GGT TCC GCC 
CTC 
This 
study 
 
 
Bacterial strains and growth conditions 
Bacterial strains used in this study are listed in the table above. E. coli cells were 
grown in LB medium supplemented with antibiotics at the following concentrations: 
ampicillin (Amp), 150 μg mL-1; chloramphenicol (Cm), 33 μg mL-1; kanamycin (Kan), 50 μg 
mL
-1
; rifampicin (Rif), 250 µg mL
-1
; streptomycin (Str), 50 µg mL
-1
; and tetracycline (Tet), 
10 μg mL-1. Bacteria were grown in baffled flasks at 37 °C with shaking (215 rpm) unless 
otherwise indicated. The F
–
 derivative of E. coli X90 (strain KW1070) was a generous gift 
from Dr. Kelly P. Williams. The ∆tolA::kan and ∆tonB::kan gene disruptions were obtained 
from the Keio collection 
184
 and introduced into E. coli X90 by bacteriophage P1-mediated 
transduction. The ∆traA::cat, ∆traT::cat and ∆trbI::cat disruptions were generated by phage 
λ Red-mediated recombination as described 185. The chloramphenicol acetyltransferase (cat) 
open reading frame was amplified with oligonucleotides containing homology to regions 
40 
 
flanking traA (traA-cat-for/traA-cat-rev) and traT (traT-cat-for/traT-cat-rev). A similar 
procedure was used for the trbI gene, but the cat  gene was amplified by two sequential 
reactions with trbI-cat-for1/trbI-cat-rev1 and trbI-cat-for2/trbI-cat-rev2 primer pairs. The 
resulting PCR products were electroporated into E. coli X90 cells expressing the Red 
proteins from plasmid pSIM6 
186
. The F´::Tn10 (from strain XL-1) and pOX38::gent 
plasmids were transferred into E. coli strain KW1070 by conjugation. Donor and recipient 
cells were mixed and spotted onto LB-agar for 4 hr at 37 °C. Exconjugants were selected on 
LB-agar supplemented with: Tet/Rif for F´::Tn10 transfer into E. coli KW1070, Gent/Rif for 
pOX38::gent transfer into KW1070, and Tet/Str for F´::Tn10 transfer into E. coli MC4100. 
 
Plasmids 
 Plasmids used in this study are listed in the table above. Plasmids pET21::cdiA-
CT/cdiI
536
 and pET21::cdiA-CT/cdiI
3937
 were used to over-produce CdiA-CT/CdiI
536
-His6 
and CdiA-CT/CdiI
3937
-His6 complexes (respectively) 
115
. All other CdiA-CT/CdiI
536
-His6 
over-expression constructs were generated by PCR and ligated into plasmid pET21P using 
NcoI/XhoI restriction sites. The DUF-CT, VENN-less and tRNase domain constructs were 
amplified using primers DUF-536-Nco-for, VENN-less-Nco-for and tRNase-Nco-for 
(respectively) in conjunction with primer 536-Xho-rev. Residues Cys13 and Cys19 of CdiA-
CT
536
 were mutated to serine by mega-primer PCR 
187
. A fragment of plasmid pET21::cdiA-
CT/cdiI
536
 was amplified using primers pET-Sph/Pst and 536-Cys(mut). This product was 
purified and used as a mega-primer in a second PCR with primer 536-Xho-rev. The final 
product was digested with NcoI/XhoI and ligated to plasmid pET21P. The colE5-CT and 
imE5 coding sequences were amplified from plasmid ColE5-099 using primers colE5-M429-
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Nco and imE5-Spe, and the product digested with NcoI/SpeI and ligated to plasmid pET21P. 
The CdiA-CT/ColE5-CT fusion construct was generated by sequential ligation of cdiA-CT
536
 
and colE5-imE5 fragments into plasmid pET21P. The colE5-CT/imE5 sequence was 
amplified with primers ColE5-Bam-for and ImE5-Xho-rev and ligated to plasmid pET21P. 
The coding sequence for Val1 – Tyr82 of CdiA-CT536 was amplified with primers 536-Nco-
for and 536-Bam-rev and ligated to plasmid pET21::colE5-CT/imE5 using NcoI and BamHI 
restriction sites. The CdiA-CT/CdiI
ECL
-His6 expression construct was generated in two steps. 
First, the T7 promoter region of pET21P was amplified with primers pET-Sph/Pst and pET-
Kpn/Nco, and the fragment ligated to PstI/NcoI-digested pET21::cdiA-CT/cdiI
3937
. The 
resulting pET21K::cdiA-CT/cdiI
3937
 plasmid contains a unique KpnI site upstream of NcoI. 
The cdiA-CT/cdiI
ECL
 region was then amplified with ECL-CT-Kpn-for and ECL-cdiI-Nhe-
rev and ligated to KpnI/SpeI-digested plasmid pET21K::cdiA-CT/cdiI
3937
. 
 The cdiI
536
, cdiI
ECL
 and imE5 immunity genes were amplified from pET21 expression 
plasmids using 536-cdiI-Eco-for, ECL-cdiI-Eco-for and imE5-Eco-for primers (respectively) 
in conjunction with the pET-Pst reverse primer. All PCR products were digested with EcoRI 
and PstI and ligated to plasmid pTrc99A. The traA coding sequence from the F plasmid was 
amplified with primers traA-Nco-for and traA-Spe-rev and the product ligated to NcoI/SpeI-
digested plasmid pTrc99A::rhsIB 
176
. The Gly120Cys mutation in traA was generated by 
PCR using primers traA-Nco-for and traA-G120C-Spe. The Asp74Gly mutation in traA was 
generated by megaprimer PCR using primer traA-D74G in conjunction with the traA-Nco-
for/traA-Spe-rev primer pair. The trbI gene was amplified with primers trbI-Kpn-for and 
trbI-Xho-rev and the product ligated to KpnI/XhoI-digested pTrc99KX and pCH450K to 
generate trbI expression constructs for complementation analysis. 
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Protein purification 
All CdiA-CT/CdiI-His6 complexes were over-produced in E. coli strain CH2016. 
Cultures were grown to OD600 ~ 0.7 and protein production induced with 1.5 mM isopropyl 
β-D-1-thiogalactopyranoside (IPTG) for three hr. Cells were harvested over ice and collected 
by centrifugation at 6,000 rpm for 10 min. Cells were resuspended in 10 mL of extraction 
buffer [20 mM sodium phosphate (pH 7.0), 150 mM sodium chloride, 0.05% Triton X-100, 
10 mM β-mercaptoethanol (β-ME), 1 mM PMSF] and broken by french press passage at 
20,000 psi. Cell lysates were cleared by two consecutive centrifugations at 14,000 rpm for 10 
min (SS-34 rotor) and supernatants were incubated with Ni
2+
-nitrilotriacetic acid (Ni
2+
-NTA) 
resin for 1.5 hr at 4 °C. The resin was washed with 20 mM sodium phosphate (pH 7.0), 150 
mM sodium chloride, 0.05% Triton X-100, 10 mM β-ME, 20 mM imidazole and loaded onto 
a Poly-Prep column (Bio-Rad) at 4 °C. CdiA-CT/CdiI-His6 complexes were eluted from the 
resin with native elution buffer [20 mM sodium phosphate (pH 7.0), 150 mM sodium 
chloride, 10 mM β-ME, 250 mM imidazole], followed by dialysis into storage buffer [20 mM 
sodium phosphate (pH 7.0), 150 mM NaCl, 10 mM β-ME]. CdiA-CT toxins were isolated 
from CdiI-His6 immunity proteins by Ni
2+
-affinity chromatography under denaturing 
conditions [6 M guanidine-HCl, 20 mM sodium phosphate (pH 7.0), 10 mM β-ME] at room 
temperature. Purified CdiA-CT toxins were dialyzed against storage buffer and quantified by 
absorbance at 280 nm.  
 
CdiA-CT inhibition assays 
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 Mid-log cells were diluted to OD600 = 0.05 in fresh LB medium and incubated at 37 
°C with shaking. After growth to OD600 = 0.1 – 0.15, purified CdiA-CT, ColE5-CT or CdiA-
CT/CdiI complex was added to the culture at a final concentration of 100 nM. Cell growth 
was monitored by measuring OD600 every 30 min. Samples were collected periodically and 
total RNA isolated by guanidine isothiocyanate-phenol extraction as described 
179
. Northern 
blot analysis was performed as described 
182
 using 5´-radiolabeled oligonucleotide probes to 
tRNAICG
Arg
 and tRNAGUA
Tyr
 . Expression of plasmid-borne traA alleles was induced with 0.5 
mM isopropyl β-D-1-thiogalactopyranoside (IPTG) prior to the addition of purified CdiA-
CT
536
. The stability of CdiA-CT
536
 in shaking broth cultures was determined by immunoblot 
analysis. Culture samples were removed at 0, 1, 3 and 5 hr and the media clarified by 
centrifugation at 14,000 g for 10 min. The supernatants (10 µL) were run on SDS-
polyacrylamide gels and blotted onto PVDF membrane. Proteins were detected using 
polyclonal antibodies raised against CdiA-CT
536
 
169
. 
 
 
Bacteriophage plating and mating efficiency 
 Bacteriophage resistance was determined by measuring the efficiency of plating. X90 
and derivatives were incubated with 10 and 100 plaque forming units (pfu) and then plated in 
soft agar. The number of plaques was divided by the number of infecting particles. Phage-
resistant strains were also challenged with 10
3
 pfu, but no plaques were detected. The traA 
and trbI mutants were tested for mating efficiency under the same conditions as CdiA-CT 
inhibition assays. F´::Tn10 donor cells (Tet
R
) were co-cultured with MC4100 recipient cells 
(Str
R
) at a 1:10 ratio in LB for 3 hr at 37 °C. Samples were collected and plated onto LB-agar 
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supplemented with Tet to enumerate F´::Tn10 donor cells and Tet/Str quantify exconjugants. 
Mating efficiency was calculated by dividing the number of exconjugants by total donor cells 
and expressed as a percentage. The effect of purified CdiA-CT
536
 proteins on conjugation 
was determined using MC4100 F´::Tn10 donors and MC4100 pTrc recipients. CdiA-CT 
proteins were added at 1 µM final concentration to conjugation co-cultures and mating 
efficiency determined as described above. Phage were inactivated with UV irradiation (64 mJ 
m
-2
) in a Stratalinker. This dose resulted in a 10
6
-fold reduction in R17 and M13 plaque-
forming units (pfu). UV-inactivated phage (~10
5
 particles mL
-1
) were added to conjugation 
co-cultures to determine the effect on mating efficiency. 
 
Results 
Purified CdiA-CT
536 
inhibits E. coli growth  
 To test whether CdiA-CT toxins enter bacteria in the absence of cell-to-cell contact, 
we treated E. coli cultures with purified toxins from Dickeya dadantii 3937 (CdiA-CT
3937
) 
and uropathogenic E. coli 536 (CdiA-CT
536
). Each toxin was first purified as a complex with 
its cognate His6-tagged CdiI protein and then separated from the immunity protein under 
denaturing conditions. CdiA-CT
536
 and CdiA-CT
3937
 refold efficiently and regain nuclease 
activity when denaturant is removed by dialysis 
115,123
. We added each toxin (100 nM final 
concentration) to E. coli X90 cultures and monitored cell growth. Purified CdiA-CT
3937
 had 
no discernable effect on growth, but cells treated with CdiA-CT
536
 were inhibited compared 
to the buffer-treated control (Fig. 1A). We also tested the CdiA-CT/CdiI
536
 complex, and 
somewhat surprisingly found that cells treated with the toxin/immunity complex were 
inhibited to the same extent as cells treated with CdiA-CT
536
 toxin alone (Fig. 1A). This 
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result suggests that only the toxin enters cells and immunity protein remains in the media. 
Alternatively, the CdiA-CT/CdiI
536
 complex might inhibit growth by a novel mechanism that 
is independent of the toxin's tRNase activity. To differentiate between these possibilities, we 
added purified CdiA-CT
536
 to cells that express plasmid-borne immunity genes. Cells 
expressing cdiI
536
 were not inhibited by added CdiA-CT
536
 toxin (Fig. 1B), indicating that 
immunity protein is protective when present in the cytoplasm. This protection is specific, 
because cells expressing non-cognate cdiI
3937
 were inhibited to the same extent as cells that 
carry no immunity gene (Fig. 1B). To confirm that purified CdiA-CT
536
 inhibits growth 
through its anticodon nuclease activity, we isolated RNA from the toxin-treated cultures and 
examined transfer RNA by northern blot. This analysis revealed cleaved tRNAICG
Arg
 in all 
CdiA-CT
536
-treated cells except those expressing the cognate cdiI
536
 immunity gene (Fig. 
1C). Together, these results show that exogenous CdiA-CT
536
 translocates into E. coli cells, 
where it cleaves tRNA to inhibit growth. 
 
The N-terminal domain of CdiA-CT
536
 is required for cell import 
Like many CdiA-CTs, CdiA-CT
536
 is composed of two domains 
123,171
. The tRNase 
activity of CdiA-CT
536
 is contained within the C-terminal 145 residues 
123
, which 
corresponds to Gly3098 – Ile3242 of full-length CdiA536 (Fig. 2A). However, E. coli cells 
were not inhibited when treated with the purified tRNase domain (Fig. 2B). This result 
suggests that the N-terminal domain of CdiA-CT
536
 is required for cell import; or 
alternatively, the C-terminal tRNase domain may be insufficient to inhibit cell growth. To 
test inhibition activity, we constructed a plasmid that produces the tRNase domain under 
control of the arabinose-inducible PBAD promoter and asked whether this construct could be 
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introduced into E. coli cells in the presence of L-arabinose. As a control, we also transformed 
the plasmid into E. coli ∆cysK cells, because CysK is required to activate the CdiA-CT536 
nuclease 
123
. The construct expressing the tRNase domain yielded no stable transformants in 
the cysK
+
 background, but was readily introduced into ∆cysK cells (Fig. 3). Furthermore, 
cysK
+
 cells were transformed at high-efficiency with either the empty vector plasmid 
(pCH450) or a construct encoding CdiA-CT
536
 with the His178Ala mutation that abolishes 
tRNase activity 
123
 (Fig. 3). Together, these results demonstrate that the C-terminal tRNase 
domain is toxic when expressed inside cells and suggest that the N-terminal domain plays a 
role in cell import. 
The VENN peptide motif is predicted to be part of a larger domain of unknown 
function, termed DUF638, which is found in many CdiA proteins 
115
. Given the conservation 
of the VENN motif, we asked whether this sequence is required for CdiA-CT
536
 import. Cells 
treated with CdiA-CT
536
 lacking this sequence (VENN-less, residues Leu3023 – Ile3242) 
were inhibited to the same extent as cells treated with the full CdiA-CT
536
 containing 
residues Val3016 – Ile3242 (Fig. 2A & 2B). Surprisingly, a larger fragment (containing 
residues Gly2969 – Ile3242) that includes the entire DUF638 region had no effect on cell 
growth (Figs. 2A & 2B), even though this protein is toxic when produced inside cysK
+
 cells 
(Fig. 3). Although CdiA-CT sequences are diverse, their N-terminal domains often contain 
paired cysteine residues that presumably form disulfide linkages. We reasoned that this 
predicted disulfide bond could be critical for toxin import, and therefore mutated Cys3028 
and Cys3034 to serine residues to generate a "Cys-less" toxin (Fig. 2A). Cells treated with 
the Cys-less CdiA-CT
536
 were not inhibited (Fig. 2B), yet this toxin variant still inhibited 
growth when produced inside E. coli cells (Fig. 3). The preceding experiments results 
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suggest a role for N-terminal domain of CdiA-CT
536
 in cell import. However, it is also 
possible that some of the toxin variants are unstable in the growth medium and do not inhibit 
cell growth because they are rapidly degraded. To address this possibility, we monitored 
CdiA-CT
536
 antigen using immunoblot analysis, which revealed that each toxin was stable in 
shaking-broth cultures for up to five hours at 37 °C (data not shown). Together, these data 
indicate that the N-terminal domain of CdiA-CT
536
 is required for import. However, the 
DUF368 region appears to block CdiA-CT
536
 translocation, perhaps by interacting with the 
N-terminal region and masking cell-import epitopes. 
The N-terminal domain of CdiA-CT
536
 shares significant sequence identity with the 
corresponding region of CdiA
ECL
 from Enterobacter cloacae ATCC 13047 (ECL), but the C-
terminal nuclease domains are not related in sequence (Fig. 4A). Moreover, the C-terminal 
domain of CdiA-CT
ECL
 has a distinct RNase activity that cleaves 16S ribosomal RNA 
188
. 
We reasoned that if the N-terminus of CdiA-CT
536
 mediates cell import, then purified CdiA-
CT
ECL
 (corresponding to residues Ala3087 – Asp3321) should also inhibit E. coli growth. 
We found that the purified CdiA-CT/CdiI
ECL
 complex had no effect on E. coli X90 cells 
(data not shown), but the isolated CdiA-CT
ECL
 toxin inhibited cell growth (Fig. 4B). This 
result may indicate that CdiI
ECL
 does not dissociate from CdiA-CT
ECL
 during translocation, 
or alternatively the bound immunity protein may prevent toxin import altogether. Regardless, 
the purified CdiA-CT
ECL
 toxin entered cells because the cdiI
ECL
 immunity gene prevented 
growth inhibition, whereas non-cognate cdiI
536
 provided no protection (Fig. 4B). Thus, the 
homologous N-terminal domains of CdiA-CT
536
 and CdiA-CT
ECL
 appear to function 
similarly in cell import. 
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The N-terminal domain of CdiA-CT
536
 is sufficient for cell import 
 The shared N-terminal domain of CdiA-CT
536
 and CdiA-CT
ECL
 is required for toxin 
import, suggesting that it carries tethered nuclease domains into the cell. We tested this 
hypothesis by asking whether the N-terminal domain still supports translocation when fused 
to a heterologous passenger domain. We fused residues Val1 – Tyr82 of CdiA-CT536 to the 
C-terminal nuclease domain of colicin E5 (ColE5-CT, residues Ala451 – Gln556) (Fig. 5A). 
We chose the ColE5-CT domain as a passenger because it is similar in size and activity to the 
CdiA-CT
536
 tRNase domain (Fig. 5A) 
101,110
. Although full-length colicin E5 enters and kills 
E. coli cells 
101
, the isolated ColE5-CT domain has no inhibition activity because it lacks 
receptor-binding and translocation domains (Figs. 5A & 5B). We fused the N-terminal 
domain of CdiA-CT
536
 to the ColE5-CT nuclease domain and tested the purified fusion 
protein on E. coli cultures. The fusion had weak activity against E. coli X90 cells (data not 
shown), but inhibited E. coli XL-1 cells more profoundly (Fig. 5B). This growth inhibition 
was blocked when cells express the imE5 gene (Fig. 5B), which encodes an immunity protein 
that specifically neutralizes ColE5-CT activity 
101,110
. Because ColE5-CT cleaves the 
anticodon loops of tRNA
His
, tRNA
Tyr
, tRNA
Asp
 and tRNA
Asn
 molecules 
101
, we examined 
tRNA
Tyr
 by northern blot to detect nuclease activity. Cleaved tRNA
Tyr
 was detected in treated 
cells that either lack immunity or express cdiI
536
 (Fig. 5C). By contrast, there was less 
cleaved tRNA
Tyr
 in cells that express imE5 (Fig. 5C), consistent with the ability of ImE5 to 
neutralize ColE5-CT activity. Together, these results indicate that the N-terminal domain of 
CdiA-CT
536
 is sufficient to translocate the colicin E5 nuclease domain into E. coli cells. 
 
CdiA-CT
536 
import is independent of BamA, Tol and Ton translocation pathways 
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 Cell-mediated CDI requires specific receptors on target cells. Therefore, we asked 
whether CdiA-CT
536
 import requires the BamA receptor using bamA101 mutant cells, which 
have approximately five-fold less BamA on the cell surface and are significantly resistant to 
cell-mediated CDI 
168,169
. E. coli bamA101 cells were inhibited by purified CdiA-CT
536
 to the 
same extent as bamA
+ 
cells (Fig. 6A), suggesting the toxin is not imported through the usual 
CDI pathway. This result led us to consider other mechanisms for CdiA-CT
536
 import. 
Colicins exploit either the Tol or Ton systems to translocate their toxin domains into E. coli 
cells 
189. Therefore, we generated X90 ∆tolA and ∆tonB strains and tested these cells for 
resistance to group A (colicin E5) and group B (colicin D) colicins. As expected from 
previous studies, we found that ∆tolA cells were completely resistant to colicin E5, but 
inhibited by colicin D (Fig. 9). Reciprocally, ∆tonB cells were resistant to colicin D and 
inhibited by colicin E5 (Fig. 9). Moreover, X90 ∆tolA cells were resistant to phage M13, but 
not phage R17 (Table 1), consistent with the established phenotype of this mutant. We then 
treated the ∆tolA and ∆tonB strains with purified CdiA-CT536 and found that the mutants 
were as sensitive as tolA
+
 tonB
+
 cells (Figs. 6B & 6C). We also tested a ∆tolA ∆tonB strain to 
test for possible redundancy and found that the double mutant was also inhibited by CdiA-
CT
536
, though it grew to slightly higher density than treated tolA
+
 tonB
+
 cells (Fig. 6D). 
Together, these findings suggest that purified CdiA-CT
536
 toxin enters E. coli cells through a 
novel pathway. 
 
CdiA-CT
536 
import requires the F pilus 
 Although E. coli X90 and XL-1 strains are inhibited by purified CdiA-CT
536
, E. coli 
strain MC4100 is resistant to the toxin (data not shown). There are several genetic 
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differences between these strains, but both sensitive strains carry F´ episomes whereas the 
resistant stain does not. Therefore, we tested E. coli X90 cells that had been cured of F´ and 
found that this isolate is resistant to purified CdiA-CT
536
 (Fig. 7A). Reintroduction of a 
different F´ episome (from E. coli XL-1) into the cured X90 cells restored toxin sensitivity 
(Fig. 7A). Moreover, E. coli MC4100 cells that carry F´ were also sensitive to purified CdiA-
CT
536
 (data not shown). Together, these results indicate that one or more genes on F are 
required for CdiA-CT
536
 import. As a first step to identify F-encoded import gene(s), we 
tested whether cells carrying a subset of F genes are sensitive to CdiA-CT
536
. Plasmid 
pOX38::gent is derivative of F that contains the tra genes required for conjugation and a 
selectable gentamicin-resistance (gent) marker 
183,190
. We introduced pOX38::gent into E. 
coli X90 F
–
 and found that the resulting cells were sensitive to CdiA-CT
536
 (Fig. 7A), 
suggesting that tra gene(s) could mediate toxin import. We took a candidate approach and 
disrupted two genes, traA and traT, that encode abundant cell-surface proteins. The traA 
gene encodes F pilin, which polymerizes to form the conjugative pilus; and traT encodes an 
outer-membrane β-barrel protein that functions to prevent mating between F+ cells 191,192. The 
∆traT mutant was still inhibited by CdiA-CT536, but ∆traA cells were completely resistant to 
purified toxin (Fig. 7B). To exclude possible polar effects from the ∆traA mutation, we 
complemented the mutant with plasmid-borne traA and restored sensitivity to the toxin (Fig. 
7C). These results suggest that the F pilus is required for the import of CdiA-CT
536
 toxin. 
 
CdiA-CT
536
 blocks F-mediated conjugation 
 We hypothesized that the N-terminal domain of CdiA-CT
536
 binds directly to F pili 
and exploits the organelle to enter cells. This import pathway could be analogous to that used 
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by some F-dependent bacteriophages to infect E. coli F
+
 cells. Therefore, we examined traA 
mutations that confer resistance to phage R17, reasoning that these alleles may also protect 
cells from purified CdiA-CT
536
. We focused on the Asp74Gly and Gly120Cys mutations, 
because they produce functional conjugative pili, but interfere with phage R17 binding 
193,194
. 
We introduced each mutation into plasmid-borne traA and used the constructs to complement 
X90 ∆traA::cat mutants. Each pilin variant supported conjugation, though the mating 
efficiency was somewhat reduced by the Asp74Gly mutation (Table 2). The mutant pilins 
also provided resistance to phage R17, but not phage M13 (Table 1). Cells expressing the 
Asp74Gly pilin were still inhibited by purified CdiA-CT
536
, but the Gly120Cys mutation 
provided partial protection against the toxin (Figs. 7D & 7E). These results suggest that 
CdiA-CT
536
 binds F pili at a site that overlaps with the phage R17 binding site. 
 Because F-dependent bacteriophage bind directly to F pili, they can interfere with 
conjugation 
195
. We reasoned that if CdiA-CT
536
 binds directly to the F pilus, then it may also 
reduce mating efficiency. We first tested the effects of M13 and R17 phages on mating 
efficiency. The phages were inactivated with ultraviolet radiation to prevent infection and 
cell lysis, then added to conjugation co-cultures. The phage particles reduced mating 
efficiency to ~50% from about 88% for mock-treated cultures (Fig. 8). We next tested 
purified CdiA-CT
536
 carrying the His178Ala mutation so that the F
+
 donor cells were not 
inhibited during culture. Purified CdiA-CT
536
 at 1 µM reduced mating efficiency 
approximately 2.5-fold compared to mock-treated cells (Fig. 8). By contrast, the purified 
tRNase domain (which lacks the N-terminal domain of CdiA-CT
536
) had little effect on 
mating efficiency (Fig. 8). Similarly, the Cys-less and DUF638-containing toxins (see Fig. 
2A) also had no substantive effect on conjugation (Fig. 8). These observations suggest that 
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the tRNase domain and the latter CdiA-CT
536
 variants do not inhibit cell growth because they 
do not bind to F pili. Taken together with the protective effect of the traA(G120C) mutation, 
these results support a model in which the N-terminal domain of CdiA-CT
536
 binds to the F 
pilus. 
 
trbI mutants are resistance to F-dependent bacteriophage and CdiA-CT
536
 
 F pili are dynamic and undergo cycles of extension and retraction 
196
. Pilus retraction 
is critical for F-dependent phage infection and provides a possible mechanism to internalize 
CdiA-CT
536
 toxin. The trbI gene is thought to be required for pilus retraction 
197
, so we 
generated an in-frame trbI deletion strain for analysis. We found that ∆trbI cells are resistant 
to both R17 and M13 phage (Table 1), but still capable of conjugation, albeit at lower 
efficiency than wild-type cells (Table 2). These observations indicate that the ∆trbI mutant 
produces functional F pili as reported previously 
197. We next treated ∆trbI cells with purified 
CdiA-CT
536
 and found that the mutant was fully resistant to the toxin (Fig. 7F). We 
attempted to complement the mutant with plasmid-borne trbI, but were unable to do so with 
both IPTG- and arabinose-inducible trbI constructs (data not shown). We note that 
Maneewannakul et al. could not complement trbI mutants with multi-copy plasmids. 
Moreover, they reported that trbI over-expression in wild-type cells phenocopies the trbI null 
mutation 
197
. We also found that trbI over-expression in the trbI
+
 background conferred 
resistance to CdiA-CT
536, similar to the ∆trbI phenotype (Fig. 7F). Therefore, pili dynamics 
appear to be adversely affected by under- and over-expression of trbI 
197
. These results are 
consistent with a model in which pilus-bound toxin is internalized during retraction. 
 
53 
 
Discussion 
 The experiments presented here reveal an unexpected import pathway for CDI toxins. 
Purified CdiA-CT
536 
and CdiA-CT
ECL
 enter E. coli F
+
 cells and inhibit growth. These toxins 
inhibit growth using different C-terminal nuclease domains, but they share a common N-
terminal domain. The N-terminal domain is not necessary for nuclease activity in vitro 
123
, 
but is required for toxin translocation into F
+
 cells. These results indicate that the N-terminal 
domain has autonomous import activity and carries tethered passenger domains into the cell. 
Indeed, the translocation domain is capable of transporting a heterologous nuclease domain 
from colicin E5 into F
+
 cells. Several observations suggest that toxin import requires a 
binding interaction between the N-terminal domain and F pili. First, purified CdiA-CT
536
 
interferes with mating when added to conjugation co-cultures. The same phenomenon is 
observed with phage R17 and M13 particles, both of which bind directly to F pili. 
Presumably, the binding of either phage or toxin to F pili disrupts the formation of 
conjugation bridges. This effect is specific because the C-terminal tRNase domain of CdiA-
CT
536
 has little to no effect on mating efficiency, and mutations within the N-terminal 
domain that block cell-import also abrogate the toxin's effect on conjugation. Furthermore, 
cells expressing F pilin with the Gly120Cys mutation are significantly resistant to purified 
CdiA-CT
536
. This mutation also disrupts the interaction between F pili and phage R17 
194
, 
suggesting that phage and CdiA-CT
536
 share overlapping binding sites. Taken together, these 
results indicate that CdiA-CT
536
 and CdiA-CT
ECL
 contain a pilus-binding domain that 
facilitates entry into F
+
 cells.  
 F pili are dynamic structures that extend in search of potential mating partners and 
retract to bring donor and recipient cells together to establish conjugation bridges 
196,198
. This 
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cycle of extension and retraction also provides a possible mechanism to import CdiA-CT
536
 
toxin across the cell envelope. Retraction is driven by pilus disassembly into pilin monomers 
within the inner membrane 
199
. Therefore, pilus-bound CdiA-CT
536
 could be carried directly 
to the inner membrane during retraction. If this model is correct, then the toxin must remain 
stably associated with the pilus as it retracts through the lumen of the type IV secretion 
assembly. Type IV secretion assemblies are large, barrel-shaped structures that span the 
entire cell envelope 
200,201
. The F-pilus assembly is composed of a hetero-oligomeric complex 
of TraV, TraK and TraB, with a tetradecameric ring of TraV forming an aperture in the outer 
membrane through which the pilus emerges 
202
. Presumably, TraV forms a tight seal around 
the pilus to prevent the loss of periplasmic contents to the media. Therefore, the associated 
CdiA-CT
536
 must pass through the TraV aperture and not be stripped from the pilus surface. 
Pilus retraction is also critical for F-dependent phage infection, and a number of phage-
resistance mutations appear to disrupt pilus dynamics 
203,204
. These resistance mutations are 
unmapped, and to our knowledge, trbI is the only F gene to be specifically linked to defects 
in pilus retraction 
197
. As predicted by the retraction-import model, in-frame deletion of trbI 
protects F
+
 cells from CdiA-CT
536
, just as it provides resistance to F-dependent phages 
197
. 
However, we note that pili dynamics have not been directly examined in ∆trbI mutants. The 
retraction-import model would be strengthened if ∆trbI retraction defects could be confirmed 
through real-time video microscopy as described by Silverman and colleagues 
196
. 
 As outlined above, there are parallels between CdiA-CT
536
 import and infection by F-
dependent phages. Two bacteriophage families exploit conjugative pili as host-cell receptors. 
The Inoviridae are filamentous, single-strand DNA viruses (e.g. phages fd and M13) that 
bind to the tip of the pilus using the g3p capsid protein 
193,194
. These phages also require TolA 
55 
 
as a co-receptor 
205
. However, CdiA-CT
536
 import does not require TolA, suggesting that the 
toxin is internalized through another pathway. Moreover, CdiA-CT
536
 appears to bind F pili 
in a manner similar to phage R17 and other leviviruses. The Leviviridae are icosahedral, 
single-strand RNA viruses that attach to the side of conjugative pili using a single copy of the 
maturation (or assembly) protein present in the phage capsid 
206-208
. Upon binding the pilus, 
the maturation protein is released from the capsid and proteolytically processed into two 
fragments 
209-211
. These peptide fragments remain associated with the phage genome and are 
internalized with viral RNA during infection 
209,212,213
. The internalization process also 
requires TraD motor function and other plasmid-transfer initiation proteins 
214-217
. Together, 
these observations suggest that the maturation protein guides the tethered genome into the 
cytoplasm. A similar mechanism may underlie CdiA-CT
536
 import into F
+
 cells. Although the 
N-terminal domain of CdiA-CT
536
 lacks homology with known maturation proteins, we note 
that these proteins are quite diverse between different phage 
218,219
. For example, the 
maturation proteins from MS2, GA and Qβ phages are only 26 – 49% identical to one 
another, yet are all thought to bind along the shafts of F pili. Given this sequence diversity, it 
seems reasonable to posit that the N-terminal domain of CdiA-CT
536
 mimics a leviviral 
maturation protein. 
 In principle, pilus-mediated import provides an additional mechanism to deliver CDI 
toxins into target bacteria. However, it is not clear that this mode of delivery occurs naturally. 
We have previously reported that E. coli EC93 cells release CdiA fragments into the 
extracellular milieu, but these fragments are not inhibitory 
112
. Similarly, CdiA
536
 fragments 
from UPEC 536 culture supernatants do not inhibit the growth of F
+
 cells (C.M.B & C.S.H., 
unpublished data). Another possibility is that the binding of CdiA
536
 to F pili augments cell-
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cell interactions to potentiate CDI. We have found that F
+
 cells are generally better CDI 
targets than F
–
 cells, but this is also true for CdiA effector proteins that lack the pilus-
interaction domain (C.M.B & C.S.H, unpublished data). Thus, there is no evidence that full-
length CdiA
536
 on the surface of inhibitor cells binds to F pili on target cells. If the interaction 
with F pili plays no role in cell-mediated CDI, then what is the biological significance of 
these findings? We hypothesize that these phenomena reflect a critical function for the N-
terminal domain in transport across the target-cell inner membrane during CDI. In this 
model, the unusual pilus-binding activity of CdiA-CT
536
 allows the toxin to by-pass the CDI 
receptor and gain entry into the periplasm. Once in the periplasm, the toxin is predicted to 
resume its normal translocation pathway, using the N-terminal domain to cross the inner 
membrane and enter the cytoplasm. Though this model has not been tested directly, there is 
evidence that the N-terminal domain of CdiA-CT
536
 is critical for CDI. Mutation of residues 
Cys3028/Cys3034 within full-length CdiA
536
 abrogates CDI, but still allows transfer of 
CdiA-CT
536
 toxin antigen to the surface of target bacteria (Julia S. Webb & D.A.L., 
unpublished data). These observations indicate that CDI is disrupted at a later stage in the 
pathway, as expected for a defect in toxin translocation. If this model is correct, then our 
results suggest that CDI toxins and leviviral genomes may use the same basic mechanism to 
cross the inner membrane of bacteria. 
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Table 1. Bacteriophage plating efficiency
a
 
 Bacteriophage 
Bacterial strain R17 M13 
X90 ∆tolA 0.93 ± 0.12 0.0b 
X90 ∆tonB 1.2 ± 0.26 1.0 ± 0.20 
X90 ∆tolA ∆tonB 1.1 ± 0.15 0.0b 
X90 ∆traA::cat pTrc 0.0b 0.0b 
X90 ∆traA::cat  pTrc::traA 1.2 ± 0.18 1.2 ± 0.15 
X90 ∆traA::cat  
pTrc::traA(D74G) 
0.0
b
 1.1 ± 0.09 
X90 ∆traA::cat  
pTrc::traA(G120C) 
0.09 ± 0.005
c
 0.77 ± 0.06
c
 
X90 ∆trbI::cat 0.1 ± 0.04c 0.1 ± 0.03c 
a
The indicated bacterial strains were infected with 10 and 100 plaque forming units (pfu). 
The number of plaques for each strain was divided by the plaques obtained with wild-type 
X90 cells. The mean plating efficiency ± SEM is reported (n = 4). 
b
No plaques were detected when bacteria were incubated with 10
3
 pfu of phage. 
c
Plaques were turbid. 
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Table 2. Mating efficiency
a
 
F
+
 donor strain 
Percent 
exconjugants (%) 
CH11717 79 ± 2.8
 
CH11717 ∆traA::cat  0.0 
CH11717 ∆traA::cat pTrc 0.0 
CH11717 ∆traA::cat  pTrc::traA 75 ± 5.4 
CH11717 ∆traA::cat  
pTrc::traA(D74G) 
58 ± 5.7 
CH11717 ∆traA::cat  
pTrc::traA(G120C) 
72 ± 0.5 
CH11717 ∆trbI::cat 13 ± 3.6 
a
Donor strains were derived from strain CH11717, which is X90 transduced with the 
Tn10 marker from E. coli XL-1. Donors were cultured at a 1:10 ratio with Str
R
 recipient cells 
as described in Methods. Mating efficiency was determined by dividing the number of Tet
R
 
Str
R
 colonies by the number of total Tet
R
 colonies and expressed as a percent. The mean 
plating efficiency ± SEM is reported for three independent experiments. 
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Figure 1. Purified CdiA-CT
536
 inhibits E. coli cell growth. A) Purified CdiA-CT (CT) or 
CdiA-CT/CdiI (CT/CdiI) complex was added to E. coli X90 cultures at 30 min (indicated by 
the arrow) and cell growth monitored by measuring the optical density at 600 nm (OD600). B) 
E. coli X90 cells carrying plasmid-borne cdiI
536
 or cdiI
3937
 immunity genes were treated with 
purified CdiA-CT
536
 where indicated the arrow. C) Northern blot analysis of CdiA-CT
536
 
treated cells. Total RNA was isolated from the cells in panel B and tRNAICG
Arg
 analyzed by 
northern blot. The migration positions of full-length and cleaved tRNAICG
Arg
 are indicated. 
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Figure 2. The N-terminal domain of CdiA-CT
536
 is required for import. A) CdiA-CT
536
 
constructs. Predicted domain organization for the C-terminal region of CdiA
536
 is depicted 
with the corresponding residue numbers. Residues Val3016 – Asn3019 comprise the VENN 
peptide motif. DUF638 is a domain of unknown function corresponding to Pfam PF04829. 
B) E. coli X90 cells were treated with the indicated CdiA-CT
536
 fragments and cell growth 
monitored by OD600 measurements. 
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Figure 3. CdiA-CT
536
 toxicity. Arabinose-inducible cdiA-CT
536
 expression plasmids were 
introduced into E. coli X90 and transformants selected on LB-agar supplemented with 
tetracycline and L-arabinose. CdiA-CT
536
 requires activation by CysK, therefore E. coli 
∆cysK cells were used to control for transformation efficiency. Construct nomenclature 
corresponds to that introduced in Fig. 2A. The His178Ala mutation ablates tRNase activity 
and plasmid pCH450 is the empty vector. 
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Figure 4. CdiA-CT
ECL
 from Enterobacter cloacae inhibits E. coli cell growth. A) 
Alignment of the CdiA-CT regions from UPEC 536 (Uniprot: Q0T963), Enterobacter 
cloacae ATCC 13047 (D5CBA0), Yersinia pestis 91001 (Q74T84) and Photorhabdus 
luminescens TT01 (Q7MB60). Proteins were aligned using Clustal-W and rendered with 
Jalview 2.8 at 30% sequence identity. The conserved cysteine residues within the N-terminal 
domain are depicted in red. B) Purified CdiA-CT
ECL
 was added to E. coli X90 cultures when 
indicated (downward arrow) and cell growth monitored by OD600 measurements. Where 
indicated, cells carried plasmid-borne cdiI
536
 (cdiI
536
) or cdiI
ECL
 immunity genes. 
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Figure 5. The N-terminal domain of CdiA-CT
536
 is sufficient for import. A) Colicin E5 is 
composed of translocation, receptor-binding and nuclease domains. The C-terminal domain 
(ColE5-CT) has anticodon nuclease activity. The NT
536
-CT
E5
 protein contains residues 
Val3016 – Gly3097 of CdiA536 fused to the ColE5-CT nuclease domain. B) E. coli XL-1 
cells were treated with purified ColE5-CT or NT
536
-CT
E5
 fusion at 30 min (indicated by the 
arrow) and growth monitored by OD600 measurements. Where indicated, cells carried 
plasmid-borne cdiI
536
 (cdiI
536
) or imE5 immunity genes. C) Northern blot analysis of toxin-
treated cells. Total RNA was isolated from the cells in panel B and tRNA
Tyr
 analyzed by 
northern blot. The migration positions of full-length and cleaved tRNA
Tyr
 are indicated. 
 
 
 
 
 
 
 
64 
 
Figure 6. CdiA-CT
536
 is not translocated via known toxin-import pathways. Wild-type E. 
coli X90 and the indicated mutants were treated with purified CdiA-CT
536
 where indicated 
(+CT), and cell growth was monitored by OD600 measurements. A) E. coli X90 (bamA
+
) and 
bamA101 mutants. B) E. coli X90 ∆tolA mutants. C) E. coli X90 ∆tonB mutants. D) E. coli 
X90 ∆tolA ∆tonB mutants. 
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Figure 7. The F pilus is required for CdiA-CT
536
 import. E. coli X90 and its derivatives 
were treated with purified CdiA-CT
536
 where indicated (+CT), and cell growth was 
monitored by OD600 measurements. A) Wild-type X90 is indicated as F´ and cured cells as F
–
. The F´::Tn10 episome and pOX38::gent (pOX38) were introduced into cured X90 and the 
resulting cells treated with CdiA-CT
536
. B) E. coli X90 ∆traA::cat and ∆traT::cat mutants. 
C) E. coli X90 ∆traA::cat cells complemented with plasmid-borne traA. D) and E) E. coli 
X90 ∆traA::cat cells complemented with plasmid-borne traA(D74G) and traA(G120C). 
Error bars correspond to the standard error of the mean for three independent experiments. F) 
E. coli X90 ∆trbI::cat mutant. Wild-type (trbI+) cells expressing trbI from a plasmid (pTrbI) 
were also tested for toxin-resistance. 
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Figure 8. Purified CdiA-CT
536
 interferes with F-mediated conjugation. The efficiency of 
conjugation was determined using the F´::Tn10 episome as described in methods. Cell 
suspensions were treated with UV-inactivated phage particles or the indicated CdiA-CT
536
 
constructs (see Fig. 2A). The CdiA-CT
536
 construct contains the His178Ala mutation to 
ablate tRNase activity. 
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Figure 9. E. coli tolA and tonB mutants are resistant to colicin E5 and D, 
respectively. A) E. coli X90 was treated with colicin E5 (ColE5, group A) at 0 min and cell 
growth monitored by optical density at 600 nm (OD600). B) E. coli X90 was treated at 0 min 
with colicin D (ColD, group B) and cell growth monitored by OD600. Strains carried tolA 
or tonB deletions where indicated. 
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Chapter 3. Receptor polymorphism restricts contact-dependent 
growth  inhibition (CDI) target range 
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Abstract 
Contact-dependent growth inhibition (CDI) systems are distributed throughout α-, β- 
and γ-proteobacteria and are thought to function in inter-cellular competition. CDI+ inhibitor 
cells express CdiA effector proteins on their surface. CdiA binds to receptors on target 
bacteria and delivers a toxin derived from its C-terminus. CDI
+
 cells also express an 
immunity protein that binds the CDI toxin and protects the cell from autoinhibition. Recent 
work has shown that CdiA
EC93
 from E. coli EC93 exploits the highly conserved BamA 
protein as a receptor, restricting its target range to E. coli strains only. Here, we identify 
OmpC and OmpF as novel receptor proteins for CdiA
UPEC536
 from uropathogenic E. coli 
strain 536 (UPEC536). OmpC is subject to very strong positive selection and exhibits 
significant variability in its extracellular loops between strains of E. coli. OmpC 
polymorphism has a dramatic effect on target cell susceptibility to CDI
UPEC536 
with our data 
indicating that loops 4 and 5 form the binding-epitope of CdiA
UPEC536
. Remarkably, many 
OmpC alleles are completely resistant to CDI
UPEC536
, while OmpC
UPEC536 
serves as an 
excellent receptor.  These results demonstrate that CDI
UPEC536
 activity is restricted to a subset 
of target strains, raising questions about the utility of these systems in intercellular 
competition. Given that the CDI
UPEC536
 appears to be optimized for toxin delivery into sibling 
UPEC536 cells, we propose that these systems function in kin selection.  
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Introduction 
Contact-dependent growth inhibition (CDI) is a bacterial competition system discovered 
in the Escherichia coli isolate, EC93
112
. Aoki et al. were curious as to how this strain was 
able to establish itself as the dominant strain of E. coli in the flora of a rat colony. Enteric 
bacteria commonly produce soluble toxins to hinder the growth of neighboring bacteria, but 
EC93 demonstrated the unique ability to inhibit the growth of other E. coli cells upon direct 
physical contact
51,112
. This competitive phenotype was termed CDI and the locus responsible 
was found to be comprised of just three genes, cdiB, cdiA, and cdiI
112
. CDI works as a two-
partner secretion system where CdiB exports the toxic effector, CdiA, onto the surface of 
cells
112
. CdiA is a large 200-600 kDa hemagglutinin repeat protein that is predicted to form a 
long β-helical filament with a toxic domain at its C-terminus220. Upon contact with 
neighboring cells, the C-terminal toxic domain (CdiA-CT) gets delivered into target cells and 
causes growth inhibition
115,116
. CdiA-CTs encode for a variety of toxins, including DNases, 
RNases, and pore-forming proteins
115
. CDI
+ 
cells are protected from their own toxin domain 
by an immunity protein that binds to and inactivates its cognate CdiA-CT
115,122
. 
The delivery process of CDI toxins remains speculative. Most CdiA-CTs act as nucleases 
that target substrates in the cytoplasm; thus they must cross the cell envelope of target 
cells
120,121
. Extensive studies have been performed on CDI
EC93
 to show that inhibition of 
target cells is dependent on the expression of the outer-membrane protein BamA (YaeT)
126
. 
BamA is a monomeric β-barrel protein with five loops that are predicted to extend into the 
extracellular space above the outer leaflet
221
. It functions in the BAM assembly complex to 
assist other β-barrel proteins to insert properly into the outer membrane222. A transposon 
insertion resulting in a 10-fold decrease in BamA expression (BamA101) results in target-cell 
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resistance to CDI
EC93 126
. Furthermore, BamA101 target cells have decreased binding to CDI
+
 
cells, and addition of anti-BamA antibodies blocks CDI
EC93 
activity
126
. Taken all together, 
these results establish BamA as the receptor protein for CDI
EC93
, though the receptor-binding 
domain of CdiA
EC93 
is not known.  
BamA is highly conserved amongst E. coli strains, but varies among even closely related 
species
118
. The regions of variability map to the extracellular loops of BamA
223
. Recently, 
Ruhe et al. established that these polymorphisms is what restricts the target range of CDI
EC93 
118
. They demonstrated that E. coli targets expressing BamA alleles from Enterobacter 
cloacae and Salmonella enterica are not susceptible to CDI
EC93 118
. Likewise, these targets 
are unable to bind CDI
EC93
 inhibitors
118
. Further analysis revealed that BamA loops 6 and 7 
form the binding-epitope for CDI
EC93 118
. This work raises questions about the use of CDI 
systems in nature. Bacteria are constantly encountering a multitude of species, so they would 
presumably want a competition system with a broad target range. However, CDI did give 
EC93 a competitive advantage in the flora of a rat colony. At this point it is unclear if all E. 
coli CdiA proteins utilize BamA as a receptor protein. Nevertheless, the fact that CDI
EC93
 is 
restricted to targeting E. coli suggests CDI systems are optimized for intra-species delivery 
and may play a role in kin selection.  
Here we demonstrate that the CDI system found in uropathogenic E. coli 536 
(CDI
UPEC536
)
 
does not utilize BamA as a receptor protein. Genetic selection and subsequent 
analyses reveal both OmpC and OmpF, the two main porins in E. coli, as the receptor 
proteins for CDI
UPEC536
. Aligning CdiA
EC93 
and CdiA
UPEC536
 gives some insight into 
identifying the receptor-binding domain as the two proteins have limited regions of 
variability. Furthermore, we demonstrate polymorphisms in the extracelullar loops of OmpC 
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restrict CDI
UPEC536
 to an even narrower target range than CDI
EC93
. Moreover, CDI
UPEC536
 
seems to be optimized for self-delivery. This work further supports the theory that CDI 
systems are involved in kin selection and reveal a potential receptor-binding domain in E. 
coli CdiA.  
 
Materials and Methods 
Bacterial strains and plasmids used in this study 
Strains or plasmids Description
a
 Reference 
Strain   
EPI100 
F
–
 mcrA ∆(mrr-hsdRMS-mcrBC) 
φ80dlacZ∆M15 ∆lacXcZ∆M15 ∆lacX recA1 
endA1 araD139 ∆(ara, leu)7697 galU galK 
λ– rpsL nupG 
Epicentre 
MFDpir 
RP4-2 Tc::[ΔMu1::aac(3)IV-ΔaphA-Δnic35-
ΔMu2::zeo] ΔdapA::(erm-pir) ΔrecA 
? 
DL4905
 
MC4100 l640-13 PpapBA-gfp-mut3, Kan
R
 
118
 
DL6536 
UPEC536 kps15::cat araBAD 
spec_araC_pBAD_cdiBAI, Cm
R 
Strpt
R 
Spec
R 
115
 
DL63881 
UPEC536 kps15::cat araBAD 
spec_araC_pBAD_cdiBACT-I, CmR StrptR 
Spec
R
 
115
 
CH2016 X90 (DE3) ∆rna ∆slyD::kan, KanR  179 
CH10226 
MC4100 bam::cat pZS21::bamA
E.coli
, 
AmpR 
This study 
CH10227 
MC4100 bam::cat pZS21::bamA
E.cloacae
, 
AmpR
 This study 
CH10013 
JCM158 spontaneous rifampicin resistance, 
Rif
R 
117
 
CH10099 JCM158Rif
R ompC This study 
CH10100 JCM158Rif
R ompF This study 
CH10136 JCM158Rif
RompC ompF This study 
CH12134 
JCM158Rif
R
 ompF ompCUPEC536::kan, 
Kan
R This study 
CH12345 
JCM158 wzb ompF ompC recA::kan, 
Kan
R This study 
CH12180 
JCM158 ompC
UPEC536
 ompF wzb 
recA::kan, KanR 
This study 
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Plasmids   
pSC189kan 
Encodes transposase and mariner transposon, 
requires Pir for replication. 
? 
pBR322::cysK Constitutive expression of CysK, Amp
R
  This study 
pCH450 
pACYC184 derivative containing E. coli 
araC and the L-arabinose-inducible ParaBAD 
promoter, Tet
R
 
182
 
pCH450Kpn::DsRed 
Arabinose-inducible expression of DsRed, 
Tet
R This study 
pZS21amp::bamA
E.coli 
Constitutive expression of bamA
E.coli
, AmpR 
118
 
pZS21amp::bamA
E.cloac
ae
 
Constitutive expression of bamA
E.cloacae
, 
AmpR 
118
 
pZS21kan 
pZS31 derivative carrying an ampicillin-
resistance cassette, Kan
R
 
This study 
pZS21kan::ompF
K12 
Constitutive expression of ompF
E.coli
, KanR This study 
pET21::colE5-immE5 Over-produces ColE5-ImmE5 -His6, Amp
R
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pTrc99aKX 
IPTG-inducible expression vector with 
KpnI/XhoI cloning sites, Amp
R
 
117
 
pTrc99aKX::ompF
K12 
Expresses OmpF
K12
, Amp
R 
This study 
pTrc99aKX::ompF
S.enter
ica
 
Expresses OmpF
S.enterica
, Amp
R
 This study 
pTrc99aKX::ompF
E.cloa
cae
 
Expresses OmpF
E.cloacae
, Amp
R
 This study 
pTrc99aKX::ompC
K12 
Expresses OmpC
K12
, Amp
R
 This study 
pTrc99aKX::ompC
S. 
enterica
 
Expresses OmpC
S.enterica
, Amp
R
 This study 
pTrc99aKX::ompC
E.cloa
cae Expresses OmpC
E.cloacae
, Amp
R
 This study 
pTrc99aKX::ompC
UPEC
536 Expresses OmpC
UPEC536
, Amp
R
 This study 
pTrc99aKX::ompC
F11
 Expresses OmpC
F11
, Amp
R
 This study 
pTrc99aKX::ompC
CFT0
73 Expresses OmpC
CFT073
, Amp
R
 This study 
pTrc99aKX::ompC
UTI89
 Expresses OmpC
UTI89
, Amp
R
 This study 
pTrc99aKX::ompC
EC93
 Expresses OmpC
EC93
, Amp
R
 This study 
pTrc99aKX::ompC
EC869
 Expresses OmpC
EC869
, Amp
R
 This study 
pTrc99aKX::ompC(E1
88G)
EC869 Expresses OmpC(E188G)
EC869 
, Amp
R
 This study 
pTrc99aKX::ompC
UTI2
 Expresses OmpC
UTI2
, Amp
R
 This study 
pTrc99aKX::ompC
UTI5
 Expresses OmpC
UTI5
, Amp
R
 This study 
pTrc99aKX::ompC
UTI8
 Expresses OmpC
UTI8
, Amp
R
 This study 
pTrc99aKX::ompC
UTI10
 Expresses OmpC
UTI10
, Amp
R
 This study 
pTrc99aKX::ompC(536
L5)
CFT073
 
Expresses the indicated OmpC, Amp
R
 This study 
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pTrc99aKX::ompC(536
L7)
CFT073
 
Expresses the indicated OmpC, Amp
R
 This study 
pTrc99aKX::ompC(536
L8)
CFT073
 
Expresses the indicated OmpC, Amp
R
 This study 
pTrc99aKX::ompC(536
L7,8)
CFT073
 
Expresses the indicated OmpC, Amp
R
 This study 
pTrc99aKX::ompC(536
L5,7)
CFT073
 
Expresses the indicated OmpC, Amp
R
 This study 
pTrc99aKX::ompC(536
L5,8)
CFT073
 
Expresses the indicated OmpC, Amp
R
 This study 
pTrc99aKX::ompC(F1
1L4)
CFT073
 
Expresses the indicated OmpC, Amp
R
 This study 
pDAL660∆1-39 Expresses CDIEC93, AmpR 112 
pDAL866 Expresses CDI
UPEC536
, Amp
R 
Cm
R 116
 
pWEB::TNC  pWEB::TNC (CDI
–
), Amp
R
, Cm
R 112
 
pCP20 
Heat-inducible expression of FLP 
recombinase, Cm
R
 Amp
R
 
225
 
a
Abbreviations: Amp
R
, ampicillin resistant; Cm
R
, chloramphenicol resistant; Kan
R
, 
kanamycin resistant; Rif
R
, rifampicin resistant; Str
R
, streptomycin resistant; Tet
R
, tetracycline 
resistant 
 
Bacterial strains and growth conditions 
The bacterial strains and plasmids used in this study are listed in the table above. 
Bacteria were grown in LB broth or LB agar unless otherwise noted. Media were 
supplemented with antibiotics at the following concentrations: ampicillin, 150 µg ml
−1
; 
kanamycin, 50 µg ml
−1
; chloramphenicol, 66 µg ml
−1
; spectinomycin, 50 µg ml
−1
; rifampin, 
200 µg ml
−1
; streptomycin, 100 µg ml
−1
. The bamA::cat allele was transduced from EPI100 
bamA::cat pZS21-bamA+ cells into MC4100 pZS21-bamA+ by bacteriophage P1-mediated 
transduction 
118
. The ∆ompC, ompF, wzb, and recA::kan gene disruptions were obtained 
from the Keio collection and introduced into E. coli JCM158Rif
R
 by P1 transduction
226
. The 
Kan
R
 cassettes were removed by transforming pCP20, selecting on LB-Amp plates at 30°C, 
then isolating colonies at 37°C. 
75 
 
pZS21kan::ompF
K12 
was made by PCR amplifying E. coli K12 genomic DNA (gDNA) 
with oligos 5' - TTT GGA TCC ATG AGG GTA ATA AAT AAT GAT G - 3' and 5' - TTT 
TCT AGA GGT GTG CTA TTA GAA CTG - 3', digesting with BamHI/XbaI and ligated to 
digested pZS21kan. pTrc99aKX::ompF alleles were made by PCR amplifying E. coli, S. 
enterica, or E. cloacae gDNA with 5' - TTT GGT ACC ATG ATG AAG CGC AAT ATT C 
- 3' (K12-ompF-for) and 5' - TTT CTC GAG TTA GAA CTG GTA AAC GAT ACC C - 3' 
for K12, 5' - TTT GGT ACC ATG AAA CTT AAG TTA GTG GCA G - 3' and 5' - TTT 
CTC GAG ATT AGA ACT GGT AGT TCA GAC C - 3' for S. enterica, and K12-ompF-for 
and 5' - TTT CTC GAG ATT AGA ACT GGT AAA CCA GAC - 3' for E. cloacae, digested 
with KpnI/XhoI and ligated into digested pTrc99aKX vector.  
All pTrc99aKX::ompC E. coli alleles were amplified with 5' - GTT GGT ACC ATG 
AAA GTT AAA GTA CTG TCC - 3' and 5' - TCA CTC GAG ATT AGA ACT GGT AAA 
CCA GAC - 3', digested with KpnI/XhoI and ligated into digested pTrc99aKX vector. 
OmpC(E188G)
EC869
, OmpC(536L5)
CFT073
,
 
OmpC(536L7)
CFT073
, OmpC(536L8)
CFT073
, 
OmpC(536L7,8)
CFT073
, OmpC(536L5,7)
CFT073
, OmpC(536L5,8)
CFT073
, OmpC(F11L4)
CFT073
 
were made via megaprimer PCR using oligos 5' - CGT TCT GAC GCA GTG CTC CAC 
GAC CGT TGT TAG T - 3' for E188G, 5' - GCT CCA AAC GTA CCG ATG CTC AGA 
ACA CCG CTG CTT ACA TAG GCA ACG GCG ACC GTG CTG - 3' for 536L5, 5' - AGG 
TAA AAA CCT GGG TAC TAT CGG TAC TCG TAA CTA CGA CGA C - 3' for 536L7, 
5' - CCA GTT CAC CCG CGA CGC TGG CAT CAA CAC TGA TAA CAT CGT AGC TC 
- 3' for 536L8, and 5' - CTT TAC GAC CAT TGT TGG TCA TGC CTT CAC CGC TTA 
CGC TGC C - 3' for F11L4.  
 
Growth competitions 
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Inhibitor and the described E. coli JCM158Rif
R
 target cells were grown to mid-log 
and mixed at a 10:1 ratio in liquid LB without antibiotics for 5 hours at 37°C with vigorous 
shaking. Samples of the co-cultures were removed, serially diluted, and plated onto selective 
LB agar to enumerate target cells as CFU ml
−1
. CDI
EC93
, CDI
UPEC536, 
CDI
-
 inhibitors are E. 
coli EPI100 cells containing pDAL660∆1-39 (CDIEC93), pDAL866 (CDIUPEC536) or 
pWEB::TNC (CDI
−
). UPEC536 CDI
+ 
or CDI
- 
inhibitors are DL6536 and DL6381, 
respectively. These latter inhibitor cells were grown in 0.2% arabinose for induction of its 
CDI locus, and 0.2% arabinose was added to the competition media. In figure 2B, the OmpC 
is being expressed in pTrc99aKX and OmpF is in pZS21kan. These are both E. coli K12 
alleles.  
Cell-cell binding 
Overnight cultures of E. coli strain DL4905 carrying cosmid pDAL660∆1-39 
(CDI
EC93
), pDAL866 (CDI
UPEC536
) or pWEB::TNC (CDI
−
) were diluted into fresh tryptone 
broth (TB) and grown to mid-log phase at 30°C. These cells were then mixed at a 5:1 ratio 
with the described E. coli JCM158Rif
R
 target cells carrying pCH450::DsRed and 
pTrc99aKX::OmpC or OmpF. In figure 2B, OmpC is being expressed in pTrc99aKX and 
OmpF is pZS21kan. The OmpC used here is from UPEC536 for more efficient binding. 
OmpF is from E. coli K12. The cell suspension was incubated with aeration for 15 min at 
30°C, diluted 1:50 into filtered 1× phosphate-buffered saline (PBS), and then analyzed on an 
Accuri C6 flow cytometer using FL1 (533/30 nm, GFP) and FL2 (585/40 nm, DS-Red) 
fluorophore filters (Becton Dickinson). 
Western blot analysis 
77 
 
Cells were grown to mid-log in 2mL liquid LB with aeration and harvested for 
protein extraction with urea lysis buffer. Equal amounts of protein were subjected to 6M urea 
10% acrylamide SDS-PAGE for 4 hours at 100V. The gel was transferred onto PVDF 
membrane, and incubated with 1:15,000 of anti-OmpC/F/A antibody, a kind gift from 
Thomas Silhavy.  
Colicin E5 purification and growth curve 
 Colicin E5 was purified as previously described
224
. Cells were grown to mid-log in 
LB-Amp and back diluted to OD600 0.05. Growth was analyzed by measuring the optical 
density every 60 minutes for 5 hours. 1 nM of colicin was added after 30 minutes of growth.  
 
Results 
CDI
UPEC536 
is not restricted by BamA
E. coli 
An alignment of CdiA
EC93 
and CdiA
UPEC536 
reveals two regions of variability (Fig. 1A). 
To test whether CDI
UPEC536 
utilizes BamA as its receptor protein, we asked if E. cloacae or S. 
enterica BamA alleles could support CDI
UPEC536
. EPI100 cells expressing CDI
EC93
, CDI 
UPEC536
,
 
or CDI
- 
cosmids were co-cultured with MC4100 bamA
- 
target cells complemented 
with E. coli or E. cloacae BamA on plasmid pZS21amp. Cells were mixed at a 10:1 ratio in 
LB broth for 5 hours and selected on LB-antibiotic plates to count cell viability (Fig. 1B). 
Firstly, each target cell grew ~1.5 logs when incubated with the control CDI
- 
inhibitors, 
indicating there is no growth defect from expressing heterologous BamA alleles. Next, 
targets expressing BamA
E. coli
 lost 3.5 and 2 logs of cell viability when competed against 
CDI
EC93 
and CDI
UPEC536 
respectively. As previously reported, target cells expressing BamA
E. 
cloacae
 are resistant to CDI
EC93
, however, these targets are still inhibited 2 logs when competed 
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against CDI
UPEC536
. These data indicate that CDI
UPEC536 
either does not require BamA as a 
receptor protein, or the epitope targeted on BamA is conserved between the two alleles 
tested.  
 
OmpC and OmpF are required for CDI
UPEC536
  
To look for novel receptor proteins targeted by CDI
UPEC536
, we set up a genetic selection 
to identify mutants that conferred resistance to CDI
UPEC536
.
 
 CdiA-CT
UPEC536  
requires the 
presence of CysK in target cells for activation
123
. Thus, plasmid-borne CysK was included in 
target cells to prevent cysK
-
 targets from coming though the screen. JCM158 pBR322::cysK 
cells were subjected to transposon mutagenesis using a mariner-based system. 
Approximately 50,000 cells containing transposon insertions were pooled and incubated with 
UPEC536 CDI
+
 inhibitor cells at a 10:1 ratio for three rounds of enrichment. After each 
round, target cell viability increased about one log and the population was completely 
resistant after round three, indicating the presence of mutants resistant to CDI
UPEC536
.  After 
proving resistance was linked to the transposon, individual mutants were subjected to 
arbitrary PCR to locate the insertion site. Ten unique transposon insertions were found in the 
open reading frames of ompC and ompF, five in each gene (Fig. 2A).  
To rule out polar effects of the transposon insertion, clean deletions of ompC and ompF 
were made in the original target strain using alleles from the Keio collection
226
. These targets 
were competed against UPEC536 CDI
+ 
and CDI
-
 mock inhibitors at a 10:1 ratio for 5 hours 
in liquid broth. Both ompC
-
 and ompF
-
 targets were completely resistant to CDI
UPEC536
 while 
WT targets lost 2 logs of viability (data not shown). Each target strain grew to full capacity 
against CDI
-
 inhibitors (data not shown). Second, plasmid-borne copies of OmpC and OmpF 
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were used to complement an ompC
-
 ompF
-
 strain. When complemented with empty vectors, 
or just OmpC or OmpF, target cells were resistant to CDI
UPEC536
, but when both OmpC and 
OmpF were present, targets became susceptible (Fig. 2B). Furthermore, each target cell 
tested grew to full capacity against UPEC536 CDI
- 
inhibitors (Fig, 2B). Taken all together, 
we have established both ompC and ompF are required for CDI
UPEC536
. 
 
OmpC and OmpF are required for cell-cell binding  
OmpC and OmpF are the two major porin proteins present in the outer membrane of E. 
coli
227. They share 60% homology and have similar β-barrel structures, though they have 
different pore sizes which facilitates selective uptake of molecules
228,229
. Both form 
homotrimers in the membrane with 7 extracellular loops per monomer. With this information 
it is reasonable to hypothesize OmpC and OmpF act as receptor proteins for CdiA
UPEC536
. As 
mentioned previously, CDI
EC93
 requires the presence of BamA to bind target cells
126
. Thus, 
we asked if both OmpC and OmpF are required for cell-cell binding.   
To do this, MC4100 GFP
+ 
cells containing cosmids expressing CDI
EC93
, CDI 
UPEC536
,
 
or 
no CDI genes were mixed with target cells expressing DsRed protein and assayed for their 
ability to bind one another by flow-cytometry. The presence of green/red aggregates 
represents inhibitor cells bound to targets. This binding event is quantified as the percent of 
targets bound to inhibitors. CDI
EC93 
inhibitors are able to bind ~ 70% of each target cell 
population due to the presence of BamA (Fig. 2C). CDI
- 
inhibitors bind ~0.5% of each target 
cell population, representing “background” levels of binding. CDIUPEC536 inhibitors bind 
targets expressing either OmpC or OmpF at background levels, but bind ~45% of OmpC
+
 
OmpF
+ 
cells (Fig. 2C). Albeit this is lower than CDI
EC93 
binding, it is still significant and 
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specific to targets expressing both OmpC and OmpF. Therefore, both OmpC and OmpF are 
required for cell-cell binding.  
 
CDI
UPEC536 
targets the extracellular loops of OmpC and OmpF 
We hypothesized CDI
UPEC536 
is targeting the extracellular loops of OmpC and OmpF, just 
as CDI
EC93 
exploits loops 6 and 7 in BamA
118
. An alignment of OmpC or OmpF to a variety 
of species demonstrates the greatest regions of variability map to the extracellular loops (Fig 
3A & 4A). We used this natural variation to test our hypothesis. To do this, we 
complemented JCM158 ompC
-
 or ompF
-
 target cells with ompC or ompF alleles from various 
species and asked if they were susceptible to CDI
UPEC536
. Each target was incubated with 
UPEC536 CDI
+ 
or CDI
- 
inhibitors at a 10:1 ratio for 5 hours. All target cells expressing an 
empty vector and all target cells incubated with CDI
- 
inhibitors grew ~1 log during co-
culture, demonstrating the foreign alleles do not affect growth (Fig. 3B & 4B). JCM158 
ompC
-
 targets expressing OmpC
E.coli
 or OmpC
E.cloacae
 lost 1-2 logs of viability while those 
expressing OmpC
S.enterica
 did not lose any viability (Fig. 3B). Similar to the OmpC results, 
JCM158 ompF
-
 targets expressing OmpF
E.coli
 or OmpF
E.cloacae
 lost about 2.5 logs of viability, 
while OmpF
S.enterica 
targets barely lost any viability (Fig. 4B). Thus, different alleles of OmpC 
and OmpF lead to varying levels of target cell susceptibility.  
Cell-cell binding was performed to see if the levels of inhibition reflected the ability of 
inhibitor cells to bind targets. To examine this, the same cell-cell binding assay was 
performed as previously described. The ability of CDI
UPEC536 
inhibitor cells to bind targets 
roughly reflects the competition results (Fig. 3C & 4C). Western blot analysis was attempted 
to show equal levels of OmpC and OmpF in each target cell. However, the antibody used was 
81 
 
raised to E. coli OmpC so this is not a reasonable method to analyze protein levels. The 
antibody did not detect OmpF
E.cloacae 
or OmpF
S.enterica
, but it did show equal levels of the 
OmpC alleles tested (data not shown). Taken all together, target cells expressing different 
alleles of OmpC and OmpF lead to varying levels of inhibition, which can be reflected in the 
ability of inhibitor cells to bind targets. Considering the main regions of variability between 
sensitive and resistant alleles are in the extracellular loops of both OmpC and OmpF, these 
data suggest CDI
UPEC536 
targets the extracellular loops of these porins.   
 
OmpC
E.coli 
polymorphism restricts CDI
UPEC536 
Not only do OmpC and OmpF vary amongst species, but they are two of the most 
positively selected proteins in E. coli
230
. This is most likely due to their function as receptor 
proteins for various bacteriophage and colicins along with being substrates for the immune 
system
230
. An alignment of OmpF from various strains of E. coli reveals two areas of 
deviation, mapping to extracellular loops 4 and 5 (Fig. 5A). Even more striking, a similar 
alignment of OmpC shows incredibly variation, including up to 8 residue insertions and 4 
residue deletions in loops 4, 5 and 7 (Fig. 5B & 5C). Given the polymorphisms seen in OmpF 
is restricted to just a few residues, we reasoned it would not vastly affect CDI
UPEC536
 and 
focused on OmpC. To test whether different E. coli OmpC alleles exhibit different levels of 
sensitivity to CDI
UPEC536
, 12 of the most divergent alleles were used to complement JCM158 
ompC
- 
target cells on plasmid pTrc99a and competed against UPEC536
 
CDI
+ 
or CDI
- 
cells. 
Each target cell grew ~ 1 log during co-culture with CDI
- 
inhibitors, indicating the variant 
alleles do not affect E. coli K12 growth (Fig. 6A). Shockingly, 5 of the alleles tested were 
completely resistant to CDI
UPEC536
 while the other 7 showed various levels of sensitivity (Fig. 
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6A).  OmpC
UPEC536 
was one of the most sensitive alleles, indicating UPEC536 CDI
+ 
cells are 
capable of self-delivery. Western blot analysis demonstrates that each OmpC allele tested 
was expressed at similar levels in target cells (Fig. 6B). These results further demonstrate that 
CDI
UPEC536 
targets the extracellular loops of OmpC, consequently restricting its target-cell 
range to a subpopulation of E. coli strains. 
 
CDI
UPEC536 
targets OmpC loops 4 and 5 
  
We have now established that CDI
UPEC536 
targets the extracellular loops of both OmpC 
and OmpF. Given that OmpF is relatively conserved amongst E. coli, we hypothesize that 
OmpC is driving the target range of CDI
UPEC536
. Therefore, we wanted to define which 
extracellular loops in OmpC serve as the binding-epitope for CdiA
UPEC536
. Given that the 
major differences between a sensitive and resistant allele are in loops 4 and 5, we reasoned 
these loops are targeted (Fig. 5B). To test this, we grafted loop 4 or 5 from a sensitive allele 
onto a resistant OmpC and asked if this sensitized the chimeric OmpC to CDI
UPEC536
. We 
chose CFT073 as the resistant allele to test, and grafted loop 4 or loop 5 from the sensitive 
F11 or UPEC536 alleles, respectively. CFT073 and UPEC536 have the same loop 4, but 
have considerable differences in loop 5 (Fig. 7A). Similarly, CFT073 and F11 have similar 
loop 5 residues, but CFT073 has an 8 residue insertion in loop 4 (Fig. 7A). JCM158 ompC
-
 
target strains were complemented with the chimeric ompC alleles on plasmid pTrc99a and 
incubated with CDI
+ 
or
 
CDI
- 
UPEC536 inhibitor cells. Targets expressing the chimeric ompC 
alleles showed no growth defect against CDI
- 
inhibitors, and as predicted OmpC
CFT073 
with 
either L5
UPEC536 
or L4
F11 
are fully sensitive to CDI
UPEC536 
(Fig. 7B). Interestingly, these 
results demonstrate that having a sensitive L4 is not sufficient for target cells to be 
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susceptible to CDI
UPEC536
, as the resistant CFT073 allele and sensitive UPEC536 allele share 
the same L4 sequence. These results indicate that OmpC loops 4 and 5 are important 
determinants for target cell susceptibility to CDI
UPEC536
.  
Crystal structure analysis of various E. coli OmpC proteins reveals that loops 4 and 5 are 
close enough to interact with one another (Fig. 5C)
229,231
. Polymorphisms in these loops 
amongst the crystalized alleles have a drastic effect on the positioning of the loops in the 
structure (Fig. 5C). With this information, along with the results from the loop-swap 
experiments performed above, we postulate that the interaction between loops 4 and 5 in 
OmpC is important for CDI
UPEC536
. OmpC
EC93 
is the most sensitive allele to CDI
UPEC536 
that 
we have identified thus far with target cells losing ~3.5 logs of viability (Fig. 8C). There are 
only 5 residues that differ in OmpC
EC869
 compared to OmpC
EC93 
(Fig. 8A), yet target cells 
expressing OmpC
EC869 
only lose 0.5-1 log of viability (Fig. 8C). Further analysis reveals that 
one of these differences, the G188E change in loop 4 of OmpC
EC869 
has the potential to 
influence the interaction between loops 4 and 5. The crystal structure of OmpC
UTI2
, an allele 
that is resistant to CDI
UPEC536
, shows that residue D231 in L5 in all 3 alleles comes in close 
proximity to E188 in L4 (Fig. 8B)
231
. When we made OmpC
EC869 
with residue E188 changed 
to a glycine, it became fully sensitive to CDI
UPEC536 
(Fig. 8C). Additionally, western blot 
analysis reveals there are similar levels of OmpC in each target cell (Fig. 8D).  Taken all 
together, these data suggest our hypothesis is correct; the interaction between loops 4 and 5 
in OmpC is important for CDI
UPEC536
 and likely make up at least part of the binding-epitope 
for CdiA
UPEC536
.  
 
OmpC/F heterotrimers support CDI
UPEC536 
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The fact that both OmpC and OmpF are required for CDI
UPEC536 
and target-cell binding is 
puzzling. There are three models that support this observation. First, one porin could act as 
the receptor and the other a translocator (translocator model), similar to how colicins transit 
through the outer membrane. Colin-bound receptor recruits a translocator to facilitate colicin 
entry into the periplasm
51
. In fact, most group A colicins use OmpF as their translocator
51
. 
Second, CdiA
UPEC536 
could bind to OmpC and OmpF homotrimers that are next to one 
another in the membrane (double-receptor model). This seems feasible as they are the two 
most abundant outer-membrane proteins in E. coli
232
. Lastly, OmpC and OmpF are 60% 
homologous and have been shown to form heterotrimers in vivo
233
. The “heterotrimer model” 
suggests a  2:1 or 1:2 ratio of OmpC to OmpF could act as the receptor protein. The fact that 
there are examples of OmpC and OmpF alleles from different species that do not support 
CDI
UPEC536
 suggests CdiA
UPEC536 
is interacting with a specific epitope on both OmpC and 
OmpF. Unfortunately, this does not rule out any of these models, it is just perhaps suggestive 
of the latter two. 
To test the heterotrimer model, we tried to covalently fuse 3 OmpF proteins together by 
linking 3 ompF genes on plasmid pTrc99a with 7 or 16 residue linkers between the 
monomers. Consequently, only homotrimers of OmpF or OmpC would be present in the 
outer membrane of target cells. If these cells are resistant to CDI
UPEC536
, this would suggest 
heterotrimers act as the receptor protein. Unfortunately, all efforts put into making this cell 
line failed, as the covalently linked trimer could not properly insert into the outer membrane 
(Fig. 9B & 9D). However, we were able to successfully link 2 OmpF proteins together with 
both the 7 (short) and 16 (long) residue linker sequences connecting the two monomers.  
85 
 
To test if the OmpF dimers are folding and inserting into the outer membrane properly, 
ompF
- 
cells were complemented with empty vector, monomeric or dimeric OmpF on a 
pTrc99a plasmid and incubated with 1 nM of colicin E5. This is a group A colicin that 
requires OmpF to enter cells and subsequently cleave a subset of tRNAs to cause cell death
51
. 
Addition of colicin E5 to cells expressing OmpF dimers were inhibited to the same level as 
WT cells or cells expressing OmpF monomers (Fig. 9C). Additionally, each cell line grew at 
the same rate and to the same level when no colicin was added, suggesting there is no growth 
defect from expressing dimeric OmpF (Fig. 9C). Furthermore, a western blot reveals full-
length OmpF dimer and no degradation products, assuring the dimer did not get processed 
into monomeric OmpF (Fig. 9D). However, OmpF naturally forms trimers in the membrane 
and it seems unlikely that the dimeric form is in the membrane on its own. Rather, dimeric 
OmpF is most likely forming a heterotrimer with OmpC to be able to insert properly and be 
functional in the membrane.  
If this is the case, cells expressing dimeric OmpF but lacking ompC should not be able to 
insert OmpF into the outer membrane, rendering them resistant to colicin E5. To test this, 
ompF
-
 ompC
-
 cells were complemented with empty vector, monomeric OmpF or dimeric 
OmpF on plasmid pTrc99a and subjected to 1 nM colicin E5. Only WT cells and cells 
expressing monomeric OmpF were inhibited by the colicin. All other cells grew to the same 
level, indicating OmpF is not present on their surface (Fig. 9A). Furthermore, western blot 
analysis again showed full-length OmpF dimers present in these cells (Fig 9B). This 
illustrates that dimeric OmpF cannot insert into the membrane without the presence of 
OmpC. Taken all together, these results demonstrate that an OmpF dimer and OmpC 
monomer can form functional heterotrimers in the outer membrane of E. coli cells. 
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Now we asked if CDI
UPEC536 
can utilize OmpC/F heterotrimers as a receptor. The same 
ompC
+ 
ompF
-
 cells complemented with monomeric or dimeric OmpF were competed against 
EPI100 cells expressing CDI
UPEC536
 or no CDI
 
genes. Incredibly, CDI
UPEC536 
inhibits target 
cells expressing OmpF dimers to the same level as WT targets, or targets expressing OmpF 
monomers (Fig. 10A). Furthermore, each target strain grew to equivalent levels against CDI
- 
inhibitors (Fig. 10A). Next, CDI
UPEC536
 was assayed for its ability to bind cells containing 
OmpC/F heterotrimers. The targets used in the competition assay were transformed with 
pCH450::DsRed and incubated with MC4100 GFP
+ 
cells expressing CDI
EC93
, CDI
UPEC536
, or 
no CDI genes. Consistent with the competition results, CDI
UPEC536 
could bind to target cells 
that contained OmpC/F heterotrimers (Fig. 10B). Thus, OmpC/F heterotrimers form a 
functional receptor for CDI
UPEC536
. 
 
Discussion 
The work presented here establishes OmpC and OmpF as novel receptor proteins for 
CDI
UPEC536
. Both porins are required for CDI and cell-cell binding, and changes in the 
extracellular loops of each protein can affect target cell susceptibility. This suggests 
CdiA
UPEC536 
binds to both OmpC and OmpF on target cells. We demonstrate that CDI
UPEC536 
can target heterotrimers of OmpC/F, supporting Nikaido’s original observation that 
functional OmpC/F heterotrimers exist in vivo
233
. Unfortunately this does not prove 
heterotrimers act as the exclusive receptor because we only showed they are capable and not 
required to support CDI. However, if heterotrimers are the relevant targets for CdiA
UPEC536
, 
suitable environmental conditions would be required for effective CDI because ompC and 
ompF expression fluctuates based on media osmolarity. OmpF is preferentially expressed in 
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low osmolarity or high cAMP levels, and while OmpC dominates in high osmolarity. We 
only tested a 2:1 OmpF to OmpC ratio, but if this is the relevant ratio to form a functional 
receptor, it seems environmental conditions, and therefore levels of each porin present could 
affect the efficiency of CDI.  
Furthermore, this works demonstrates that BamA is not the universal receptor for all E. 
coli CDI systems. In fact, BamA might be the outlier. The amount of variability seen in the 
extracellular loops of OmpC could conceivably support discrete binding sites for multiple 
CdiA proteins. In support of this model, the CDI system found in Enterobacter cloacae 
ATCC 13047
 
also uses both OmpC and OmpF as receptor proteins, and seems to target a 
different epitope on OmpC than CDI
UPEC536
 (data not shown). An alignment of CdiA from 
EC93 and UPEC536 shows two regions of variability, the greatest one clustered around 
amino acids 1300-1600 (Fig. 1A). Given these two CDI systems target distinct receptor 
proteins, it seems conceivable that this region corresponds to the receptor-binding domain of 
CdiA. Identifying this domain is enticing as it could lead to the ability to engineer CDI 
systems capable of targeting specific species or even strains of bacteria. This has promising 
implications for the design of antibiotics specific to the pathogen present in a host.   
CDI
EC93 
was shown to target loops 6 and 7 of BamA
E.coli
, limiting its target range to 
strictly E. coli
118
. OmpC and OmpF vary amongst strains of E. coli with extracellular loops 4 
and 5 in OmpC showing the greatest amount of polymorphism. We illustrated that these two 
loops are targeted by CDI
UPEC536
, limiting its target range even further than CDI
EC93
 to 
specific strains of E. coli. Interestingly, all five resistant ompC alleles tested are from 
uropathogenic E. coli (UPEC). OmpC and OmpF are two of the most positively selected 
proteins in E. coli, but also specifically in UPEC strains
230,234
. Given that UPEC536 shares 
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the same niche as these other urinary tract infection (UTI) strains, it seems unusual for 
CdiA
UPEC536 
to target such polymorphic receptor proteins. In fact, we sequenced the ompC 
allele from 52 human UPEC isolates, and 46 cat or dog UPEC isolates and found 33 unique 
OmpC proteins. Of these 33, 19 were resistant to CDI
UPEC536
.  This raises questions about the 
function of CDI
UPEC536 
as a competition system in nature. Given its selective target range and 
the ability to proficiently target its own OmpC, this suggests CDI
UPEC536 
is optimized to 
deliver into sibling cells as a mechanism of kin selection. 
One idea, which was proposed by Ruhe et al., is that CDI systems can be used to regulate 
community behavior. When bacteria decide to switch to the pathogenic state, it requires the 
group to collectively turn on the proper genes, which are often located in pathogenicity 
islands (PAIs)
235
. This is going to come at a cost to the cell as is must use protein machinery 
and ATP to make and the resources needed to invade a host. If there are siblings in the 
population that have failed to turn on their pathogenic genes (“cheaters”) this can prevent the 
group from efficiently invading the host
236
. CDI
UPEC536 
is located in pathogenicity island-II in 
UPEC536. In fact, CDI systems are typically found in PAIs. While nothing is known about 
the regulation of CDI
UPEC536
, one could imagine a situation where it is under the same 
regulation as the pathogenic genes found in the island. If a cell has neglected to start 
expressing those genes, it will not be protected from sibling cells delivering CdiA-CT
 
because it is not expressing its cognate immunity protein, CdiI. This would allow CDI
+ 
cells 
to pick out “cheaters” in the population when the group has decided to turn pathogenic and 
invade a host
237
. While this is completely speculative, it is supported by the presence of CDI 
systems in PAIs, as well as the restricted target range seen now in CDI
EC93
and CDI
UPEC536
.  
Furthermore, with the evidence of OmpC and OmpF being under positive selection in UPEC 
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strains, and CdiA
UPEC536 
existing exclusively in UPEC strains, perhaps CDI is a method of 
kin selection within UTI strains.  
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Figure 1. CDI
UPEC536 
is not restricted by BamA
E. coli
. A) An alignment of residues 1200-
2400 of CdiA from EC93 and UPEC536. Full length CdiA is 3132 and 3201 residues for 
EC93 and UPEC536, respectively. Boxed regions highlight the regions of variability seen 
between the two proteins. Alignment was performed by PRALINE Multiple Sequence 
Alignment. B) MC4100 bamA::cat target cells expressing either BamAE. coli  or BamAE. 
cloacae 
were co-cultured with EPI100 inhibitor cells expressing CDI
EC93
,
 
CDI
UPEC536 
, or CDI
- 
cosmids for 5 hours in LB broth at a 10:1 inhibitor to target ratio. Growth inhibition was 
assessed by quantifying the number of viable target cells as colony-forming units per 
milliliter (CFU/mL) and data are reported as the mean ± SEM for two independent 
experiments. 
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Figure 2. OmpC and OmpF are required for CDI
UPEC536
. A) Open reading frames of 
ompC and ompF in their genomic context. Arrows indicate 5 unique transposon insertions in 
ompC and ompF that confer resistance to CDI
UPEC536
.  B) JCM158 ompC ompF target 
cells expressing the indicated constructs were co-cultured with UPEC536 CDI
+ 
or CDI
-
 
inhibitor cells for 5 hours in LB broth at a 10:1 inhibitor to target ratio. Growth inhibition 
was assessed by quantifying the number of viable target cells as colony-forming units per 
milliliter (CFU/mL) and data are reported as the mean ± SEM for two independent 
experiments. C) The same target cells used in the competition experiments were labelled red 
and incubated with MC4100 GFP
+
 cells carrying CDI
EC93
, CDI
UPEC536
, or CDI
- 
cosmids for 
10 minutes at a 5:1 inhibitor to target ratio and analyzed by flow-cytometry.   
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Figure 3. Heterologous ompC alleles show varying levels of target cell susceptibility. A) 
A heat map alignment of OmpC from various proteobacteria performed by PRALINE 
Multiple Sequence Alignment. B) JCM158 ompC target cells expressing the annotated 
constructs were co-cultured with UPEC536 CDI
+ 
or CDI
-
 inhibitor cells for 5 hours in LB 
broth at a 10:1 inhibitor to target ratio. Growth inhibition was assessed by quantifying the 
number of viable target cells as colony-forming units per milliliter (CFU/mL) and data are 
reported as the mean ± SEM for two independent experiments. C) The same target cells used 
in the competition experiments were labelled red and incubated with MC4100 GFP
+
 cells 
carrying CDI
EC93
, CDI
UPEC536
, or CDI
- 
cosmids for 10 minutes at a 5:1 inhibitor to target ratio 
and analyzed by flow-cytometry.   
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Figure 4. Heterologous ompF alleles show varying levels of target cell susceptibility. A) 
A heat map alignment of OmpF from various proteobacteria performed by PRALINE 
Multiple Sequence Alignment. B) JCM158 ompF target cells expressing the indicated 
constructs were co-cultured with UPEC536 CDI
+ 
or CDI
-
 inhibitor cells for 5 hours in LB 
broth at a 10:1 inhibitor to target ratio. Growth inhibition was assessed by quantifying the 
number of viable target cells as colony-forming units per milliliter (CFU/mL) and data are 
reported as the mean ± SEM for two independent experiments. C) The same target cells used 
in the competition experiments were labelled red and incubated with MC4100 GFP
+
 cells 
carrying CDI
EC93
, CDI
UPEC536
, or CDI
- 
cosmids for 10 minutes at a 5:1 inhibitor to target ratio 
and analyzed by flow-cytometry.   
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Figure 5. OmpC and OmpF vary amongst strains of E. coli. A) A heat map alignment of 
OmpF from various E. coli strains performed by PRALINE Multiple Sequence Alignment. 
B) OmpC from the same E. coli strains as A) were aligned using PRALINE Multiple 
Sequence Alignment. Black lines designate the 8 loops that connect the 16 β-strands of an 
OmpC monomer. C) The heat map depicted in B) was grafted onto the crystal structure of E. 
coli K12 OmpC in monomeric form. Extracellular loops 1-2 and 4-8 are labelled. D) An 
overlay of E. coli K12 OmpC in light blue, and CFT073 OmpC in green. 
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Figure 6. OmpC
E.coli 
polymorphism restricts CDI
UPEC536
. A) JCM158 ompC target cells 
expressing ompC alleles from a variety of E. coli strains were co-cultured with UPEC536 
CDI
+ 
or CDI
-
 inhibitor cells for 5 hours in LB broth at a 10:1 inhibitor to target ratio. Growth 
inhibition was assessed by quantifying the number of viable target cells as colony-forming 
units per milliliter (CFU/mL) and data are reported as the mean ± SEM for two independent 
experiments. B) Western blot analysis of protein extracted from target cells in A). The 
antibody used was raised to E. coli OmpC but recognizes OmpC, OmpF, and OmpA.  
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Figure 7. CDI
UPEC536
targets OmpC extracellular loops 4 and 5. A) A heat map alignment 
of OmpC from E. coli strains CFT073, F11, and UPEC536 performed by PRALINE Multiple 
Sequence Alignment. Loops 4 and are designated by black bars. B) JCM158 ompC target 
cells expressing the indicated ompC alleles were co-cultured with UPEC536 CDI
+ 
or CDI
-
 
inhibitor cells for 5 hours in LB broth at a 10:1 inhibitor to target ratio. Growth inhibition 
was assessed by quantifying the number of viable target cells as colony-forming units per 
milliliter (CFU/mL) and data are reported as the mean ± SEM for two independent 
experiments.  
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Figure 8. The interaction between OmpC extracellular loops 4 and 5 is important for 
CDI
UPEC536
. A) A heat map alignment of OmpC from E. coli strains EC869 and EC93 
performed by PRALINE Multiple Sequence Alignment. Loops 4 and 5 are designated by 
black bars. B) Crystal structure of OmpC from E. coli strain UTI2 in homotrimer form. 
Residue E188 found in UTI2 and EC869 and residue D231 found in UTI2, EC869, and EC93 
are depicted in stick form.  C) JCM158 ompC target cells expressing the annotated ompC 
alleles were co-cultured with UPEC536 CDI
+ 
or CDI
-
 inhibitor cells for 5 hours in LB broth 
at a 10:1 inhibitor to target ratio. Growth inhibition was assessed by quantifying the number 
of viable target cells as colony-forming units per milliliter (CFU/mL) and data are reported as 
the mean ± SEM for two independent experiments. D) Western blot analysis of protein 
extracted from target cells in C). The antibody was raised to E. coli OmpC but recognizes 
OmpC, OmpF, and OmpA.  
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Figure 9. Formation of functional OmpC/F heterotrimers in vivo. A) Western blot 
analysis of the indicated cells. The antibody was raised to OmpC but recognizes OmpC/F/A. 
Monomeric, dimeric, and trimeric OmpF are labeled.  B) Growth curve analysis of the 
designated cells with or without the addition of 1 nM of colicin E5 after 30 minutes of 
growth. C) D) Same analysis as A) and B) but cells are ompC
+
. 
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Figure 10. OmpC/F heterotrimers support CDI
UPEC536
. A) The indicated target cells were 
co-cultured with UPEC536 CDI
+ 
or CDI
-
 inhibitor cells for 5 hours in LB broth at a 10:1 
inhibitor to target ratio. Growth inhibition was assessed by quantifying the number of viable 
target cells as colony-forming units per milliliter (CFU/mL) and data are reported as the 
mean ± SEM for two independent experiments. B) The same target cells used in the 
competition experiments were labelled red and incubated with MC4100 GFP
+
 cells carrying 
CDI
EC93
, CDI
UPEC536
, or CDI
- 
cosmids for 10 minutes at a 5:1 inhibitor to target ratio and 
analyzed by flow-cytometry.   
 
 
 
 
 
 
 
 
100 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4. Contact-dependent growth inhibition (CDI) systems 
deploy a toxic ribosomal RNase 
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Note: This research was originally published in Structure. I collaborated on this project with 
Robert Morse in the laboratory of Celia Goulding at the University of California, Irvine. 
Figures 1 and 2 are solely his work. Furthermore, the majority of the writing in this chapter 
was done by Christopher Hayes and Celia Goulding.   
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protein of Enterobacter cloacae deploys a toxic ribosomal RNase.” Structure. 2014 May 
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Abstract 
 Contact-dependent growth inhibition (CDI) is a form of inter-bacterial competition. 
CDI
+
 cells export large CdiA effectors that carry a variety of C-terminal toxin domains 
(CdiA-CT). CdiA-CT toxins are specifically neutralized by cognate CdiI immunity proteins 
to protect toxin-producing cells from auto-inhibition. Here, we use high-resolution structure 
determination to elucidate the activity of a unique CDI toxin from Enterobacter cloacae 
(ECL). The CdiA-CT
ECL
 structure is similar to the C-terminal nuclease domain of colicin E3, 
which cleaves 16S ribosomal RNA to disrupt protein synthesis. In accord with this structural 
homology, we show that CdiA-CT
ECL
 uses the same nuclease activity to inhibit bacterial 
growth. Surprisingly, although colicin E3 and CdiA
ECL
 carry equivalent toxin domains, the 
corresponding immunity proteins are unrelated in sequence, structure and toxin-binding site. 
Together, these findings reveal unexpected diversity amongst 16S rRNases and suggest that 
these nucleases are robust and versatile payloads for a variety of toxin-delivery platforms. 
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Introduction 
 Bacterial genomes and plasmids encode a variety of peptide and protein toxins that 
mediate inter-bacterial competition. Colicins were the first such toxins to be identified and 
characterized from strains of Escherichia coli. Subsequently, it became apparent that other 
bacteria release similar toxins, which are now collectively termed bacteriocins 
238
. 
Bacteriocins are diffusible proteins that parasitize cell-envelope proteins to enter and kill 
bacteria. These toxins are composed of three domains, each responsible for a distinct step in 
the cell killing pathway. The central domain binds specific receptors on the surface of 
susceptible bacteria. The N-terminal domain mediates translocation across the cell envelope, 
and the C-terminal domain carries the bacteriocidal activity. This modular structure allows 
for delivery of diverse C-terminal toxins using conserved translocation and receptor-binding 
domains. For example, colicins E2 through E9 share virtually identical N-terminal domains 
but carry different C-terminal toxins with DNase 
91
, ribosomal RNase 
100,239
 or tRNA 
anticodon nuclease activities 
101
. Bacteriocin genes are always closely linked to immunity 
genes, which encode small proteins that bind the toxin domain and neutralize its toxicity. 
Thus, cells that harbor bacteriocinogenic plasmids are protected from toxin activity, but they 
may still be susceptible to the bacteriocins produced from other plasmids. Several different 
bacteriocin/immunity types are typically present in a given environment 
14,15
, and these 
plasmids are predicted to have a significant impact on bacterial population structures 
240,241
. 
 Research over the past decade has uncovered bacterial competition systems that 
require direct cell-to-cell contact for toxin delivery 
112,115,137,242,243
. There are at least two 
pathways – mediated by type V and type VI secretion systems – for contact-dependent toxin 
delivery between Gram-negative bacteria 
167,244
. The type V mechanism was the first to be 
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identified and this phenomenon was termed "CDI" for contact-dependent growth inhibition 
112
. CDI is mediated by the CdiB/CdiA family of two-partner secretion proteins. CdiB is a 
predicted β-barrel protein that resides in the outer membrane and is required for export of 
CdiA effectors. CdiA proteins are very large (250 – 600 kDa) and are thought to extend from 
the inhibitor cell to interact with neighboring target bacteria. Although CdiA and bacteriocins 
are unrelated, these effector proteins share a number of general features. Like bacteriocins, 
CdiA proteins bind to specific receptors on the surface of target bacteria and these 
interactions determine the target-cell range 
118,126
. Additionally, CDI toxin activity is carried 
at the extreme C-terminus of CdiA, and some portion of this CdiA-CT region is translocated 
into target bacteria 
115,116,122
. CDI loci also encode CdiI immunity proteins, which bind and 
inactivate CdiA-CTs to protect toxin-producing cells from auto-inhibition. Finally, CDI 
systems deploy a variety of distinct toxin domains, which have different biochemical 
activities. Remarkably, functional chimeric effector proteins can be produced experimentally 
by fusing different toxins onto CdiA at a conserved VENN peptide motif, which demarcates 
the CdiA-CT region 
115
. There is also substantial evidence that cdiA-CT/cdiI gene pairs are 
exchanged horizontally between bacteria 
121
, suggesting that modularity is exploited to 
diversify toxin/immunity pairs. In fact, bacteria collectively share a large repository of 
toxin/immunity gene pairs and these modules appear to be exchanged between a number of 
different toxin-delivery systems 
121,172,245,246
. For example, at least two CdiA proteins carry 
toxin domains that resemble bacteriocin nucleases. CdiA
Dd3937
 from Dickeya dadantii 3937 
carries a CT domain with 35% identity to pyocin S3 
115
, and the C-terminal region of 
CdiA
K96243
 from Burkholderia pseudomallei K96243 is 49% identical to colicin E5. 
Biochemical analyses have confirmed that each CDI toxin has the same nuclease activity as 
105 
 
the corresponding bacteriocin 
115,120
. Together, these observations suggest that CDI loci 
integrate toxin/immunity gene pairs from diverse sources and that this diversity contributes to 
inter-strain competition. 
 In an effort to understand CDI toxin/immunity diversity and uncover new toxin 
activities, we have initiated structural studies of CdiA-CT/CdiI pairs from various bacteria. 
Here, we describe the structure and function of the CDI toxin/immunity protein pair from 
Enterobacter cloacae ATCC 13047 (ECL). The CdiA-CT
ECL
 toxin shares no significant 
sequence identity with proteins of known function, but the three-dimensional structure of 
CdiA-CT
ECL
 resembles the C-terminal nuclease domain of colicin E3. In accord with this 
structural homology, CdiA-CT
ECL
 cleaves 16S rRNA at the same site as colicin E3 and this 
nuclease activity is responsible for the inhibition of bacterial growth. In contrast, CdiI
ECL
 
does not resemble the colicin E3 immunity protein (ImE3), and the two immunity proteins 
bind to different sites on their respective cognate toxin domains. Inspection of other CdiA 
proteins from Erwinia chrysanthemi EC16 (Uniprot: P94772), Enterobacter hormaechei 
ATCC 49162 (F5S237) and Pseudomonas viridiflava UASWS0038 (K6CF79) has revealed 
that their toxin domains share a common nuclease motif with colicin E3 
104
. Analysis of 
CdiA-CT
EC16
 from Erwinia chrysanthemi EC16 confirms that this toxin has 16S rRNase 
activity and demonstrates that the associated CdiI
EC16
 immunity protein is specific to CdiA-
CT
EC16
 and does not provide protection against the CdiA-CT
ECL
 nuclease. Together, these 
observations indicate that 16S rRNase toxins are more diverse and widespread than 
previously recognized. 
 
Materials and Methods 
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Bacterial strains and plasmids used in this study 
Strain or plasmid Description Reference 
Strains
a
   
BL21-
Gold(DE3) 
E. coli B, F
–
 ompT hsdS(rB
–
 mB
–
) dcm
+
 gal 
l(DE3) endA Hte, Tet
R
 
Stratagene 
X90 
F´ lacI
q
 lac´ pro´/ara ∆(lac-pro) nal1 argE(amb) 
rif
r 
thi-1, Rif
R
  
177
 
EPI100 
F
–
 mcrA ∆(mrr-hsdRMS-mcrBC) φ80dlacZ∆M15 
∆lacXcZ∆M15 ∆lacX recA1 endA1 araD139 ∆(ara, 
leu)7697 galU galK λ– rpsL nupG, StrR 
Epicentre 
Enterobacter 
cloacae ATCC 
13047 
Type strain, Amp
R
 ATCC 
DY378 W3110 lcI857 ∆(cro-bio) 247 
CH1944 X90 (DE3) ∆rna, RifR 248 
CH2016 X90 (DE3) ∆rna ∆slyD::kan, KanR 248 
CH10013 
Spontaneous rifampicin-resistant derivative of E. 
coli JCM158, Rif
R
 
This study 
CH10420 CH1944 ∆rsmE::kan, KanR This study 
CH11196 E. cloacae ∆vasK1::kan, AmpR KanR This study 
CH11247 E. cloacae spc-araC
Eco
::cdiB, Amp
R
 Spc
R
 This study 
CH11248 
E. cloacae spc-araC
Eco::cdiB ∆araBAD::kan, 
Amp
R
 Spc
R
 Kan
R
 
This study 
CH11249 
E. cloacae spc-araC
Eco
::cdiB ∆araBAD, AmpR 
Spc
R
 
This study 
CH11250 
E. cloacae spc-araC
Eco::cdiB ∆araBAD 
∆vasK1::kan, AmpR SpcR KanR 
This study 
CH11275 E. cloacae ∆wzb::kan, AmpR KanR This study 
CH11432 E. cloacae ∆wzb, AmpR This study 
CH11445 E. cloacae ∆wzb ∆cdiA::spc, AmpR SpcR This study 
CH11475 E. cloacae ∆wzb ∆cdiAI::kan, AmpR KanR This study 
Plasmids 
pTrc99a IPTG-inducible expression plasmid, Amp
R
 
GE 
Healthcare 
pCH450 
pACYC184 derivative with E. coli araBAD 
promoter for arabinose-inducible expression, Tet
R
 
249
 
pKOBEG 
L-arabinose inducible expression phage l red 
genes, temperature-sensitive replication origin, 
Cm
R
 
250
 
pCP20 
Heat-inducible expression of FLP 
recombinase, Cm
R
 Amp
R 
225
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pWEB-TNC Cosmid cloning vector, Amp
R
 Cm
R
 Epicentre 
pKAN 
pBluescript with kanamycin-resistance cassette 
ligated to SmaI site, Amp
R
 Kan
R
 
251
 
pSPM 
pBluescript with spectinomycin-resistance 
cassette ligated between BamHI and EcoRI sites, 
Amp
R
 Spc
R
 
252
 
pCH8001 
pET21KS::yqcFG, expression construct 
containing the Bacillus subtilis 168 yqcFG operon, 
Amp
R
 
lab 
collection 
pCH10163 
Cosmid pCdiA-CT/pheS* that carries a kan-
pheS* cassette in place of the E. coli EC93 cdiA-
CT/cdiI coding sequence. Used for allelic 
exchange and counter-selection. Cm
R
 Kan
R
 
122
 
pET21K::cdiA-
CT/cdiI
ECL
 
Overproduces CdiA-CT/CdiI
ECL
-His6 under 
control of phage T7 promoter, Amp
R
 
This study 
pET21K::cdiA-
CT(D203A)/cdiI
ECL
 
Overproduces CdiA-CT(D203A)/CdiI
ECL
-His6 
under control of phage T7 promoter, Amp
R
 
This study 
pET21K::cdiA-
CT(D205A)/cdiI
ECL
 
Overproduces CdiA-CT(D205A)/CdiI
ECL
-His6 
under control of phage T7 promoter, Amp
R
 
This study 
pET21K::cdiA-
CT(H207A)/cdiI
ECL
 
Overproduces CdiA-CT(H207A)/CdiI
ECL
-His6 
under control of phage T7 promoter, Amp
R
 
This study 
pET21K::cdiA-
CT(K214A)/cdiI
ECL
 
Overproduces CdiA-CT(K214A)/CdiI
ECL
-His6 
under control of phage T7 promoter, Amp
R
 
This study 
pET21S::cdiA-
CT/cdiI
EC16
 
Overproduces CdiA-CT/CdiI
EC16
-His6 under 
control of phage T7 promoter, Amp
R
 
This study 
pET21K::cdiI
EC16
 
Overproduces CdiI
EC16
-His6 under control of 
phage T7 promoter, Amp
R
 
This study 
pCH450::cdiA-
CT
ECL
 
Arabinose-inducible expression of cdiA-CT
ECL
, 
Tet
R
 
This study 
pCH450::cdiA-
CT(D203A)
ECL
 
Arabinose-inducible expression of cdiA-
CT(D203A)
ECL
, Tet
R
 
This study 
pCH450::cdiA-
CT(D205A)
ECL
 
Arabinose-inducible expression of cdiA-
CT(D205A)
ECL
, Tet
R
 
This study 
pCH450::cdiA-
CT(H207A)
ECL
 
Arabinose-inducible expression of cdiA-
CT(H207A)
ECL
, Tet
R
 
This study 
pCH450::cdiA-
CT(K214A)
ECL
 
Arabinose-inducible expression of cdiA-
CT(K214A)
ECL
, Tet
R
 
This study 
pCH450::cdiA-
CT
EC16
 
Arabinose-inducible expression of cdiA-
CT
EC16
, Tet
R
 
This study 
pTrc99a::cdiI
ECL
 IPTG-inducible expression of cdiI
ECL
, Amp
R
 This study 
pTrcKX::cdiI
EC16
 IPTG-inducible expression of cdiI
EC16
, Amp
R
 This study 
pCH450::cdiI
ECL
 
Arabinose-inducible expression of cdiI
ECL
, 
Tet
R This study 
pCH450::cdiI
ECL
- Arabinose-inducible expression of cdiI
ECL
-his6 This study 
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his6 for purification of CdiI
ECL
-His6, Tet
R
 
pCH450KX::cdiI
E
C16
 
Arabinose-inducible expression of cdiI
EC16
, 
Tet
R
 
This study 
pCH10445 
Constitutive expression of chimeric cdiA
EC93
-
CT
ECL
 and cdiI
ECL
 genes, Cm
R This study 
pCH10508 
Derivative of pCH10445 carrying the H207A 
mutation in the cdiA-CT
ECL
 coding sequence, Cm
R This study 
pCH11050 pKAN-∆vasK1ECL, AmpR KanR This study 
pCH11506 pKAN-∆wzbECL, AmpR KanR This study 
pCH11507 pSPM-∆cdiAECL, AmpR SpcR This study 
pCH11508 pKAN-∆cdiAIECL, AmpR KanR This study 
a
All bacterial strains are Escherichia coli unless otherwise noted. 
 
Bacterial strains and growth conditions 
 All bacterial strains and plasmids used in this study are listed in the table above. 
Bacteria were grown in LB media or LB-agar with antibiotics at the following 
concentrations: ampicillin (Amp) 150 μg/mL; kanamycin (Kan) 50 μg/mL; rifampicin (Rif) 
200 µg/mL; spectinomycin (Spc) 100 μg/mL; and tetracycline (Tet) 10 μg/mL. The 
∆rsmE::kan mutation 184 was transferred into E. coli strain CH1944 by bacteriophage P1-
mediated transduction. E. cloacae genes were deleted using the same protocol as described 
for E. coli 
251
. DNA sequences located upstream and downstream of target genes were 
amplified and cloned into plasmid pKAN 
251
 or pSPM 
252
 to flank kanamycin- or 
spectinomycin-resistance cassettes, respectively. The resulting plasmids were linearized by 
restriction endonuclease digestion and electroporated into E. cloacae cells expressing the 
phage λ Red proteins from plasmid pKOBEG 250,253. 
 The wzb upstream region was amplified with oligonucleotides (restriction sites 
underlined) ECL-wzb(KO)-Sac (5´ - TTT GAG CTC CTG CAG GCG CTG ATG C)/ECL-
wzb(KO)-Bam (5´ - TTT GGA TCC GCG GAT TAC CAG GTA TG), and the downstream 
region with ECL-wzb(KO)-Eco (5´ - TTT GAA TTC CAG CAG GGA TAA CAA TGA 
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C)/ECL-wzb(KO)-Kpn (5´ - TTT GGT ACC CCC TTT CGG CAG CAC). The kanamycin-
resistance cassette was removed from the resulting strain CH11275 using FLP recombinase 
185,225
 to generate strain CH11432. The cdiA
ECL
 upstream region was amplified with ECL-
cdiA(KO)-Sac (5´ - TTT GAG CTC GTT TTC AGC GCC CGG TTG)/ECL-cdiA(KO)-
Bam (5´ - TTT GGA TCC TGT CCC TTA GAA AGC CAC TG), and the downstream 
region with ECL-cdiA(KO)-Eco (5´ - GCG GAA TTC ACA GGA TTA AGG ACT AGT 
G)/ECL-cdiA(KO)-Kpn (5´ - CTC GGT ACC GAG CTC TGT TTC AGT TG). The 
resulting construct was used to generate strain CH11445. The cdiI
ECL
 downstream region was 
amplified with primers ECL-cdiI(KO)-Eco (5´ - ACA GAA TTC ACT ACC GAG CCG 
GGA GC)/ECL-cdiA(KO)-Kpn (5´ - CGG GGT ACC TAC GCG TAG TGA ATT ATC), 
and used with the cdiA
ECL
 upstream homology fragment to generate the ∆cdiAI::kan deletion 
construct. This construct was used to delete the cdiI
ECL
 gene from strain CH11445, thereby 
generating immunity-deficient strain CH11475 to serve as target bacteria for competition 
experiments. 
 Inducible E. cloacae inhibitor cells (strain CH11250) were generated in several steps. 
The E. coli araBAD promoter was first recombined upstream of the cdiBAI gene cluster in E. 
cloacae. A region containing the promoter, araC and a spectinomycin-resistance cassette was 
amplified from TGI1 
115
 with primers ECL-spec-araC-cdiB(OE)-for (5´ - AGT TGC GCG 
TTT TTT GAC AGG CAA GTC TGA AAA CGG ACT TTT AGC AAT GCT TGC ATA 
ATG) and ECL-spec-araC-cdiB(OE)-rev (5´ - CGA CGT TTT CCC TGA CAT GGT GAA 
TTC CTC CTG CTA GCC CAA AAA AAC GGG TAT GGA G). A region upstream of 
cdiB
ECL
 was amplified with ECL-spec-araC-cdiB(UP)-for (5´ - CGC TTT CAG TTC CAG 
TTT GC) and ECL-spec-araC-cdiB(UP)-rev (5´ - GCC TGT CAA AAA ACG CGC); and 
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the downstream homology region amplified with ECL-spec-araC-cdiB(DS)-for (5´ - CCA 
TGT CAG GGA AAA CGT CGA TAC) and ECL-spec-araC-cdiB(DS)-rev (5´ - AAT TTT 
CCC TTC GAG GCC G). The three products were combined by OE-PCR and the resulting 
product was electroporated into E. cloacae to generate strain CH11247. The araBAD
ECL
 
operon was then deleted. Primers ECL-araBAD(OE)-for (5´ - GTT TTC TGA TGG AGC 
AAC ACC GAA TTG GAG CTC CAC CGC) and ECL-araBAD(OE)-rev (5´ - GTT TTA 
TGC TGG GTT TAT ATA CAG TCA AAA GCT GGG TAC CGG G) were used to amplify 
the kanamycin-resistance cassette from pCH70. Primers ECL-araBAD(UP)-for (5´ - TTT 
AAG CTT GAT TAT CCC TTC CCC ACG C) and ECL-araBAD(UP)-rev (5´ - GGT GTT 
GCT CCA TCA GAA AAC) were used to amplify a region upstream of araB; and primers 
ECL-araBAD(DS)-for (5´ - ACT GTA TAT AAA CCC AGC ATA AAA C) and ECL-
araBAD(DS)-rev (5´ - TTT CTC GAG CAG GGG CGG TAA TAA ACC G) were used to 
amplify a region downstream of araD. The PCR products were combined with the 
kanamycin-resistance cassette by overlap extension-PCR (OE-PCR) 
254
 and the final product 
electroporated into CH11247 cell to generate strain CH11248. The kanamycin-resistance 
cassette was subsequently removed to produce strain CH11249. Finally, the vasK1 gene was 
deleted from the inhibitor cells. The vasK1 upstream region was amplified with primers 
ECL-vask1(KO)-Sac (5´- TTT GAG CTC GAA ATC GAC GCC GGT CTG)/ECL-
vask1(KO)-Bam (5´ - TTT GGA TCC TTT CCT TGC GGC AAT CCG); and the 
downstream region with primers ECL-vask1(KO)-Eco (5´- TTT GAA TTC CAA  GGA 
CAG CCG TAT GAC)/ECL-vask1(KO)-Kpn (5´ - TTT GGT ACC GAA TCG ACA TCA 
GCA TCT C). The resulting construct was electroporated into CH11249 cells followed by 
selection for kanamycin-resistant recombinants. 
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Protein expression constructs 
 Protein overproduction constructs were generated using plasmid pET21S 
115
 and its 
derivative pCH8001, which contains a KpnI restriction site immediately upstream of NcoI. 
The cdiA-CT/cdiI
ECL
 coding sequence was amplified from E. cloacae genomic DNA using 
primers ECL-CT-Kpn/Nco-for (5´ - GGG GGT ACC ATG GCT GAG AAT AAC TCG 
CTG GC and ECL-cdiI-Nhe-rev (5´ - CTC TGC TAG CGT TGT TAA GAC TAT GAT 
AAA AAT C). The PCR product was digested with KpnI/NheI and ligated to KpnI/SpeI-
digested pCH8001 to generate plasmid pET21K::cdiA-CT/cdiI
ECL
. Point mutations were 
introduced into cdiA-CT
ECL
 using megaprimer PCR 
187
. Megaprimers were first generated 
using mutagenic forward primers: ECL-CT(D203A)-for (5´ - CTA CAT TAC CCC CGC 
TAT TGA TAG TCA TAA), ECL-CT(D205A)-for (5´ - CAT TAC CCC CGA TAT TGC 
TAG TCA TAA TGT TAC), ECL-CT(H207A)-for (5´ - CCC GAT ATT GAT AGT GCT 
AAT GTT ACT AAT GG), and ECL-CT(K214A)-for (5´ - GTT ACT AAT GGC TGG 
GCG ATG TTC AAT AGT AAA GG) in conjunction with primer ECL-cdiI-Nhe-rev. 
These products was used in subsequent reactions with ECL-CT-Kpn/Nco-for to generate 
complete cdiA-CT/cdiI
ECL
 modules, which were ligated into pCH8001. The cdiA-CT/cdiI
EC16
 
region was amplified from Erwinia chrysanthemi EC16 genomic DNA using primers EC16-
CT-Nco-for (5´ - AGG CCA TGG TGG AGA ATA ACC TTT TGT CTG C) and EC16-
virA-Spe-rev (5´ - TCA TAC TAG TTT GGG AAT CAA GGA TCT CAT ATC G). The 
resulting product was digested with NcoI/SpeI and ligated to plasmid pET21S. The cdiI
EC16
 
gene was amplified with primers EC16-virA-Kpn-for (5´ - TTT GGT ACC ATG CAA 
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GAG CCA GTA AG) and EC16-virA-Spe-rev, digested with KpnI/SpeI and ligated into 
pCH8001.  
 Arabinose-inducible cdiA-CT expression constructs were generated using plasmid 
pCH450 
249
. The cdiA-CT
ECL
 and cdiA-CT
EC16
 coding sequences were amplified using ECL-
CT-Kpn/Nco-for with ECL-CT-Xho-rev (5´ - TCC CTC GAG ACC ACT AGT CCT TAA 
TCC), and EC16-CT-Nco-for with EC16-CT-Xho-rev (5´ - TTT CTC GAG TTA TTT 
TAC CTT TAA ATC), respectively. The products were digested with NcoI/XhoI and ligated 
to plasmid pCH450. For in vivo immunity assays, compatible cdiI expression constructs were 
generated using plasmid pTrc99A derivatives. The cdiI
ECL
 gene was amplified with ECL-
cdiI-Eco-for (5´ - GAT TAA GGA ATT CTG GTA TGT TTG G) and ECL-cdiI-Sac-rev 
(5´ - AGT GAG CTC TGT TTC AGT TGT TAA GAC) and ligated to pTrc99A using EcoRI 
and SacI restriction sites. The cdiI
ECL
 gene was also amplified with ECL-cdiI-Eco-for and 
pET-Pst (5´ - CGG CTG CAG CAG CCA ACT CAG TGG) and ligated to plasmid pCH450 
for the overproduction and purification of CdiI
ECL
-His6. The cdiI
EC16
 gene was amplified with 
EC16-virA-Kpn-for and EC16-virA-Xho-rev (5´ - TTT CTC GAG TTA TTG GGA ATC 
AAG GAT C) and ligated to plasmid pTrc-rhsIB 
252
 using KpnI and XhoI restriction sites. 
The cdiI
ECL
 and cdiI
EC16
 genes were also subcloned into plasmid pCH450 to test immunity 
function in E. cloacae growth competitions. 
 The EC93-ECL chimeric CDI system was constructed by allelic exchange of the 
counter-selectable pheS* marker from cosmid pCH10163 as described 
122
. The cdiA-
CT/cdiI
ECL
 coding region was amplified with primers ECL-CT-chim-for (5´ - TCG CTG 
GCA CTG GTT GCC AGA GGT TG) and ECL-cdiI-chim-rev (5´ - TTA GTT GTT AAG 
ACT ATG ATA AAA ATC). An upstream cdiA
EC93
 homology region was amplified with 
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primers DL1527 (5´ - GAA CAT CCT GGC ATG AGC G) and ECL-chim(OE)-rev (5´ - 
CAA CCT CTG GCA ACC AGT GCC AGC GAA TTA TTC TCA ACC GAG TTC CTA 
CCT G), and a downstream homology region amplified with primers ECL-chim(OE)-for (5 
´- GAT TTT TAT CAT AGT CTT AAC AAC TAA CCC AAA GGT TAG ACA CCA GAC 
C) and DL2368 (5´ - GTT GGT AGT GGT GGT GCT G). The three PCR products were 
combined by OE-PCR using oligonucleotides DL1527 and DL2368. The final DNA product 
(100 ng) was electroporated together with pCH10163 (300 ng) into E. coli strain DY378 cells 
247
 and recombinants selected on yeast extract glucose-agar supplemented with 33 µg/mL 
chloramphenicol and 10 mM D/L-p-chlorophenylalanine. 
 
Protein purification and crystallography 
 The CdiA-CT
ECL
/CdiI
ECL
-His6 complex was overproduced from plasmid 
pET21K::cdiA-CT/cdiI
ECL
 in either E. coli BL21 (DE3) Gold (Stratagene) or E. coli CH2016 
cells induced with 1 mM isopropyl β-D-thiogalactopyranoside (IPTG). Selenomethionine 
(SeMet) labeled complex was produced from cells grown in M9 minimal medium 
supplemented with leucine, isoleucine and valine at 50 mg/L; phenylalanine, lysine and 
threonine at 100 mg/L; and SeMet at 75 mg/L) as previously described 
255
. Cells were 
washed with resuspension buffer [20 mM sodium phosphate (pH 7.0), 200 mM NaCl], then 
broken by sonication on ice in resuspension buffer supplemented with 10 mg/mL lysozyme 
and 1 mM phenylmethylsulfonyl fluoride. Unbroken cells and debris were removed by 
centrifugation at 18,000 g for 30 min followed by filtration through a 0.45 μm filter. 
Clarified lysates were loaded onto a Ni
2+-
charged HiTrap column (GE Healthcare) and 
washed with resuspension buffer containing 10 mM imidazole. The CdiA-CT
ECL
/CdiI
ECL
-
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His6 complex was eluted with a linear gradient of imidazole (10 – 500 mM) in resuspension 
buffer. Fractions were collected, combined, and concentrated to ∼500 µL in a centrifugal 
concentrator. Complexes were further purified by gel filtration on a Superdex 200 column 
equilibrated with 20 mM Tris-HCl (pH 7.4), 150 mM NaCl using an AKTA FPLC. SeMet-
labeled complex was concentrated to 9 mg/mL in 20 mM Tris-HCl (pH 7.4), 150 mM NaCl 
for crystallization trials. 
Crystals of SeMet-labeled CdiA-CT
ECL
/CdiI
ECL
 complex were grown over 1 month at 
room temperature by hanging drop-vapor diffusion with a reservoir containing 1.5 M 
(NH4)2SO4, 0.1 M Bis Tris (pH 5.1) and 1% (wt/vol) PEG 3350. The hanging drop contained 
a 2:1 (vol:vol) ratio of protein to reservoir solutions. The SeMet-labeled complex crystallized 
in space group P4122 with unit cell dimensions of 85.64 Å  85.64 Å  75.17 Å and one 
complex per asymmetric unit. Crystals were mounted and data collected under cryo-
conditions with the addition of 40% (vol/vol) glycerol as cryoprotectant to the reservoir 
condition. A Se-MAD dataset was collected at 70K at the Se-absorption edge (0.9759 Å), 
inflection (0.9794 Å) and remote (1.377 Å). Data reduction for each wavelength was carried 
out with the HKL2000 suite 
256
, resulting in three 100% complete datasets with combined 
significant anomalous differences up to 4.6 Å resolution. Experimental phasing and initial 
model building was performed using AutoSol and Autobuild in PHENIX 
257
, in which six Se 
atoms were located per asymmetric unit. A high-resolution dataset was collected with a 
second P4122 Se-Met-labeled crystal with a slightly smaller unit cell (85.25 Å  85.25 Å  
74.91 Å) at 70K at 1.00 Å. Data reduction was carried out with the HKL2000 suite, resulting 
in a 100% complete dataset up to 2.4 Å. The structure was solved via molecular replacement 
utilizing phenix.automr, and the final model obtained through iterative manual building in 
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Coot and refinement with phenix.refine 
258-260
. The final model includes residues 160 – 235 
of CdiA-CT
ECL
 (numbered from Ala1 of the AENN motif) and residues 1 – 141 of CdiIECL 
with a final Rwork/Rfree (%) 18.3/23.7. CdiA-CT
ECL
 residues Leu160 – Lys163, His188 and 
loop L4 (residues Ser206 – Asn211) were modeled as alanines due to lack of observable side 
chain density. Additionally, residues Glu72, Lys73, Glu99 and His102 of CdiI
ECL
 were 
modeled as alanines. Atomic coordinates and structure factors have been deposited in the 
Protein Data Bank (www.pdb.org) as PDB ID code 4NTQ. 
          
Toxin-immunity binding and RNase assays 
 CdiA-CT/CdiI-His6 complexes were denatured in binding buffer [20 mM sodium 
phosphate (pH 7.0, 150 mM NaCl, 10 mM β-mercaptoethanol] supplemented with 6 M 
guanidine-HCl, and CdiA-CT proteins isolated in the void volume during Ni
2+
-affinity 
chromatography 
115
. Toxins were refolded by dialysis against binding buffer. CdiI-His6 
proteins were purified by Ni
2+
-affinity chromatography under non-denaturing conditions as 
described 
120
. The isolated toxins and immunity proteins were dialyzed against reaction 
buffer and quantified by absorbance at 280 nm. Purified CdiA-CT and CdiI-His6 protein were 
mixed at 10 µM final concentration in binding buffer and binding interactions assessed by 
co-purification during Ni
2+
-affinity chromatography as described 
115,120
. In vitro nuclease 
activity assays were conducted in binding buffer supplemented with 10 mM MgCl2. 
Ribosomes were isolated from S30 lysates of E. coli strain CH1944 by centrifugation at 
100,000 x g for 4 hr at 4 °C. Ribosomes (10 µM) were incubated with purified CdiA-CT (1 
µM) in binding buffer supplemented 10 mM MgCl2 for 1 hr at 37 °C. Where indicated, CdiI-
His6 immunity protein was also included at 1 µM final concentration or 15uM of antibiotic. 
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Reactions were analyzed by denaturing electrophoresis on 50% urea – 6% polyacrylamide 
gels in 1 Tris-borate-EDTA buffer. Gels were transferred to nylon membrane and 
hybridized to 5´-radiolabeled oligonucleotide (5´ - TAA GGA GGT GAT CCA ACC GCA), 
which is complementary to the 3´-end of E. coli 16S rRNA. For primer extension analysis, 
ribosomes were isolated from E. coli CH10420 cells that lack the RsmE methyltransferase. 
Reactions were quenched with guanidinium isothiocyanate-phenol and rRNA extracted as 
described 
248
. Primer extension was performed as previously described 
261
 using 5´-
radiolabeled oligonucleotide (5´ - GGT TCC CCT ACG GTT ACC TTG) as a primer. 
 CdiA-CT toxicity and in vivo nuclease activity was assessed in E. coli strain X90 
(Table S2). Arabinose-inducible pCH450::cdiA-CT expression constructs were introduced 
together with IPTG-inducible pTrc::cdiI plasmids and transformants selected on LB-agar 
supplemented with Tet, Amp, 0.4% D-glucose and 1 mM IPTG. The resulting strains were 
grown to mid-log phase in LB media with Tet, Amp, 0.4% D-glucose and 1 mM IPTG, then 
cells collected by centrifugation and resuspended in fresh LB supplemented with Tet, Amp, 1 
mM IPTG and 0.2% L-arabinose. Cell growth was monitored by measuring the optical 
density at 600 nm (OD600) as a function of time. Culture samples were harvested into an 
equal volume of ice-cold methanol, cells were collected by centrifugation and frozen at –80 
°C. RNA was isolated from the frozen cell pellets using guanidine isothiocyanate-phenol and 
10 µg of total RNA used for northern blot analysis as described 
248
. 
 
Growth competitions 
 E. cloacae inhibitor cells (CH11250 or CH11196) were co-cultured with target E. 
cloacae ∆cdiAI cells (CH11475) at a 10:1 ratio on LB-agar with 0.2% L-arabinose. Co-
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cultures were incubated at 37 °C for 4 hr and then cells harvested into 1 mL M9 salts for 
serial dilution and colony forming unit (CFU) enumeration on selective media. Immunity 
function was evaluated through expression of cdiI genes in targets from pCH450 constructs. 
Cross-species competitions were performed under the same conditions using E. coli strain 
CH10013 as targets. Immunity function was assessed in E. coli targets through cdi 
expression from pTrc constructs. 
The chimeric EC93-ECL CDI system was expressed in E. coli EPI100 cells from cosmids 
pCH10445 and pCH10508. The CDI
+
 inhibitors were mixed at a 1:1 ratio with E. coli 
CH10013 target cells in LB media and incubated at 37 °C with shaking in a baffled flask for 
three hours. Samples were taken periodically for enumeration of viable target cells as 
CFU/mL. E. coli EPI100 carrying cosmid pWEB-TNC (Epicentre) was used as a mock 
(CDI
–
) inhibitor and immunity function was assessed using plasmid pTrc expression 
constructs. Co-culture samples were harvested into an equal volume of ice-cold methanol for 
subsequent RNA analysis as described above. 
 
Results 
Crystallization and structure of the CdiA-CT
ECL
/CdiI
ECL
 complex 
 In a previous study, we used structural analysis to elucidate the activities of CDI 
toxins from E. coli EC869 and Burkholderia pseudomallei 1026b 
122
. Because the CDI 
toxin/immunity pair from E. cloacae ATCC 13047 shares no obvious sequence homology 
with proteins of known function, we followed a similar structure-based approach to 
characterize this system. The CdiA-CT
ECL
 region is demarcated by the AENN peptide motif 
and corresponds to residues Ala3087 to Asp3321 of full-length CdiA
ECL
. We co-expressed 
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CdiA-CT
ECL
 with His6-tagged CdiI
ECL
 and purified the complex to near homogeneity. The N-
terminal region of CdiA-CT
ECL
 underwent significant degradation during crystallization, 
presumably because this region is disordered. Similar N-terminal degradation has been 
observed with other CdiA-CTs 
122
. The CdiA-CT
ECL
/CdiI
ECL
 complex crystallized in space 
group P4122 with one heterodimeric complex per asymmetric unit. The structure was solved 
by selenium multiple wavelength anomalous dispersion (Se-MAD) phasing to 2.4 Å 
resolution. The final refined model contains CdiA-CT
ECL
 residues 160 – 235 (numbered from 
Ala1 of the AENN motif) and CdiI
ECL
 residues 1 – 145. In addition, 62 well-resolved water 
molecules are included in the final model resulting in Rwork/Rfree of 18.3/23.7.                                     
 The resolved
 
C-terminal domain of CdiA-CT
ECL
 consists of an N-terminal -helix 
followed by a twisted five-stranded antiparallel β-sheet (Fig. 1A). The domain contains two 
long loops, L2 and L4, which connect β1 to β2 and β3 to β4, respectively (Fig. 1A). Weak 
electron density was observed for loop L4, likely due to its flexibility, and thus Ser206 – 
Asn211 were modeled as alanine residues. The CdiI
ECL
 immunity protein comprises three- 
and four-stranded antiparallel β-sheets, forming a β-sandwich that is decorated with three -
helices (Fig. 1A). The toxin and immunity protein interface is elaborate and mediated by a 
series of hydrogen-bonds (H-bond), electrostatic and hydrophobic interactions. CdiA-CT
ECL
 
residues within loops L2 – L6 form H-bonds and ion-pair interactions with CdiIECL residues 
in loops L1´, L2´ and L3´ and the edge of the β-sandwich (β3´, β5´ and β6´) (Fig. 1B). 
Notably, Arg222 and the C-terminal Asp235 residue of CdiA-CT
ECL
 interact extensively with 
the immunity protein. A water-mediated network of H-bonds also contributes to the interface, 
resulting in more than 20 ion-pair/H-bond interactions between toxin and immunity proteins. 
In addition, there is a hydrophobic interface of approximately 300 Å
2
 consisting of Ile178, 
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Val192, Tyr199 and Phe216 from CdiA-CT
ECL
, and Phe76, Phe78, Val95 and Phe97 from 
CdiI
ECL 
(Fig. 1C). Overall, the CdiA-CT
ECL
/CdiI
ECL
 complex has an interface of 1399 Å
2
, 
burying 27.6 and 17.1% of the solvent-accessible surface areas of the toxin and immunity 
proteins, respectively.          
 
CdiA-CT
ECL
 is structurally homologous to the nuclease domain of colicin E3 
 CdiA-CT
ECL
 shares no structural homology with previously characterized CDI toxins 
from E. coli EC869 and B. pseudomallei 1026b 
120,122
. Searches for structural homologues 
using the DALI server 
262
 revealed that CdiA-CT
ECL
 is similar to the C-terminal nuclease 
domain of colicin E3 (ColE3-CT). Colicin E3 is a plasmid-encoded bacteriocin found in 
some E. coli strains, and its nuclease domain cleaves 16S rRNA between residues A1493 and 
G1494 (E. coli numbering) to interfere with protein synthesis 
105,108
. The CdiA-CT
ECL 
and 
ColE3-CT domains share a twisted antiparallel β-sheet and superimpose with an rmsd of 2.1 
Å over 76 -carbons, corresponding to a Z-score of 4.8, whereas the sequence identity 
between the two domains is approximately 18% (Figs. 2A & S2). Residues Asp510, His513 
and Glu517 of colicin E3 are thought to function directly in catalysis 
104,105,263
, and CdiA-
CT
ECL
 residues Asp203, Asp205 and Lys214 superimpose upon the colicin E3 active-site 
residues (Figs. 2B & S2). Together, these structural similarities suggest that CdiA-CT
ECL
 
may also share 16S rRNA nuclease activity with colicin E3. 
Although the CdiA-CT
ECL
 and ColE3-CT toxin domains are structurally similar, the 
corresponding immunity proteins are not related to one another in either primary or tertiary 
structure (Figs. S3A & S3B). The colicin E3 immunity protein (ImE3) is significantly 
smaller than CdiI
ECL
 (~9.9 versus 16.9 kDa), and the two proteins have different folds (Fig. 
120 
 
S3B). A DALI search reveals that CdiI
ECL
 is most similar to the Whirly family of single-
stranded DNA binding proteins 
264
. The closest structural homologues are two proteins of 
unknown function from cyanobacteria (PDB ID codes: 2IT9 and 2NVN), which superimpose 
onto CdiI
ECL
 with rmsd of 3.6 – 4.0 Å over 120 – 122 α-carbons (Fig. S3C). The two 
immunity proteins also bind to different sites on their cognate toxin domains. ImE3 binds to 
an 'exosite' that leaves the colicin E3 active site exposed 
103
, whereas CdiI
ECL
 binds directly 
over the predicted active site (Fig. 2C). Structural alignment of the complexes reveals that the 
immunity binding occurs at distinct non-overlapping positions (Fig. 2D). Interestingly, 
ColE3-CT contains a C-terminal extension not found in CdiA-CT
ECL
 (Fig. 2A). This C-
terminal tail forms a short -helix in some ColE3-CT structures, and this structure would 
likely interfere with CdiI
ECL
 binding were it present in CdiA-CT
ECL
. Similarly, the 
orientation of loop L2 differs considerably between the toxins (Fig. 2A), and these loops 
could block the binding of non-cognate immunity proteins (Fig. 2D). Despite these 
differences, each immunity protein is predicted to prevent its cognate toxin from entering the 
ribosome A site (Figs. S4A & S4B), and therefore toxin inactivation is fundamentally the 
same for both systems.  
 
CdiA-CT
ECL
 cleaves 16S rRNA in vivo and inhibits cell growth 
 To test CdiA-CT
ECL
 for nuclease activity, we cloned the cdiA-CT
ECL
 coding sequence 
under the control of the arabinose-inducible PBAD promoter and expressed the toxin in E. coli 
cells. Cells carrying this construct do not grow in the presence of L-arabinose, but control 
cells with the empty plasmid vector grow unimpeded (Fig. 3A). Northern blot analysis 
revealed that the 3´-end of 16S rRNA is cleaved in cells that express cdiA-CT
ECL
 but not in 
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control cells (Fig. 3B). We next tested whether this toxin activity is neutralized by CdiI
ECL
. 
We cloned the cdiI
ECL
 immunity gene under control of an IPTG-inducible promoter and 
introduced the resulting plasmid into cells that harbor the arabinose-inducible toxin construct. 
Cells that co-express cdiA-CT
ECL
 and cdiI
ECL
 grow at the same rate as control cells carrying 
the empty vector (Fig. 3A), indicating that the immunity protein is fully protective. 
Furthermore, no 16S rRNA cleavage is detected in cells that co-express toxin and immunity 
proteins (Fig. 3B), strongly suggesting that the nuclease activity is responsible for growth 
inhibition. 
 Kleanthous and colleagues have predicted that a different CdiA-CT from Erwinia 
chrysanthemi EC16 also possesses colicin E3-like activity 
104
. CdiA-CT
EC16
 appears to have 
the same catalytic motif as ColE3-CT 
104,265
, but does not share significant sequence identity 
with CdiA-CT
ECL
 (Fig. S2B). The CdiI
EC16
 and CdiI
ECL
 immunity proteins also appear to be 
unrelated based on primary sequence. We expressed cdiA-CT
EC16
 in E. coli cells and found 
that this toxin also inhibits cell growth and induces 16S rRNA cleavage (Figs. 3A & 3B). 
Both growth inhibition and nuclease activities are blocked by co-expression of cdiI
EC16
, but 
not cdiI
ECL
 (Figs. 3A & 3B). Similarly, expression of cdiI
EC16
 does not protect against the 
toxic effects of cdiA-CT
ECL
 expression (Figs. 3A & 3B). Thus, although the CDI toxins 
appear to share biochemical activities, only cognate immunity proteins are able to block 
toxicity.  
 
CdiA-CT
ECL
 cleaves 16S rRNA in vitro 
 In principle, CdiA-CT
ECL
 and CdiA-CT
EC16
 could induce an endogenous nuclease that 
is actually responsible for 16S rRNA cleavage. Therefore, we tested purified CdiA-CTs for 
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nuclease activity in vitro. Each CdiA-CT/CdiI-His6 pair was first purified as a complex, and 
then the toxins were isolated from immunity proteins using Ni
2+
-affinity chromatography 
under denaturing conditions. Purified CdiA-CTs were refolded by dialysis against non-
denaturing buffer prior to activity assays. Before testing for RNase activity, we first 
confirmed that each refolded toxin is able to re-bind its cognate immunity protein. We mixed 
CdiI-His6 with either cognate or non-cognate CdiA-CT and subjected the mixtures to Ni
2+
-
affinity chromatography under non-denaturing conditions. Each CdiA-CT co-purified with its 
cognate immunity protein (Fig. S5A), indicating that the toxins can re-establish specific 
binding interactions after denaturation and refolding. We next treated ribosomes with the 
CdiA-CTs and analyzed the reactions by northern blot hybridization. Purified CdiA-CT
ECL
 
and CdiA-CT
EC16
 both cleave a 3´-fragment from 16S rRNA, and the activity of each toxin is 
blocked by equimolar cognate CdiI protein (Fig. 4).  
 We next used primer extension analysis to determine whether the CDI toxins cleave 
16S rRNA at the same position as colicin E3. We generated an oligonucleotide that 
hybridizes to residues C1501 – C1521 of E. coli 16S rRNA (Fig. 5A) and used it as a primer 
in reverse transcription reactions to screen for cleavage sites. Residue U1498 of 16S rRNA is 
methylated at the N3 position (Fig. 5A) and this modified base is predicted to interfere with 
reverse transcription. Therefore, we repeated the in vitro nuclease reactions using ribosomes 
isolated from an E. coli ∆rsmE::kan mutant, which lacks the U1498 methyltransferase 266. 
Analysis of these nuclease reactions shows a strong primer-extension arrest corresponding to 
residue G1494 (Figs. 5A & 5B). This primer extension product is not observed when 
ribosomes are mock-treated with buffer, nor when the reactions contain equimolar cognate 
CdiI protein (Fig. 5b). These data are consistent with CdiA-CT-mediated cleavage of the 
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phosphodiester bond linking residues A1493 and G1494 (Fig. 5A). Thus, CdiA-CT
ECL
 and 
CdiA-CT
EC16
 both appear to cleave 16S rRNA at the same site as colicin E3. 
 Colicin E3 binds near the A site of 70S ribosomes
103
. We reasoned that CdiA-CT
ECL 
should also bind in the A site if it cleaves at the same position as colicin E3. To test this, we 
incubated 70S ribosomes with the A site acting antibiotics streptomycin and gentamicin and 
asked if they could block CdiA-CT
ECL 
activity. As a specificity control, erythromycin, which 
is an antibiotic that functions at the exit tunnel, was included. The Northern blot analysis to 
the reactions show that CdiA-CT
ECL 
activity is blocked by the addition of A site acting 
antibiotics, but not erythromycin (Fig S1), indicating CdiA-CT
ECL 
likely binds to the A site 
of ribosomes.  
 
Mutational analysis of the CdiA-CT
ECL 
active site  
 The side-chains of CdiA-CT
ECL
 Asp203 and Lys214 overlay with active-site residues 
Asp510 and Glu517 (respectively) of colicin E3 (Figs. 2B & S2). However, because loop L4 
is not well resolved in the CdiA-CT
ECL
 structure, it is difficult to unambiguously identify a 
catalytic residue corresponding to His513 of colicin E3. Therefore, we mutated CdiA-CT
ECL
 
residues Asp203, Asp205, His207 and Lys214 individually to alanine and tested the resulting 
proteins for toxicity in vivo and 16S rRNase activity in vitro. CdiA-CT
ECL
 variants containing 
Asp203Ala, His207Ala or Lys214Ala mutations have no effect on E. coli cell growth (Fig. 
6A), suggesting that nuclease activity is disrupted. The Asp205Ala variant shows a delayed 
inhibition phenotype, in which cell growth is arrested ~90 min after toxin expression is 
induced (Fig. 6A). Comparable results were obtained with in vitro reactions using purified 
toxin variants. CdiA-CT
ECL
 carrying the Asp203Ala, His207Ala and Lys214Ala mutations 
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have no detectable rRNase activities in vitro, whereas the Asp205Ala variant exhibits lower 
activity than the wild-type enzyme (Fig. 6B). We note that all the CdiA-CT
ECL
 variants 
appear to be folded properly, because each protein efficiently re-binds cognate CdiI
ECL
 
immunity protein (Fig. S5B). Together, these experiments indicate that Asp203, His207 and 
Lys214 are required for toxin activity and could function in catalysis, whereas Asp205 plays 
an important yet non-essential role. 
 
CdiA-CT
ECL
 is delivered into target bacteria during CDI 
 We next asked whether the E. cloacae CDI system is expressed and deployed for 
competition. We reasoned that E. cloacae mutants lacking the immunity gene should be 
susceptible to inhibition. We deleted the cdiA
ECL
 and cdiI
ECL
 genes and tested the resulting 
double-mutant strain in competition co-cultures with wild-type E. cloacae cells. We found 
that the E. cloacae ∆cdiAECL ∆cdiIECL mutants are not inhibited by wild-type cells in either 
liquid or solid media (Fig. 7A and data not shown), suggesting that the CDI
ECL
 system is not 
functional or may not be expressed under laboratory conditions. Therefore, we introduced the 
E. coli araBAD promoter upstream of the E. cloacae cdi locus to allow inducible expression 
of the system with arabinose and used this inducible inhibitor strain for competitions on solid 
growth media. When the CDI
ECL
 system is induced, the growth of target cells is suppressed 
approximately 16-fold compared to co-cultures with E. cloacae cells carrying the wild-type 
cdi locus  (Fig. 7A). Moreover, target cell growth is restored if they carry a plasmid-borne 
copy of the cdiI
ECL
 immunity gene, but the non-cognate cdiI
EC16
 gene provides no protection 
(Fig. 7A). We also tested the inducible E. cloacae inhibitor cells in co-cultures with E. coli 
target cells. Because E. cloacae ATCC 13047 uses one of its type VI secretion systems to 
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inhibit E. coli 
118
, we first deleted the vasK1 gene (ECL_01536) from the E. cloacae inhibitor 
strain to inactivate type VI secretion. Remarkably, E. coli cells are more sensitive to growth 
inhibition, with viable target cell counts reduced ~100-fold after four hrs of co-culture (Fig. 
7B). Notably, E. coli cell growth is unaffected during co-culture with E. cloacae containing 
the wild-type cdi locus (Fig. 7B), again indicating that the CDI
ECL
 system is not expressed on 
lab media. Moreover, E. coli targets are protected by plasmid-borne cdiI
ECL
, but not cdiI
EC16
 
(Fig. 7B), confirming that growth inhibition is due to CdiA-CT
ECL
 toxin activity. 
 Many CdiA-CT toxins are modular and can be exchanged between different CdiA 
proteins to generate functional effector molecules 
115,116,120,122
. To test whether the CdiA-
CT/CdiI
ECL
 toxin/immunity protein complex is functional in the context of another CDI 
system, we replaced the cdiA-CT/cdiI
EC93
 region of the E. coli EC93 CDI system with the E. 
cloacae toxin/immunity coding sequences. This fusion produces a chimeric CdiA protein 
with CdiA-CT
ECL
 grafted onto CdiA
EC93
 at the VENN peptide motif. E. coli cells expressing 
the CdiA
EC93
-CT
ECL
 chimeric effector protein are potent inhibitors. Viable E. coli target cells 
are reduced ~10
4
-fold after three hrs of co-culture in broth with CdiA
EC93
-CT
ECL
 inhibitors 
(Fig. 8A). Again, target cells that carry the cdiI
ECL
 immunity gene are not inhibited and grow 
to the same level as cells cultured with mock-inhibitor cells that lack a CDI system (Fig. 8A). 
However, target cells expressing non-cognate cdiI
EC16
 are inhibited to the same extent as 
cells that carry no immunity gene (Fig. 8A). Because the inhibition effect is so profound in 
these co-culture experiments, we asked whether toxin-damaged ribosomes could be detected 
in the target cells. We isolated total RNA from each competition co-culture and performed 
northern blot analysis to assay for RNase activity. Cleaved 16S rRNA is readily detected 
when the target cells lack immunity or express non-cognate cdiI
EC16
 immunity (Fig. 8B). This 
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nuclease activity is not observed when target cells carry the cognate cdiI
ECL
 gene (Fig. 8B). 
We also generated and tested a chimeric CdiA
EC93
-CT
ECL
 effector carrying the His207Ala 
active site mutation in the CdiA-CT
ECL
 toxin domain. Cells expressing this mutant effector 
do not inhibit E. coli targets, and no 16S rRNA cleavage is detected in the competition co-
culture (Figs. 8A & 8B). Together, these results demonstrate that the CdiA-CT
ECL
 toxin is 
delivered into target bacteria during CDI and that 16S RNase activity is solely responsible for 
growth inhibition. 
 
Discussion 
 These studies demonstrate that the C-terminal toxin domain of CdiA
ECL
 adopts a 
structure that is similar to the C-terminal nuclease domain of colicin E3. In accord with the 
structural homology, the CdiA-CT
ECL
 toxin domain has the same 16S rRNase activity as 
colicin E3, and this activity is required for growth inhibition. A catalytic mechanism of 
colicin E3 activity has been proposed by Ramakrishnan, Kleanthous and their colleagues 
based on the structure of ColE3-CT bound to the ribosome 
105
. Their model postulates that 
Glu517 of colicin E3 acts a general base to abstract a proton from the 2´-OH of 16S rRNA 
residue A1493. The resulting alkoxide subsequently attacks the phosphodiester linking 
A1493 and G1494 to cleave the 16S rRNA chain. The charged imidazole side-chain of 
His513 is thought to stabilize the transition state as well as donate a proton to the 5´-OH 
leaving group after cleavage. Colicin E3 residues Asp510 and Glu515 are within hydrogen-
bonding distance of His513 and may promote its protonation 
105
. Although ColE3-CT and 
CdiA-CT
ECL
 have a similar arrangement of predicted active-site residues, there are also 
differences that may be functionally significant. For example, CdiA-CT
ECL
 loop 4, which 
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contains the predicted active-site residues, is longer and displaced relative to the 
corresponding loop in colicin E3. Loop 4 also interacts directly with CdiI
ECL
, so it is possible 
that this region is positioned akin to colicin E3 in the absence of immunity protein. 
Flexibility of this region could also explain why the side-chains for loop L4 (Ser206 – 
Asn211) are not resolved in the final model. Superimposition of nuclease domains reveals 
that the side-chains for residues Asp203, Asp205 and Lys214 of CdiA-CT
ECL
 are in the same 
relative positions as Asp510, His513 and Glu517 of colicin E3, respectively. Mutagenesis of 
these CdiA-CT
ECL
 residues indicates that they are important for nuclease activity, but it is 
unclear whether they play the same catalytic roles as in colicin E3. For example, Lys214 in 
CdiA-CT
ECL
 is unlikely to function as a generalized base as proposed for Glu517 of ColE3-
CT, especially as nearby residues Asp203 and Asp205 in CdiA-CT
ECL
 should favor side-
chain protonation. Lysine residues are often found in the active sites of nucleases, where they 
typically function to position the scissile phosphodiester or stabilize pentavalent transition 
states 
267-269
. Additionally, residue His207 is also critical for CdiA-CT
ECL
 activity. A more 
definitive model of CdiA-CT
ECL
 catalysis must likely await a structure of the toxin bound to 
the ribosome. 
 The colicin E3 nuclease domain makes a series of specific contacts with the ribosome 
A site that are presumably important for substrate binding. The residues mediating the 
ribosome contact are highly conserved amongst other E3-like enzymes such as colicins E4, 
E6 and cloacin DF, but in most instances, the CdiA-CT
ECL
 nuclease domain does not share 
this homology. In particular, ColE3-CT loop L2 (linking β1 to β2) makes a number of 
specific contacts with the ribosome A site. Arg495 and Gln489 bind the nucleobase and 
phosphate of A1493, Lys496 interacts with C518 and Lys494 holds G530 in the syn 
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conformation through a bridging water molecule 
105
. Not one of these residues is shared with 
CdiA-CT
ECL
 (see Fig. S2A). In fact, loop L2 of CdiA-CT
ECL
 is significantly displaced 
compared to the corresponding loop in ColE3-CT. This displacement may result from the 
binding of CdiI
ECL
, which would clash with loop L2 if it were in the ColE3-CT 
conformation. In the absence of CdiI
ECL
, it is possible that loop L2 adopts a conformation 
similar to that of the ColE3-CT domain, but L2 sequence divergence suggests that each loop 
makes distinct contacts with the ribosome. Similarly, colicin E3 residues that contact 
ribosomal protein S12 are not conserved within CdiA-CT
ECL
. Colicin E3 residues Tyr460 – 
Tyr464 form an intriguing pseudo-β-sheet interaction with S12, with the side-chains of 
His462, Asp463 and Tyr464 making specific hydrogen-bond contacts with S12 
105
. The 
corresponding region of CdiA-CT
ECL
 was degraded during crystallization, precluding direct 
comparison with colicin E3. However, the relevant primary sequences reveal no obvious 
homology, suggesting that this region makes unique contacts if it does indeed interact with 
ribosomal protein S12.   
 The other striking difference between the two systems is the immunity protein. 
CdiI
ECL
 and ImE3 are significantly different in size, share less than 12% sequence identity, 
and bind to distinct, non-overlapping sites on their nuclease domains. Moreover, the two 
immunity proteins have different tertiary structures and folds. Structural homology searches 
reveal that the Whirly family of single-stranded DNA-binding proteins are most similar to 
CdiI
ECL
. This homology is relatively weak (Z-scores 4.1 to 4.3 and rmsd ~4.0 Å), but these 
proteins all share the same topology. The fact that the immunity proteins for colicin E3 and 
CdiA-CT
ECL
 toxins are unrelated in both primary sequence and tertiary structure suggests 
that these toxin-immunity pairs have independent origins. Toxin-immunity protein pairs are 
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thought to evolve through initial changes in the immunity protein, followed by compensatory 
changes in the toxin that restore high binding affinity between the two proteins 
270,271
. In 
general, there are fewer functional constraints to impede the mutational drift of immunity 
genes, which often only need to encode proteins that bind to toxins. By contrast, toxins are 
often enzymes that must retain the ability to bind substrates and catalyze reactions. These 
general assumptions are largely supported by analyses of CDI toxin-immunity families, in 
which immunity proteins typically share less sequence identity than the toxins 
167
. Thus, it is 
formally possible that ImE3 and CdiI
ECL
 arose from a common ancestor, but the different 
folds of these proteins make this possibility less likely. Moreover, in the overwhelming 
majority of cases, cognate toxin/immunity gene pairs are closely linked and therefore must 
presumably co-evolve as a unit. Therefore, it seems unlikely that the cdiI
ECL
 immunity gene 
evolved from an imE3 homologue. Based on this reasoning, we speculate that the CdiA-
CT
ECL
/CdiI
ECL
 protein pair evolved from a lineage that is distinct from ColE3-CT/ImE3. In 
this model, the structural and enzymatic similarities between CdiA-CT
ECL
 and ColE3-CT are 
the result of convergent evolution to target a highly conserved and critical structure in 
bacterial cells. 
 CDI systems are modular and related cdiA-CT/cdiI gene pairs are often found in 
different bacterial species. For example, Enterobacter sp. R4-368 contains a predicted CDI 
system that encodes a toxin (Uniprot: R9VTZ7) with 79% sequence identity (over 101 C-
terminal residues) to CdiA-CT
ECL
 and an immunity protein (Uniprot: R9VPD7) with 61% 
sequence identity to CdiI
ECL
. Several other enterobacteria (Yersinia aldovae, Photorhabdus 
luminescens, Photorhabdus asymbiotica and Xenorhabdus bovienii) carry "orphan" cdiA-
CT/cdiI modules that are also clearly related to the cdiA-CT
ECL
/cdiI
ECL
 pair. Orphan modules 
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represent the displaced 3´-ends of cdiA genes together with the linked immunity reading 
frame. These gene pairs are often found in tandem arrays downstream of cdiBAI loci 
121
. 
Additionally, the CdiA-CT
ECL
 toxin domain is also found at the C-terminus of two other 
large proteins that are unrelated to CdiA. Streptomyces sp. HGB0020 encodes a YD-repeat 
protein (Uniprot: S2YVI0) with the toxin domain, and Amycolatopsis orientalis HCCB10007 
contains an uncharacterized protein of ~110 kDa (Uniprot: R4T474) that also contains a C-
terminal domain related to the CdiA-CT
ECL
 nuclease. We have recently shown that YD-
repeat proteins from both Gram-negative and Gram-positive bacteria deliver protein toxins 
into other bacteria in a contact-dependent manner 
252
, strongly suggesting that the 
Streptomyces YD-repeat protein deploys a 16S rRNase domain to inhibit neighboring cells. 
Consistent with this model, this YD-repeat gene is immediately followed by an unannotated 
reading frame that encodes a small protein sharing 36% sequence identity with CdiI
ECL
. 
Presumably, the 110 kDa protein from Amycolatopsis also functions in intercellular 
competition. The Amycolatopsis genomic neighborhood contains genes encoding VgrG and 
PAAR-domain proteins, which are often associated with antibacterial type VI secretion 
systems 
153,244,252
. Thus, the 110 kDa protein from Amycolatopsis may represent a new type 
of type VI effector protein. Finally, many strains of Neisseria gonorrhoeae and Neisseria 
meningitidis carry predicted toxins related to the CdiA-CT
ECL
 nuclease domain. The 
encoding genes are all found associated with mafABI loci, which are thought to encode 
adhesins that bind glycolipids on host mammalian cells 
272
. However, mafB genes encode 
variable C-terminal domains that are related to known toxins, strongly suggesting that they 
represent yet another contact-dependent toxin delivery system. Together, these observations 
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strongly suggest that sequences toxin/immunity gene pairs are horizontally exchanged 
between bacteria and fused to various toxin-delivery platforms. 
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Figure 1. Structure of the CdiA-CT/CdiI
ECL
 complex. A) The CdiA-CT
ECL
 toxin (teal) 
and CdiI
ECL
 immunity protein (salmon pink) are depicted in ribbon representation with 
secondary structure elements. The amino and carboxyl termini are indicated by N and C, 
respectively. CdiI
ECL
 elements are denoted with a prime symbol (´) to differentiate them from 
the toxin secondary structure elements. B) The CdiA-CT/CdiI
ECL
 interface is mediated by an 
extensive network of ion-pair and hydrogen-bond interactions. Residues are indicated in one-
letter code and rendered as stick representations. Water molecules are depicted as red spheres 
and interacting bonds as dotted lines. C) The CdiA-CT/CdiI
ECL
 interface also contains 
hydrophobic interactions mediated by the indicated residues.  
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Figure 2. CdiA-CT
ECL
 share structural similarities with the nuclease domain of colicin 
E3. A) Superimposition of CdiA-CT
ECL
 (teal) and the C-terminal nuclease domain of colicin 
E3 (ColE3-CT, orange) (PDB ID: 2B5U). The toxin domains superimpose with an rmsd of 
2.1 Å. B) Colicin E3 residues Asp510, His513 and E517 are involved in catalysis and 
superimpose with residues Asp203, Asp205 and Lys214 of CdiA-CT
ECL
. His207 of CdiA-
CT
ECL
 is located within disordered loop L4 and is modeled as an alanine residue. Residues 
are indicated in one-letter code and rendered as stick representations. C) The predicted CdiA-
CT
ECL
 active site is occluded by bound CdiI
ECL
. Interacting bonds are represented by black 
dotted lines. D) Superimposition of CdiA-CT/CdiI
ECL
 with the ColE3-CT/ImE3 complex. 
Ribbon representations of CdiA-CT
ECL
 (teal), CdiI
ECL
 (salmon pink), ColE3-CT (orange) and 
ImE3 (yellow) are depicted. Also see Figures S2 and S3. 
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Figure 3. CdiA-CT toxin activity in vivo. A) cdiA-CT
ECL
 and cdiA-CT
EC16
 expression was 
induced at 0 hr and cell growth monitored by measuring the culture optical density at 600 nm 
(OD600). Red curves are from cells that lack an immunity gene; and the green and blue curves 
represent cells that co-express cdiI
ECL
 and cdiI
EC16
, respectively. The black curve shows cell 
growth in the absence of toxin expression. B) Total RNA was isolated from the cells in panel 
A and analyzed by northern blot using a probe to the 3´-end of E. coli 16S rRNA. Toxin and 
immunity genes are indicated as ECL for E. cloacae and EC16 for E. chrysanthemi EC16. 
The migration positions of full-length and cleaved 16S rRNA are indicated. Also see Figure 
S4.  
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Figure 4. CdiA-CT toxin activity in vitro. A) Purified CdiA-CTs were mixed with 
equimolar CdiI
ECL
-his6 or CdiI
EC16
-his6 and put over a Ni
2+ 
column (input). The unbound 
(free) and bound (bound) fractions were collected and analyzed by SDS-PAGE. B) Isolated 
E. coli ribosomes were treated with purified CdiA-CT
ECL
 and CdiA-CT
EC16
, and the reactions 
analyzed by northern blot using a probe to the 3´-end of 16S rRNA. Where indicated, CdiI-
His6
ECL
 (ECL) or CdiI-His6
EC16
 (EC16) was added at an equimolar ratio to the toxin. Mock 
reactions are ribosome samples that were treated with buffer. The migration positions of full-
length and cleaved 16S rRNA are indicated. 
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Figure 5. CdiA-CT
ECL
 and CdiA-CT
EC16
 cleave 16S rRNA between A1393 and G1394. 
A) Nucleotide sequence and secondary structure of the 30S subunit decoding center. The 
sequence of the reverse transcription (RT) primer is shown in heteroduplex with its 
complementary sequence in 16S rRNA. Oligonucleotides C1496, G1494 and G1491 were 
used as gel-migration standards. The 16S rRNA cleavage site is indicated by an arrow. B) 
Ribosomal RNA was extracted from the indicated in vitro nuclease reactions and hybridized 
to radiolabeled RT primer for primer extension analysis using reverse transcriptase. 
Reactions were resolved on a denaturing gel and visualized by phosphorimaging. The 
migration positions of oligonucleotides C1496, G1494 and G1491 are indicated. 
 
 
 
 
 
 
 
 
137 
 
Figure 6. Mutagenesis of predicted active-site residues in CdiA-CT
ECL
. A) Expression of 
cdiA-CT
ECL
 and the indicated mutated variants were induced at 0 hr with L-arabinose and cell 
growth monitored by measuring the optical density of the culture at 600 nm (OD600). The 
black curve shows the growth of a control culture without toxin expression. B) Isolated E. 
coli ribosomes were treated with purified CdiA-CT
ECL
 toxins and RNA extracted for northern 
blot analysis. Where indicated, purified CdiI-His6
ECL
 was included in the reaction. The gel-
migration positions of full-length and cleaved 16S rRNA are indicated. C) See Figure S5.  
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Figure 7. Intercellular competitions with E. cloacae inhibitor cells. A) Intra-species 
competition. E. cloacae inhibitor cells were co-cultured with E. cloacae ∆cdiAECL ∆cdiIECL 
target cells on LB-agar supplemented with arabinose. Where indicated, target cells were 
provided with plasmid-borne cdiI
ECL
 or cdiI
EC16
 immunity genes. Total viable target cells 
were determined as colony forming units. Open bars correspond to competitions with 
arabinose-inducible inhibitor cells (PBAD-cdiBAI
+
), and grey bars correspond to competitions 
with inhibitors that carry the wild-type locus (cdiBAI
+
). B) Inter-species competition. E. 
cloacae inhibitor cells were co-cultured with E. coli target cells on LB-agar supplemented 
with arabinose. Where indicated, the target cells were provided with plasmid-borne cdiI
ECL
 or 
cdiI
EC16
 immunity genes. Viable target cells were determined as colony forming units (CFU), 
and data are reported as the mean ± SEM for two independent experiments. 
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Figure 8. The CdiA-CT
ECL
 toxin domain is modular. A) E. coli target cells were co-
cultured with inhibitor cells that express chimeric CdiA
EC93
-CT
ECL
 in broth. Where indicated, 
target cells were provided with plasmid-borne copies of the cdiI
ECL
 or cdiI
EC16
 immunity 
genes. The inhibitors labeled H207A express CdiA
EC93
-CT
ECL
 containing the His207Ala 
mutation in the toxin domain. Mock inhibitors lack the CDI system. Viable target cell counts 
were determined as CFU/mL, and data are reported as the mean ± SEM for two independent 
experiments. B) Total RNA was isolated from the co-culture experiments described in panel 
A and analyzed by northern blot using a probe to the 3´-end of 16S rRNA. 
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Figure S1. A-site antibiotics block CdiA-CT
ECL 
activity in vitro. 1uM CdiA-CT
ECL
 was 
incubated with 10uM of ribosomes with or without 15uM of Streptomycin (Strpt), 
Gentamicin (Gent), or Erythromycin (Erm) for 1 hour at 37º C. The reactions were analyzed 
by Northern blot to the 3’-end of 16S rRNA.  
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Figure S2. Alignment of CDI toxins with the nuclease domain of colicin E3. A) The 
sequences of CdiA-CT
ECL
 and ColE3-CT were aligned based on the superimposed structures 
of the nuclease domains. Secondary structure elements are indicated as blue α-helices and 
orange β-sheets. The underlined residues correspond to loop L2 regions, which adopt 
different positions in the two domains. Italicized residues in CdiA-CT
ECL
 correspond to the 
unresolved loop L4 region. Identical residues are rendered in green and the predicted active-
site residues are shown in red. B) Alignment of CdiA-CT
EC16
 and ColE3-CT sequences. The 
toxin sequences were aligned using Clustal-W. Identical residues are rendered in green and 
the predicted active-site residues are shown in red. 
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Figure S3. CdiI
ECL
 and ImE3 immunity proteins are unrelated. A) Alignment of CdiI
ECL
 
and ImE3 immunity proteins sequences using Clustal-W. The proteins share 11.7% identity, 
with identical residues are rendered in green. B) Topologies of CdiI
ECL
 and ImE3 immunity 
proteins. The N- and C-termini are indicated for each immunity protein as are the secondary 
structure elements. C) Superimposition of CdiI
ECL
 and Uniprot entry Q31MH7 from 
Synechococcus elongatus PCC 7942 (PDB: 2NVN). The proteins overlay with rmsd 3.6 Å 
over 121 α-carbons and a Z-score of 4.1. 
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Figure S4. Modeling of CdiA-CT
ECL
 on the ribosome. A) Superimposition of CdiA-CT
ECL
 
(teal ribbon) onto the structure of ColE3-CT bound to the ribosome in the post-cleavage state 
(PDB: 1JCH). The surface of the ribosome is rendered in grey, and the cleaved 16S rRNA 
strand is shown in ribbon representation. The ColE3-CT domain has been removed for 
clarity. Putative CdiA-CT
ECL
 active-site residues and 16S rRNA residue A1493 are shown in 
stick representation with nitrogen, oxygen and phosphate atoms colored blue, red and orange, 
respectively. B) CdiI
ECL
 (salmon pink) is superimposed upon the model to illustrate steric 
clashes that should prevent the complex from binding the ribosome A site. 
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Figure S5. CdiA-CT/CdiI binding interactions. A) SDS-PAGE analysis of CDI 
toxin/immunity protein binding. Isolated CdiA-CT toxins and CdiI-His6 immunity proteins 
were mixed and subjected to Ni
2+
-affinity chromatography under non-denaturing conditions. 
Lanes labeled input represent CdiA-CT/CdiI-His6 mixtures prior to chromatography, lanes 
labeled free are proteins that fail to bind Ni
2+
-resin, and lanes labeled bound are samples that 
were eluted with imidazole. B) CdiA-CT
ECL
 toxin variants retain specific binding interactions 
with CdiI-His6
ECL
. Mutated toxins were mixed with cognate or non-cognate CdiI-His6 and 
processed as described for panel A. The migration positions of molecular weight standards 
are indicated and masses given in kDa. 
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Chapter 5. Exploring the role of CysK in the activation of a 
contact-dependent growth inhibition (CDI) toxin 
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Note: I collaborated on this project with Robert Morse and Parker Johnson from the 
laboratory of Celia Goulding at the University of California, Irvine. The crystal structure of 
CysK/CdiA-CT(H178A) was completed by Robert Morse and the structure of CysK/CdiA-
CT/CdiI was done by Parker Johnson. Other than the two structures, this work is my own.  
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Abstract 
Contact-dependent growth inhibition (CDI) is a bacterial competition system found 
throughout proteobacteria. It is compised of three genes, cdiBAI, where CdiB exports the 
large effector protein CdiA to the surface of CDI
+ 
cells. The C-terminal toxin domain of 
CdiA (CdiA-CT) gets delivered into target cells to cause growth inhibition while CdiI binds 
to CdiA-CT to neutralize its lethal activity. CdiA-CTs are polymorphic and encode for a 
variety of toxic activities. CdiA-CT from UPEC536 (CdiA-CT
UPEC536
) demonstrates general 
tRNase activity that requires the protein co-factor, CysK, for activity both in vitro and in 
vivo. Here, we show the crystal strucure of the CysK/CdiA-CT/CdiI
UPEC536
 ternary complex, 
suporting previous studies that CdiA-CT
UPEC536
 binds in the active site of CysK. We identify 
the active-site residues of CdiA-CT
UPEC536
 and demonstrate that a variety of distant cysK 
alleles can still bind to and activate CdiA-CT
UPEC536
. We identify a distant homolog of CdiA-
CT
UPEC536
 from the Gram-positive species Ruminoccocus lactaris that does not require CysK 
and consequently has unique tRNase activity. Lastly, we show this distant homolog can be 
delivered into Gram-negative target cells via the CDI pathway. Taken all together, our results 
suggest CysK acts as a chaperone for CdiA-CT and reveal the qualities it contains to allow it 
to serve as a sufficient co-factor in the CDI pathway.   
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Introduction 
Contact-dependent growth inhibition (CDI) is a bacterial competition system that requires 
physical contact for delivery of a toxic effector protein into target cells
112
. CDI systems are 
widespread throughout proteobacteria and are often found in pathogenicity islands. A three 
gene locus, cdiBAI, mediates competition, where cdiB/A encodes for a two-partner secretion 
system
112,114
. CdiB is an outer membrane protein that exports CdiA onto the surface of cells. 
CdiA is a 200-600 kDa hemagglutinin repeat protein that is predicted to extend several 
hundred angstroms from CDI
+
 cells
220
. The C-terminal domain of CdiA (CdiA-CT) encodes 
a toxin
121
. When CdiA comes in contact with a receptor protein on target cells, through an 
unknown mechanism, CdiA-CT gets delivered into the cytoplasm, resulting in growth 
inhibition
116
. cdiI encodes for an immunity protein that binds to and inactivates CdiA-CT, 
thus protecting CDI
+
 cells from its own toxin
122
.  
CdiA is highly conserved amongst different Escherichia coli strains until the last 200 
amino acids where the toxic domain is demarcated by a conserved VENN peptide motif
121
. 
Consistent with the polymorphism seen in CdiA-CTs, they have distinct toxic activities
121
. 
Thus far, CdiA-CTs have been shown to be nucleases or pore-forming proteins
167
. The 
nucleases target tRNA or DNA to stop protein synthesis and replication, respectively
122
. The 
pore-formers dissipate proton-motive force upon insertion into the inner membrane
125
. With 
varying CdiA-CT sequence and activity, it is conceivable that each CdiI protein is 
polymorphic, as only a cognate immunity protein will inactivate toxin activity
115
. Likewise, 
in vitro experiments demonstrate that immunity proteins bind specifically to their cognate 
CdiA-CTs and block nuclease activity
115
. Non-cognate immunity proteins do not bind and 
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therefore will not block activity
115
. Ultimately, CDI systems contain a repertoire of toxins, 
thus allowing for diverse competition in the environment.   
In 2013, Diner et al. showed that CdiA-CT from uropathogenic E. coli 536 (CdiA-
CT
UPEC536
) is a general tRNase that cleaves in the single-stranded anti-codon loop of 
tRNA
123
. Surprisingly, this toxin requires a protein co-factor, CysK, which is necessary for 
tRNase activity both in vitro and in vivo
123
. CysK is a metabolic enzyme involved in the last 
step of cysteine biosynthesis. CysE takes serine and acetylates it to form O-acetylserine 
(OAS), and then CysK replaces the acetate with sulfide to form cysteine
273
. In E. coli, and 
closely related species, the C-terminus of CysE binds in the active site of CysK, forming the 
cysteine synthase complex
274
. CysM is an isomer of CysK that shares 39% sequence 
homology but does not bind CysE. CysM can use both sulfide and thiosulfate as the sulfur 
donor while CysK can only use sulfide
273
. It is thought that CysM is expressed under 
anaerobic conditions, while CysK dominates under aerobic conditions. The accumulation of 
OAS will result in spontaneous cyclisation to form N-acetylserine (NAS), which does not act 
as a substrate for CysK
275
. Instead, NAS serves as a co-factor for CysB, which will stimulate 
expression of cysK; thus accumulation of OAS will lead to increased expression of cysK
275
.   
Diner et al. showed that CysK, but not CysM physically binds to CdiA-CT 
UPEC536 123
. 
Furthermore, the absence of CysE does not affect target cell susceptibly to CDI
UPEC536
 (data 
not shown). This suggests the physical binding of CysK to the toxin, and nothing to do with 
cysteine biosynthesis, is what activates it for tRNase activity.  Interestingly, CdiI
UPEC536 
can 
still interact with the toxin when it is bound to CysK, suggesting CdiI
UPEC536 
and CysK have 
discrete binding sites
123
. Furthermore, the C-termini of CysE and CdiA-CT
UPEC536 
are similar, 
the former ending in GDGI, the latter in GYGI. Diner et al. demonstrated that residues GYGI 
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in the toxin are necessary, but not sufficient for binding to CysK (unpublished data). 
Additionally, they showed that incubating CysK with its substrate, OAS, could compete with 
toxin binding while NAS could not
123
. Taken together, this suggests CdiA-CT
UPEC536
 binds in 
a similar manner as CysE, in the active site of CysK.  
Here we show the crystal structure of E. coli CysK bound to CdiA-CT/CdiI
UPEC536
. The 
structure demonstrates that CdiA-CT
UPEC536
 does in fact bind in the active site of CysK and 
CdiI
UPEC536 
shows no interactions with CysK. We perform mutational analysis to identify  the 
active-site residues required for tRNase activity in vitro and in vivo. We show that a cohort of 
CysK alleles from different species can still bind to and activate CdiA-CT
UPEC536
, 
demonstrating the importance of exploiting a conserved co-factor. Lastly, we look at a distant 
homolog of CdiA-CT
UPEC536
, which does not require CysK for activity, for some insights into 
the evolution of the toxin. From here forward, CdiA-CT
UPEC536 
will be referred to as CdiA-
CT or simply, CT.  
 
Materials and Methods  
Strain or 
plasmid 
Description Reference 
Strains
a
   
BL21-
Gold(DE3) 
E. coli B, F
–
 ompT hsdS(rB
–
 mB
–
) dcm
+
 gal l(DE3) 
endA Hte, Tet
R
 
Stratagene 
X90 
F´ lacI
q
 lac´ pro´/ara ∆(lac-pro) nal1 argE(amb) 
rif
r 
thi-1, Rif
R
  
177
 
EPI100 
F
–
 mcrA ∆(mrr-hsdRMS-mcrBC) φ80dlacZ∆M15 
∆lacXcZ∆M15 ∆lacX recA1 endA1 araD139 
∆(ara, leu)7697 galU galK ë– rpsL nupG, StrR 
Epicentre 
DY378 W3110 lcI857 ∆(cro-bio) 247 
CH1944 X90 (DE3) ∆rna, RifR 248 
CH2016 X90 (DE3) ∆rna ∆slyD::kan, KanR 248 
151 
 
CH10801 JCM158Rif
R cysK This study 
CH8602 X90 cysK 
123
 
Plasmids 
pTrc99a 
IPTG-inducible expression plasmid, 
Amp
R
 
GE 
Healthcare 
pCH450 
pACYC184 derivative with E. coli 
araBAD promoter for arabinose-inducible 
expression, Tet
R
 
249
 
pCP20 
Heat-inducible expression of FLP 
recombinase, Cm
R
 Amp
R 
225
 
pWEB-TNC Cosmid cloning vector, Amp
R
 Cm
R
 Epicentre 
pCH10163 
Cosmid pCdiA-CT/pheS* that carries a 
kan-pheS* cassette in place of the E. coli 
EC93 cdiA-CT/cdiI coding sequence. Used 
for allelic exchange and counter-selection. 
Cm
R
 Kan
R
 
122
 
pET21P::cdiA-
CT/cdiI
UPEC536
 
Overproduces CdiA-CT/CdiI
UPEC536
-His6 
under control of phage T7 promoter, Amp
R
 
123
 
pET21P::cdiA-
CT(D155A)/cdiI
UPEC536
 
Overproduces CdiA-
CT(D155A)/CdiI
UPEC536
-His6 under control 
of phage T7 promoter, Amp
R
 
This study 
pET21P::cdiA-
CT(W176A)/cdiI
UPEC536
 
Overproduces CdiA-
CT(W176A)/CdiI
UPEC536
-His6 under control 
of phage T7 promoter, Amp
R
 
This study 
pET21P::cdiA-
CT(H178A)/cdiI
UPEC536
 
Overproduces CdiA-
CT(H178A)/CdiI
UPEC536
-His6 under control 
of phage T7 promoter, Amp
R
 
This study 
pET21P::cdiA-
CT(E181A)/cdiI
UPEC536
 
Overproduces CdiA-
CT(E181A)/CdiI
UPEC536
-His6 under control 
of phage T7 promoter, Amp
R
 
This study 
pET21P::cdiA-
CT(T185I)/cdiI
UPEC536
 
Overproduces CdiA-
CT(T185I)/CdiI
UPEC536
-His6 under control of 
phage T7 promoter, Amp
R
 
This study 
pBAD::cdiI
UPEC536 Overproduces CdiI
UPEC536
-His6 under 
control of araBAD promoter, Amp
R
 
123
 
pCH450::cdiA-
CT
UPEC536
 
Arabinose-inducible expression of cdiA-
CT
UPEC536
, Tet
R
 
224
 
pCH450::cdiA-
CT(N149D)
UPEC536
 
Arabinose-inducible expression of cdiA-
CT(N149AD)
UPEC536
, Tet
R
 
This study 
pCH450::cdiA-
CT(K152A)
UPEC536
 
Arabinose-inducible expression of cdiA-
CT(K152A)
UPEC536
, Tet
R
 
This study 
pCH450::cdiA-
CT(D155A)
UPEC536
 
Arabinose-inducible expression of cdiA-
CT(D155A)
UPEC536
, Tet
R
 
This study 
pCH450::cdiA- Arabinose-inducible expression of cdiA- This study 
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CT(W176A)
UPEC536
 CT(W176A)
UPEC536
, Tet
R
 
pCH450::cdiA-
CT(H178A)
UPEC536
 
Arabinose-inducible expression of cdiA-
CT(H178A)
UPEC536
, Tet
R
 
224
 
pCH450::cdiA-
CT(E181A)
UPEC536
 
Arabinose-inducible expression of cdiA-
CT(E181A)
UPEC536
, Tet
R
 
This study 
pCH450::cdiA-
CT(T185A)
UPEC536
 
Arabinose-inducible expression of cdiA-
CT(T185A)
UPEC536
, Tet
R
 
This study 
pCH450::cdiA-
CT(T185I)
UPEC536
 
Arabinose-inducible expression of cdiA-
CT(T185I)
UPEC536
, Tet
R
 
This study 
pCH450::cdiA-
CT(R187A)
UPEC536
 
Arabinose-inducible expression of cdiA-
CT(R187A)
UPEC536
, Tet
R
 
This study 
pCH450::cdiA-
CT(T185I)
EC93o1
 
Arabinose-inducible expression of cdiA-
CT(T185I)
EC93o1
, Tet
R
 
This study 
pET21P::cysK 
Overproduces CysK-His6 under control 
of phage T7 promoter, Amp
R
 
123
 
pET21P::CT/Imm.
R.
lactaris
 
Overproduces CT/Imm.
R.lactaris
-His6 under 
control of phage T7 promoter, Amp
R
 
This study 
pCH450:: 
CT/Imm.
R.lactaris
/DAS 
Arabinose-inducible expression of 
CT/Imm.
R.lactaris
/DAS, Tet
R
 
This study 
pCH450::cdiA-
CT/cdiI
UPEC536
/DAS 
Arabinose-inducible expression of cdiA-
CT/cdiI
UPEC536
/DAS, Tet
R
 
123
 
pCH450::cdiA-
CT(R.lactP139-
D143)/cdiI
UPEC536
/DAS 
Arabinose-inducible expression of cdiA- 
CT(R.lactP139-D143)cdiI
UPEC536
/DAS, Tet
R
 
This study 
pCH450::cdiA-
CT(R.lactP139-
D143,K127-
G134)/cdiI
UPEC536
/DAS 
Arabinose-inducible expression of cdiA- 
CT(R.lactP139-D143,K127-
G134)/cdiI
UPEC536
/DAS, Tet
R
 
This study 
pCH450::cdiA-
CT(R.lactN138-
L149)/cdiI
UPEC536
/DAS 
Arabinose-inducible expression of cdiA- 
CT(R.lactN138-L149)/cdiI
UPEC536
/DAS, Tet
R
 
This study 
pTrc99a::cdiI
UPEC53
6 Expresses CdiI
UPEC536 
This study 
pTrc99aKX::imm.
R.
lactaris Expresses Imm.
R.lactaris
 This study 
pDAL660∆1-39       Expresses CDIEC93, AmpR 112 
pDAL866       Expresses CDI
UPEC536
, Amp
R 
Cm
R 116
 
CH12389 
Constitutive expression of chimeric 
cdiA
EC93
-NT
UPEC536
CT
R.lactaris
 and imm.
R.lactaris
 
genes, Cm
R
 
This study 
CH12390 
Constitutive expression of chimeric 
cdiA
EC93
-NT
EC3006
CT
R.lactaris
 and imm.
R.lactaris
 
genes, Cm
R
 
This study 
pTrc99a::cysK-his6 
Constitutive expression of CysK-his6, 
Amp
R  
pTrc99a::cysK
D.dada
Constitutive expression of CysK-his6, This study 
153 
 
ntii
-his6 Amp
R
 
pTrc99a::cysK
E.cloac
ae
-his6 
Constitutive expression of CysK-his6, 
Amp
R
 
This study 
pTrc99a::cysK
B.subtili
s
-his6 
Constitutive expression of CysK-his6, 
Amp
R
 
This study 
pTrc99a::cysK
H.influe
nza
-his6 
Constitutive expression of CysK-his6, 
Amp
R
 
This study 
pTrc99a::cysK
N.lacta
mica
-his6 
Constitutive expression of CysK-his6, 
Amp
R
 
This study 
pTrc99a::cysK(K42
A)-his6 
Constitutive expression of CysK-his6, 
Amp
R
 
This study 
pTrc99a::cysK(Q14
3,F144A)-his6 
Constitutive expression of CysK-his6, 
Amp
R
 
This study 
pTrc99a::cysK(R10
1E,K102E)-his6 
Constitutive expression of CysK-his6, 
Amp
R
 
This study 
pTrc99a::cysK(K10
5E)-his6 
Constitutive expression of CysK-his6, 
Amp
R
 
This study 
pTrc99a::cysK(K22
1E)-his6 
Constitutive expression of CysK-his6, 
Amp
R
 
This study 
pTrc99a::cysK(K22
6A)-his6 
Constitutive expression of CysK-his6, 
Amp
R
 
This study 
pTrc99a::cysK(Q22
8E)-his6 
Constitutive expression of CysK-his6, 
Amp
R
 
This study 
pTrc99a::cysK(K28
3E)-his6 
Constitutive expression of CysK-his6, 
Amp
R
 
This study 
pTrc99a::cysK(30
7-324) 
Constitutive expression of CysK-his6, 
Amp
R
 
This study 
 
Bacterial strains and growth conditions 
 All bacterial strains and plasmids used in this study are listed the table above. 
Bacteria were grown in LB media or LB-agar with antibiotics at the following 
concentrations: ampicillin (Amp) 150 μg/mL; kanamycin (Kan) 50 μg/mL; rifampicin (Rif) 
200 µg/mL; spectinomycin (Spc) 100 μg/mL; chloramphenicol (Cm) 100 μg/mL and 
tetracycline (Tet) 10 μg/mL. The ∆cysK::kan mutation was transferred from the Keio 
collection into E. coli strain JCM158 by bacteriophage P1-mediated transduction
226
. The 
Kan
R 
cassette was removed via pCP20
225
.  
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Plasmid constructs 
 Protein overproduction constructs were generated using plasmid pET21S
115
. 
pET21P::cdiA-CT/cdiI constructs were made by amplifying cdiA-CT/cdiI with primers 536-
CT- Nco-for (5' - AGA CCA TGG TTG AGA ATA ATG CGC TGA G) and 536-cdiI-Xho-
rev (5' - GAT CTC GAG TAC AAT TAT CTG ATT GAT TTT T), digested with 
NcoI/XhoI, and ligated into digested pET21P. Point mutations were introduced into cdiA-CT 
using megaprimer PCR 
187
. Megaprimers were first generated using mutagenic reverse 
primers: 536-CT(D155A)-rev (5' - GAG AGT TCC AAT AAT AGC ATG ATC TTT CAG - 
3'), 536-CT(W176A)-rev (5' - CCT GCA TAT GAT CCG CAT ATC CTC CAT TC - 3'), 
536-CT(E181A)-rev (5' - GCG TAT TTT GCA TTG CCT GCA TAT GAT CC - 3'), 536-
CT(T185I)-rev (5' - TTC TTA ATC CTC TGA GGA TAT TTT GCA TTT CCT GC - 3') in 
conjunction with 536-cdiI-Xho-rev. These products were used in subsequent reactions with 
536-CT-Nco-for to generate complete cdiA-CT/cdiI modules, which were ligated into 
pET21P. The CT/immI
R.lactaris
 region was generated by IDT, digested with NcoI/SpeI and 
ligated into pET21P and p6520
123
. 
cdiA-CT(R.lactP139-D143)/cdiI/DAS was made with megaprimer 5' - CAT GCG GAT 
ACG TTG AAA AAC CCC AAC CTC TCA GAC GTC AAC AAT CCT GAA GCT C - 3'   
cdiA-CT(R.lactP139-D143,K127-G134)/cdiI/DAS with 5' - CGC TCA GAG GAT TAA 
GAA AGA TCA AAA AGG GAT TAG AGG GGA CGT TGA AAA ACC CCA AC - 3' off 
of the P139-D143 construct. cdiA-CT(R.lactN138-L149)/cdiI/DAS was generated via OE-
PCR using oligos 5' - AAT CCA AAC CTC TCT GAT GTA GAT AGA GCA TTA TTG 
CAG GCT GCG TAT GGC - 3' and 5' - CTA CAT CAG AGA GGT TTG GAT TTT TTA 
GTG AAC CTT CCA ACG TAT CCG CAT G - 3'. The imm.
R.lactaris
 gene was amplified with 
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primers R.lact-imm-Kpn-for (5' - TTT GGT ACC ATG CAA GAC AAG AGA AAA ATA 
AAA G - 3') and R.lact-imm-Xho-rev (5' - TTT CTC GAG ATC ACA TTA TTT TTT TGG 
ATA AAG TAT CTA TC - 3'), digested with KpnI/XhoI and ligated into pTrc99aKX.  
 Arabinose-inducible cdiA-CT expression constructs were generated using plasmid 
pCH450 
249
. The cdiA-CT coding sequence was amplified using 536-CT-Nco-for with 536-
CT-Xho-rev (5' - TTA CTC GAG GTA ATC ATA TTC CAT A), digested with NcoI/XhoI 
and ligated into pCH450. D155A, W176A, E181A, and T185I were amplified from the pET 
constructs while N149D, K152A, T185A, and R187A were generated using the megaprimers 
5' - GAT AAC ACT ATA AAA GAT GCT CTG AAA GAT C - 3', 5' - CTA TAA AAA 
ATG CTC TGG CAG ATC ATG ATA TTA T - 3', 5' - CTT AAT CCT CTG AGC GCA 
TTT TGC ATT TCC TGC - 3' and 5' - ATG CAA AAT ACG CTC GCA GGA TTA AGA 
AAT C - 3', respectively.  
pTrc99a::cysK-his6 constructs were made by amplifying gDNA from the various species, 
digested with NcoI/SpeI (XhoI for N. lactamica) and ligated into pTrc99a. Primer pairs 5' - 
CGG GCC ATG GGT AAG ATC TAC GAA GAC/5' - GGA ACT AGT CTG CTG CAG 
TTC CTG TTC GG for D. dadantii, 5' - GGC CAT GGG TAA GAT TTA TGA AGA CAA 
C/5' - GCT GAC TAG TCT GTT GCA GTT CTT TCT CGG for E. cloacae, 5' - GTC GAC 
CAT GGT ACG TGT AGC AAA CTC C/5' - GCT TAC TAG TAT CGA ATT GGT ACA 
GCG GCG for B. subtilis, 5' - ATA CCA TGG CAA TTT ATG CAG AC/5' - TTT ACT 
AGT TCC CTC AAT CCC TTC AAA C  for H. influenza, and 5' - AGA CCA TGG AAA 
TTG CAA ACA GCA TCA CC / 5' - AAA CTC GAG CGC CAA ATC GGC AAA CAG 
GGG CG –for N. lactamica were used for PCR. Each mutant CysK was generated using 
megaprimer PCR with oligos K42A 5' - CCA GCT TCA GCG TTG CGT GCC GTA TCG 
156 
 
GTG CC, Q143A F144A 5' - GCT GCT GCA AGA AGC CAG CAA TCC GGC AAA CC, 
R101E K102E 5' - CGC TTT CAG CAG CTC TTC GCG TTC AAT ACT CAT G , K105E 
5' - TTG CAC CTA ACG CTT CCA GCA GCT TGC GGC G, K221E 5' - GCA GGT GAA 
GAG ATT GAA CCT GGC CCG CAT A, K226A 5' - AAA CCT GGC CCG CAT GCA 
ATT CAG GGT ATT GG, Q228E 5' - CCG CAT AAA ATT GAG GGT ATT GGC GCT G, 
K283E 5' - GTT GCC GCG GCG TTG GAA CTA CAA GAA GAT G. CysK 307-324 was 
generated with CysK-Nco-for and 5' - AAA CTC GAG TTA ATA ACG CTC ACC CGA 
TGA - 3', digested with Nco/Xho, and ligated into pTrc99a.  
The EC93-536-R.lactaris and EC93-3006-R.lactaris chimeric CDI systems were 
constructed by allelic exchange of the counter-selectable pheS* marker from cosmid 
pCH10163 as described 
122
.  Primer pairs 5' - GAG CAT CAG TTA ATG TAT TAT CTA 
CTT TTT CAT TTT GCT GCT TAG GAT C/CDI204 for NT
UPEC536
 or 5' - GAG CAT CAG 
TTA ATG TAT TAT CTA CTT TCA GAA CTT CTA TCT TAC TGG CC /CDI204 for 
NT
EC3006
, 5' - AAA GTA GAT AAT ACA TTA ACT GAT GCT C/ 5' - GGT CTG GTG 
TCT AAC CTT TGG GAT CAC ATT ATT TTT TTG GAT AAA GTA TCT ATC and 
DL1663/ CDI205 were used to generate the 3 PCR products. CDI205 and 205 were used in 
OE-PCR to combine the 3 PCR products. The final DNA product (100 ng) was 
electroporated together with pCH10163 (300 ng) into E. coli strain DY378 cells 
247
 and 
recombinants selected on yeast extract glucose-agar supplemented with 33 µg/mL 
chloramphenicol and 10 mM D/L-p-chlorophenylalanine. 
 
Protein purification and crystallography 
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 The CdiA-CT/CdiI-His6 complex was overproduced from plasmid pET21P::cdiA-
CT/cdiI in either E. coli BL21 (DE3) Gold (Stratagene) or E. coli CH2016 cells induced with 
1 mM isopropyl b-D-thiogalactopyranoside (IPTG). Selenomethionine (SeMet) labeled 
complex was produced from cells grown in M9 minimal medium supplemented with leucine, 
isoleucine and valine at 50 mg/L; phenylalanine, lysine and threonine at 100 mg/L; and 
SeMet at 75 mg/L) as previously described 
255
. Cells were washed with resuspension buffer 
[20 mM sodium phosphate (pH 7.0), 200 mM NaCl], then broken by sonication on ice in 
resuspension buffer supplemented with 10 mg/mL lysozyme and 1 mM 
phenylmethylsulfonyl fluoride. Unbroken cells and debris were removed by centrifugation at 
18,000 g for 30 min followed by filtration through a 0.45 μm filter. Clarified lysates were 
loaded onto a Ni
2+-
charged HiTrap column (GE Healthcare) and washed with resuspension 
buffer containing 10 mM imidazole. The CdiA-CT/CdiI-His6 complex was eluted with a 
linear gradient of imidazole (10 – 500 mM) in resuspension buffer. Fractions were collected, 
combined, and concentrated to ∼500 µL in a centrifugal concentrator. Complexes were 
further purified by gel filtration on a Superdex 200 column equilibrated with 20 mM Tris-
HCl (pH 7.4), 150 mM NaCl using an AKTA FPLC. SeMet-labeled complex was 
concentrated to 9 mg/mL in 20 mM Tris-HCl (pH 7.4), 150 mM NaCl for crystallization 
trials.  
The CdiA-CT(H178A)/CysK binary complex crystallized in space group P41 with two 
CdiA-CT/CysK complexes per asymmetric unit.  The initial phases were determined by 
molecular replacement by molecular replacement using the structure of CysK as a search 
model (pdb ID 1OAS), and the CdiA-CT
UPEC536 
molecules were manually built.  The final 
model contains CdiA-CT
UPEC536
 and CysK residues 127-227 and 2-314, respectively, and 110 
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water molecules resulting in an Rwork/Rfree (%) of 20.0/22.4.  Additionally, both CysK 
molecules in the asymmetric unit contain a pyridoxal 5′-phosphate (PLP) bound in a Schiff 
base linkage to Lys42. 
The CdiA-CT/CdiI/CysK ternary complex was solved to 3.0 Å resolution by MR using 
the UPEC536 CdiA-CT/CysK binary complex as search model, and the structure of the CdiI 
protein was manually built. The proteins crystallized with four complexes per asymmetric 
unit in space group P21. The final complex model contains 531 residues per complex and 
includes Leu133-Ile228 (91 residues) of CdiA-CT, Ile2-Val128 (127 residues) of CdiI, and 
Gly2-Asp314 (313 residues) of CysK, with 110 water molecules (per asymmetric unit) as 
well as a PLP molecule linked to Lys42 in the active site of each CysK monomer, resulting in 
a final Rwork/Rfree of 19.65/24.5. 
 
Western blot analysis       
Cells were grown to mid-log in 2mL liquid LB-Amp with aeration and harvested for 
protein extraction with urea lysis buffer. Equal amounts of protein were subjected to 10% 
acrylamide SDS-PAGE for 1 hr at 100V. The gel was transferred onto nitrocellulose 
membrane, and incubated with 1:25,000 of anti-his6 antibody, a kind gift from David Low.  
 
In vitro binding and RNase assays 
 CdiA-CT/CdiI-His6 complexes were denatured in binding buffer [20 mM sodium 
phosphate pH 7.0, 150 mM NaCl] supplemented with 6 M guanidine-HCl, and CdiA-CT 
proteins isolated in the void volume during Ni
2+
-affinity chromatography 
115
. Toxins were 
refolded by dialysis against binding buffer. CdiI-His6 and CysK-His6  proteins were purified 
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by Ni
2+
-affinity chromatography under non-denaturing conditions as described 
120
. 
Imm.
R.lactaris
-His6
 
was refolded after the denaturing prep. The isolated toxins and immunity 
proteins were dialyzed against binding buffer and quantified by absorbance at 280 nm. 
Purified CdiA-CT, CysK-His6 and CdiI-His6 proteins were mixed at 10 µM final 
concentration in binding buffer and binding interactions assessed by co-purification during 
Ni
2+
-affinity chromatography as described 
115,120
. In vitro nuclease activity assays were 
conducted in reaction buffer [20mM Tris pH7.5, 150mM NaCl, MgCl2]. S30 lysates of E. 
coli strain CH1944 were made by centrifugation at 30,000 x g for 30 min at 4 °C. X90 total 
RNA was made by guanidine isothiocyanate-phenol extraction as previously described
121
 and 
reactions were carried out for 1 hr at 37 °C. Reactions were analyzed by denaturing 
electrophoresis on 50% urea – 6% polyacrylamide gels in 1 Tris-borate-EDTA buffer. Gels 
were transferred to nylon membrane and hybridized to 5´-radiolabeled oligonucleotides to 
hybridize various tRNAs. 
 
In vivo toxicity assays 
CdiA-CT toxicity and in vivo nuclease activity was assessed in E. coli strain X90. 
Arabinose-inducible pCH450::cdiA-CT/cdiI/DAS expression constructs were introduced 
together with IPTG-inducible pTrc::cdiI plasmids and transformants selected on LB-agar 
supplemented with Tet, Amp, 0.4% D-glucose and 1 mM IPTG. The resulting strains were 
grown to mid-log phase in LB media with Tet, Amp, 0.4% D-glucose and 1 mM IPTG, then 
cells collected by centrifugation and resuspended in fresh LB supplemented with Tet, Amp, 1 
mM IPTG and 0.2% L-arabinose. Cell growth was monitored by measuring the optical 
density at 600 nm (OD600) as a function of time. Culture samples were harvested into an 
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equal volume of ice-cold methanol, cells were collected by centrifugation and frozen at –80 
°C. RNA was isolated from the frozen cell pellets using guanidine isothiocyanate-phenol and 
10 µg of total RNA used for northern blot analysis as described 
248
. 
X90 or X90 cysK cells were made TSS-competent, 100 ng of pDNA was transformed 
and cells were recovered with 0.4% glucose for 1 hr at 37 °C. Cells were plated on LB-agar 
plates supplemented with Tet, Amp, 0.4% D-glucose or L-arabinose. 
 
Growth competitions 
 E. coli EPI100 inhibitor cells carrying the indicated CDI cosmids were co-cultured 
with the designated target cells at a 1:1 ratio in LB broth, shaking at 215rpm at 37 °C for 3 
hrs. Cells were harvested at time 0 and 3 hours into M9 salts for serial dilution and colony 
forming units/mL (CFU/mL) enumeration on selective media. CysK complementation and 
immunity function was evaluated through expression of cysK or cdiI genes in targets from 
plasmid pTrc99a.  
 
Results  
Characterization of CdiA-CT 
Structure of the CysK/CdiA-CT/CdiI complex 
CdiA-CT/CdiI-his6 and CysK-his6 were purified separately under native conditions and 
combined for co-crystallization. The ternary complex was solved to 3.0 Å resolution with 
four complexes per asymmetric unit in space group P21. The final complex model contains 
531 residues per complex and includes Leu133-Ile228 (91 residues) of CdiA-CT, Ile2-
Val128 (127 residues) of CdiI, and Gly2-Asp314 (313 residues) of CysK, with 110 water 
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molecules (per asymmetric unit) as well as a PLP molecule linked to Lys42 in the active site 
of each CysK monomer, resulting in a final Rwork/Rfree of 19.65/24.5. The cysteine 
synthase complex is made up of CysE as a dimer of homotrimers bound to a maximum of 
two molecules of CysK in the form of a dimer
276
. The CysK/CdiA-CT/CdiI complex shows 
CysK as a dimer (Fig. 1A), however it is unclear what ratio the CysK/CdiA-CT/CdiI 
complex is in vivo. 
The structure confirms previous analysis that the extreme C-terminus of CdiA-CT binds 
in the active site of CysK (Fig. 1B) and that CdiI binds to a discrete position on CdiA-CT 
(Fig. 1A). The fold of CdiA-CT does not provide any obvious clefts for tRNA docking (Fig. 
2A).  Furthermore, an electrostatic map does not reveal any dramatic pockets of positive 
charge that would facilitate interactions with the phosphate backbone of tRNA (Fig. 2B). We 
have previously reported that an H178A mutation renders the toxin inactive, but it can still 
bind to CdiI and CysK
123
. However, the location of this residue on the structure still does not 
give significant insight into identifying the active site (Fig. 2B & 2C). Of course, the 
presence of CdiI could be changing the conformation of CdiA-CT to an inactive state. To 
rule this out, CdiA-CT(H178A) was co-crystalized with CysK to look for conformational 
changes between the CdiI-bound and unbound CT. The protein complex crystallized in space 
group P41 with two CdiA-CT/CysK complexes per asymmetric unit. The final model contains 
CdiA-CT and CysK residues 127-227 and 2-314, respectively, and 110 water molecules 
resulting in an Rwork/Rfree (%) of 20.0/22.4.  Additionally, both CysK molecules in the 
asymmetric unit contain a pyridoxal 5′-phosphate (PLP) bound in a Schiff base linkage to 
Lys42. An overlay of CdiA-CT/CysK with CdiA-CT(H178A)/CysK shows CdiA-CT has no 
significant change in conformation or fold in the presence or absence of CdiI (Fig. 2A). 
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While CdiA-CT(H178A) is technically not the active form of the toxin, it is doubtful that this 
single-residue change, especially given its location on CdiA-CT, could drastically change the 
conformation of the CT. Taken all together, the toxin conformation remains the same with or 
without immunity bound. Unfortunately, this still leaves us perplexed as to where the active 
site of the toxin is located.     
 
Identifying active-site residues in CdiA-CT 
To help reveal some of the residues involved in tRNA binding or cleavage, and therefore 
the location of the active site, we looked at an alignment of CdiA-CT homologs. We 
reasoned that conserved residues would be involved with enzymatic activity, while non-
conserved residues have drifted because their function is to maintain the fold of the toxin. An 
alignment of 7 homologs to CdiA-CT reveals numerous conserved residues, and therefore 
does not disclose information about the active site (Fig. 3A). We then looked at the 
mechanism of how other proteins bind to tRNA, especially to the anti-codon loop. It has been 
demonstrated that some tRNA synthetases stabilize the interaction with their cognate tRNA 
by flipping out a base in the single-stranded sections of the molecule (3’ acceptor stem or 
anti-codon loop) and stacking it with an aromatic residue, thus allowing for pi-stacking
277
. 
Closer analysis of the alignment performed reveals a conserved aromatic residue at position 
176, which maps to close proximity with H178A on the structure (Fig. 2A & 2B).  
Many endonucleases coordinate divalent cations to help stabilize negative transition 
states
278
. We reasoned that some negatively charged residues should be required for CdiA-
CT tRNase activity since its activity in vitro is dependent on a divalent cation (data not 
shown). Furthermore, we predicted some positively charged residues might be involved in 
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electrostatic interactions to help bind negatively charged tRNA. Lastly, we considered 
residues capable of hydrogen bonding as this interaction would also assist in binding to 
tRNA. This led us to mutate the following residues to alanine and test their ability to cleave 
tRNA. W176 was chosen based on its possible role in stacking a base from the anti-codon 
loop of bound tRNA. D155 and E181 were selected for possible cation coordination. N149, 
K152, and R187 were chosen for their potential to bind tRNA and T185 was chosen for its 
ability to form hydrogen bonds. Furthermore, each of these residues is highly conserved (Fig. 
3A) and map to a location on the toxin that would allow them access to a tRNA substrate 
(Fig. 3B). 
 
In vivo analysis of active-site residues  
Each mutant was cloned into plasmid pCH450 which contains an araC promoter that is 
induced with arabinose and suppressed by glucose. Equivalent amounts of plasmid DNA 
were transformed into E. coli or E. coli cysK
- 
cells and plated on LB-glucose, LB, or LB-
arabinose plates for increasing levels of induction. Firstly, WT toxin is able to kill cells even 
when suppressed with glucose, but unable to kill cysK
-
 cells under any condition, as expected 
(Fig. 4). Mutants D155A, H178A, and E181A were unable to kill cells under any condition 
while W176A showed partial toxicity to WT cells (Fig. 4). Interestingly, T185A showed WT 
levels of killing, but T185I has a decrease in activity, suggesting the bulky side chain of 
isoleucine can disrupt substrate binding (Fig. 4). Lastly, N149D, K152A, and R187A each 
killed cells to WT level, indicating they are not involved in tRNase activity (Fig. 4).  
 
In vitro analysis of active-site residues  
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To assess whether each of these mutants can still fold properly, we purified each toxin 
and evaluated its ability to bind CysK in vitro. Each CdiA-CT was purified by denaturing it 
away from Ni
2+
-bound CdiI-his6. The toxins were then refolded and incubated with CysK-
his6. “Input” refers to what was loaded onto a Ni2+ column, “unbound” represents what did 
not bind to the column, and “bound” is what eluted off the column.  Each mutant toxin tested 
is able to bind CysK, suggesting they can re-fold properly (Fig. 5A).  
Next, these mutants were tested for their ability to cut tRNA in vitro. 1uM of each 
purified toxin was incubated with 1uM of CysK-his6 and 5ug of guanidine isothiocyanate-
phenol extracted total RNA. 1uM of CdiI was included where indicated. Ethidium bromide 
and Northern blot analysis to Ile
1
 tRNA shows D155A, H178A, and E181A have abolished 
activity, while W176A and T185I have decreased activity compared to the WT enzyme (Fig. 
5B). These results are consistent with the in vivo toxicity assay. Taken all together, these data 
demonstrate that residues D155, W176, H178, E181, and T185 each play a role in enzymatic 
activity or substrate binding.  
 
Characterization of CysK 
Mutational analysis of CysK 
Now that we have established a potential active site for CdiA-CT, we wanted to identify 
the role of CysK in the complex. We reasoned CysK could be directly involved in substrate 
binding or even enzymatic activity. We used genetic selection to reveal mutations in CysK 
that correlated with abolished tRNase activity. However, we only found mutations that 
impeded the ability of CysK to bind CdiA-CT. Therefore, we took a similar approach as the 
one used to identify active-site residues in CdiA-CT. We looked for conserved CysK residues 
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that had the potential to be involved in substrate binding or enzymatic activity (Fig. 6A). 
Each CysK mutant was cloned into pTrc99a and co-transformed into E. coli cysK
- 
cells with 
either pCH450::CdiA-CT or pCH450::CdiA-CT(H178A) and selected on LB-glucose plates. 
We found that even with suppressed toxin expression, each mutant was still able to activate 
CdiA-CT and kill cells (Fig. 6B).  
Each pTrc99a::cysK-his6 mutant was also expressed in JCM158 cysK
- 
 target cells and 
competed against EPI100 cells expressing no CDI genes, CDI
UPEC536 
or a chimeric CDI 
system where CdiA-CT/CdiI
UPEC536 
is deployed by CdiA
EC93
. We reasoned this would be a 
more sensitive method of testing the ability of each mutant allele to activate CdiA-CT as 
much less toxin is delivered into target cells than the amount present when expressed from 
plasmid pCH450. Targets were tested against both CDI
+ 
inhibitors because CdiA
UPEC536 
delivers CdiA-CT into target cells with lower efficiency. We hoped using this inhibitor 
would be an even more sensitive method to test for CdiA-CT activation. Western blot 
analysis using anti-his6 antibody showed relatively equal expression of each mutant, as 
compared to WT (data not shown). Furthermore, each target grew to full capacity in the 
competitions against CDI
- 
mock inhibitors, demonstrating expression of these mutant alleles 
does not affect cell growth (Fig. 6C). In competition against the two CDI
+ 
inhibitors, each 
mutant was inhibited to WT levels, except for R101E K102E and 307-324 (Fig. 6C). 
Unfortunately, after deeper analysis of these mutants, it was discovered that neither support 
growth in minimal media in the absence of cysM. This suggests these mutants do not have 
functional enzymatic activity, most likely due to aberrant folding, and therefore should not be 
studied further. These results suggest CysK might not play a role in enzymatic activity or 
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substrate binding. Alternately, perhaps a single-residue change is not enough to potentiate a 
phenotype that would reveal itself in our toxicity assays.   
 
Distant CysK alleles activate CdiA-CT 
We have not been able to find small changes in CysK that influence CdiA-CT activity. 
Therefore, we decided to make big changes and ask if they have any consequence on toxin 
activation. We reasoned if we made such changes but found a conserved region that was 
required for activation, this might direct us to the region of CysK involved in tRNase 
activity. Instead of making drastic changes to E. coli CysK and hoping it would still be able 
to fold properly, we used CysK alleles from different species of bacteria. Figure 7A shows an 
alignment of the species chosen. Each allele was cloned into pTrc99a and subjected to the 
same co-transformation toxicity assay as described above. Remarkably, each CysK allele was 
able to activate CdiA-CT (7B). CysK
N.lactamica
 was the only allele that required arabinose 
induction of the CT to kill cells (Fig. 7B). Thus, even distant alleles of CysK are still able to 
activate CdiA-CT in vivo.  
 
In vitro analysis of distant CysK alleles  
To test whether these CysK alleles could bind to the toxin, the same protein-binding 
assay was used as described earlier. We found CysK
H.influenza
 and CysK
N.lactamica
 are the only 
two alleles with reduced binding to the CT (Fig. 7C). This is only somewhat reflective of the 
in vivo transformation assay results, as CysK
H.influ
 seemed to activate CdiA-CT to WT levels 
(Fig. 7B). 
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To examine if the distant CysK alleles could alter tRNase activity, perhaps by changing 
the cleavage site or specificity of the substrate, RNA from in vitro reactions was analyzed. 
0.1uM, 1uM, or 10uM of CysK-his6 was incubated with 1uM CT and 5ug of guanidine 
isothiocyanate-phenol extracted total RNA. 1uM of CdiI was added where indicated. The 
reactions were subjected to gel electrophoresis and imaged by ethidium bromide staining or 
Arg
2 
radiolabeled probe. There was no change in cleavage pattern, indicating each CysK 
allele still supports CdiA-CT to cut in the anti-codon loop of all tRNAs (Fig. 8).  
Furthermore, the results are consistent with the protein-binding data in that reactions 
containing CysK
H.influ
 or CysK
N.lact
 show a decrease in tRNase activity (Fig. 8).  
 
Distant CysK alleles support CDI  
Competition analysis was used as a more sensitive method to look for a decrease in 
CdiA-CT activation. Again, JCM158 cysK
- 
target cells were complemented with 
pTrc99a::cysK-his6 constructs and competed against EPI100 cells expressing no CDI genes, 
CDI
UPEC536 
or CDI
EC93 
deploying CdiA-CT/CdiI
UPEC536
. Western blot analysis to his6 
illustrates that each allele of CysK is expressed to similar levels as CysK
E.coli 
(Fig. 9).  
Interestingly, this competition analysis only somewhat mirrors the in vitro results. Each 
target strain grew 2 logs against the CDI
- 
mock control, indicating expression of the foreign 
alleles does not affect target cell growth (Fig. 9). Strikingly, target cells carrying CysK
E.cloacae,
 
B.subtilis, or N.lactamica
 are inhibited 1 log less than targets expressing the rest of the CysK alleles 
(Fig. 9). It is unclear if this is physiologically relevant, or can give us insight into the role of 
CysK in toxin activation. Considering each distant allele of CysK is still able to activate 
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CdiA-CT, these data again suggest that the physical binding of CysK is the mechanism of 
toxin activation.  
 
Insights from a distant homolog of CdiA-CT 
CT
R.lactaris 
does not require CysK in vivo 
When looking at an alignment of CdiA-CT to distant homologs, it becomes apparent the 
toxins found in Gram-positive species contain a 9 residue insertion between residues K197 
and N198 in CdiA-CT
UPEC536 (Fig. 10A).  This insertion maps to a loop connecting two α-
helices that protrude out from the CysK active site (Fig. 10B). Given the above results, we 
now postulate the role of CysK is to simply bind to and stabilize the CT so it can perform its 
enzymatic activity. We hypothesized that the insertion found in the toxins from Gram-
positive species might stabilize the toxin to the point where it would no longer require CysK 
for activity. To test this, we looked at in vivo toxicity of a homolog from the Gram-positive 
species, Ruminococcus lactaris (CT
R lactaris
). We transformed pCH450::CT/I
R.lactaris
-DAS into 
cysK
+ 
or cysK
- 
E. coli cells and selected on LB-glucose or LB-arabinose plates. Upon 
arabinose induction, the DAS-tagged immunity protein will deliver the CT/I-DAS complex 
to the ClpXP degradation machinery. The machinery will selectively degrade the DAS-
tagged immunity protein, leaving the CT free in the cytoplasm of cells to perform its toxic 
function. First, each construct was able to grow under glucose conditions, indicating the 
transformation was efficient (Fig. 10C).  Second, upon arabinose induction, pCH450::CdiA-
CT/CdiI-DAS killed WT cells but not cysK
- 
cells, as expected (Fig. 10C). However, 
pCH450::CT/I
R.lactaris
-DAS killed both WT and cysK
- 
 cells when induced with arabinose. 
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These results demonstrate that the CdiA-CT homolog from R. lactaris does not require CysK 
for activity in vivo. 
 
CT
R.lactaris 
does not require or bind CysK in vitro 
Next, we asked if CT
R.lactaris
 requires CysK for in vitro activity. To test this, we incubated 
1uM of each toxin in the presence or absence of 1uM CysK with 5ug of guanidine 
isothiocyanate-phenol extracted total RNA. 1uM of immunity protein was added where 
indicated. Not surprisingly, CT
R.lactaris 
shows the same level of activity, independent of CysK 
(Fig. 11A). We were curious if CT
R.lactaris 
could still bind to CysK. Its C-terminal tail ends in 
PYGGIN, so it was not likely. Indeed, when purified CT
R.lactaris 
was incubated with CysK-
his6, no binding was observed (Fig. 11B), consistent with the in vitro results. Thus, CT
R.lactaris 
does not require CysK for in vitro tRNase activity. 
 
CT
R.lactaris 
acts as a specific tRNase in vitro 
As previously mentioned, CdiA-CT is a general tRNase that cleaves in the anticodon 
loop, and it behaves as such in the assay performed above (Fig. 11A). Strikingly, even 
though CT
R.lactaris 
seems to cleave in the same position as CdiA-CT, it has diminished tRNase 
activity in vitro (Fig. 11A). However, the in vivo toxicity assay showed CT
R.lactaris 
to be just as 
lethal as CdiA-CT (Fig. 10C). We hypothesized that CT
R.lactaris 
is cutting only a subset of 
tRNAs, targeting all tRNAs but less efficiently, or requires a different cofactor to be 
completely active.  
To test the dependence on a distinct cofactor, we performed in vitro reactions in the 
presence or absence of S30 cell extract. S30 extract contains all elements of a cytoplasm, so 
170 
 
it would presumably contain any cofactors that were present in the in vivo toxicity assay. 
CdiA-CT activity was enhanced greatly by the addition of S30, likely because of the addition 
of CysK found in the extract (Fig. 11C). Conversely, CT
R.lactaris 
activity was not enhanced in 
the presence of S30, suggesting it does not use a cofactor found in S30 cell extract (Fig. 
11C).  
To test if it cuts all tRNAs, but less efficiently, Northern blot analysis to the in vitro 
reactions was performed. This reveals cleaved tRNA
Ala1B
 in reactions containing CdiA-CT 
but not CT
R.lactaris 
(Fig. 11A). Notably, the toxin was denatured during the purification 
process. However, we made sure it re-folded properly by demonstrating it could re-bind to its 
cognate immunity protein (Fig. 12C). Taken all together, these results indicate that CT
R.lactaris 
does not utilize a co-factor or act as a general tRNase in vitro, suggesting it targets a specific 
subpopulation of tRNA species. 
 
CT
R.lactaris 
acts as a specific tRNase in vivo 
We next asked if CT
R.lactaris
  has the same activity in vivo as it does in vitro. To test this, 
we took RNA samples from cells expressing CdiA-CT or CT
R.lactaris
 with their cognate or 
noncognate immunity protein. Upon guanidine isothiocyanate-phenol extraction, RNA was 
subjected to Northern blot analysis. Cleaved tRNA
Ala1B 
was observed in cells expressing 
CdiA-CT, but not in cells expressing CT
R.lactaris 
(Fig. 12B). This result supports the 
hypothesis that CT
R.lactaris 
is a specific tRNase both in vitro and in vivo. More work will have 
to be done to identify the specific tRNA(s) targeted by CT
R.lactaris
.  
 
Chimeric CdiA-CT
UPEC536
/CT
R.lactaris 
shows specific tRNase activity 
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The point of studying CT
R.lactaris 
was to gain some insight into the requirement of CysK 
for CdiA-CT activation. We have now established that CT
R.lactaris 
does not bind to or require 
CysK in vivo or in vitro, while CdiA-CT does. Since the main difference between these two 
toxins is a 9 residue insertion between two α-helices, we reasoned this insertion is what 
drives the CysK-independent activity seen in CT
R.lactaris
. To test this, we engineered 3 
chimeric proteins (UPEC536/R.lact CT1, CT2, and CT3) to try to stabilize CdiA-CT to 
render it CysK-independent. Figure 13A shows the sequences of the 3 chimeric constructs 
that were cloned into pCH450::CdiA-CT/I-DAS and assayed for their toxicity in cysK
+ 
and 
cysK
- 
E. coli cells. Unfortunately, the toxicity of the first 2 chimeras is CysK-dependent (data 
not shown) and CT3 has a defect in toxicity in WT cells, suggesting aberrant folding (Figure 
13B). As a longshot, we asked if the chimeric proteins have altered tRNase activity. To do 
this, we purified RNA from cysK
+
 cells expressing each of these constructs and performed a 
Northern blot to look at tRNA
Thr2
. Remarkably, UPEC536/R.lact CT1 no longer shows 
characteristic general tRNase activity (Fig. 13C) even though it inhibited the growth of E. 
coli cells to the same levels as the WT construct
 
(Fig. 13B). This suggests the insertion of 
residues NPNLSD at position K197 in CdiA-CT and removal of N189 (Fig. 13A), has turned 
CdiA-CT into a specific tRNase, perhaps cutting the same subset of tRNAs as CT
R.lactaris
. 
Further analyses will have to be performed to prove this hypothesis.  
 
Immunity
R.lactaris 
displays partial protection of CdiA-CT
UPEC536 
activity  
 
 
As expected, the immunity proteins of CdiA-CT and CT
R.lactaris 
are similar. An alignment 
displays 18% sequence identity (Fig. 10A).  It is reasonable to believe that these immunity 
proteins might offer some cross-protection for their noncognate toxin. The in vitro reactions 
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discussed above were performed with both cognate and noncognate immunity proteins. The 
results show Imm.
R.lactaris 
providing partial protection of CdiA-CT activity (Fig. 11A). 
Furthermore, in vivo analysis also reveals almost full protection from both growth inhibition 
(data not shown) and tRNase activity when expressed inside E. coli cells (Fig. 12B). 
Consistent with the in vitro and in vivo results, Immunity
R.lactaris
-his6 is able to partially bind 
to CdiA-CT (Fig. 12C).  
 
CT
R.lactaris 
can be delivered via CDI 
As mentioned previously R. lactaris is a Gram-positive species, which contain different 
types of contact-dependent competition systems than those found in Gram-negative species. 
Homologs of CT
R.lactaris
 in Gram-positives can be found in rearrangement hotspot (Rhs) 
proteins, a competition system that also requires direct cell-to-cell contact for delivery of a 
toxic domain derived from its C-terminus (Rhs-CT). Rhs proteins are involved in intra-
species competition and thus Rhs-CTs must cross the membrane of Gram-positive cells. We 
asked if CT
R.lactaris 
could cross the outer and inner membranes of Gram-negative bacteria via 
the CDI pathway. CdiA-CTs can be further broken down into an N- and C-terminal domain 
(CdiA-CT
NT
 and CdiA-CT
CT
). CdiA-CT
CT 
encodes for the toxic domain, while CdiA-CT
NT
 is 
what directs the toxin to a specific inner-membrane protein to be delivered to the cytoplasm 
(data not shown). We reasoned CT
R.lactaris 
would not have the proper domain at its N-terminus 
to be directed through the inner membrane of Gram-negative bacteria. Therefore, we fused 
CT
R.lactaris
 to the N-terminal domain of CdiA-CT
UPEC536 
or CdiA-CT
EC3006
 and then fused the 
subsequent chimeric CdiA-CTs to CdiA
EC93
. The resulting chimeric CdiA proteins are 
depicted in Figure 14A. EPI100 inhibitor cells expressing CDI
UPEC536
,
 
CDI
UPEC536/R.lactaris
,
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CDI
EC3006/R.lactaris
,
 
or CDI
- 
cosmids were co-cultured with target cells expressing no immunity, 
cognate, or noncognate immunity protein. Strikingly, the inhibitors carrying the two chimeric 
CdiA constructs are able to deploy CT
R.lactaris 
into target cells (Fig. 14B). This is 
demonstrated by targets losing viability against CDI
EC3006/R.lactaris 
inhibitors and only growing 
~0.25 logs against CDI
UPEC536/R.lactaris 
inhibitors. Furthermore, expression of cognate 
immunity protein rescues this growth inhibition. Moreover, these results further support the 
ability of Imm.
R.lactaris
 to partially block CdiA-CT activity.  
 
Discussion 
CdiA-CT is the only known example of a CDI toxin that requires a cofactor for 
activation. In fact to this date, no bacteriocin or type VI effector protein has been shown to 
require a cofactor
51,128
. Many questions have arisen since its discovery. First, why does 
CdiA-CT even require a CysK? One idea is that the binding event protects CdiA-CT from 
degradation in target cells, prolonging its enzymatic activity. However, there are numerous 
examples of CDI toxins that do not require a cofactor and kill target cells with the same 
efficiency as CdiA-CT
117,120
. Nonetheless, CdiA-CT does require a cofactor in its CDI 
pathway, and there are many reasons CysK is a worthy protein to exploit. Firstly, we 
demonstrated that CysK from a cohort of distantly related species was still able to bind to and 
activate CdiA-CT. Considering CDI systems are widespread amongst proteobacteria, it is 
ideal to utilize a cofactor that is conserved. Another preferred characteristic of a cofactor in 
the CDI pathway would be that it is essential, this way target cells cannot lose its function 
and become resistant to CdiA-CT activity. CysK is not essential, as it has an analog, CysM, 
which is also able to produce cysteine from OAS
273
. However, the two enzymes can use 
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different substrates and we have observed that CysK is more efficient than CysM at cysteine 
metabolism (unpublished data). Therefore, under some physiological conditions, CysK could 
potentially identify as an essential protein. This could even suggest that CDI systems 
delivering CdiA-CT
UPEC536
 have evolved to be expressed or utilized most efficiently under 
such conditions.  
Next, what is CysK’s role in tRNase activity? Does it provide any residues that are 
involved in electron transfer, stabilization of intermediates, or coordination of a metal ion? 
Or rather, does it simply bind to and stabilize the toxin? With help from the crystal structure 
and homologs we were able to identify active-site residues of CdiA-CT. While it is unclear 
where a tRNA species would bind to the CysK/CdiA-CT complex, we propose residue W176 
flips out a base in the anti-codon loop of bound tRNA which allows residue D155 or E181 to 
act as a general base and strip a proton from the 2’ hydroxyl of the tRNA. This would lead to 
auto-attack of the backbone where H178 could offer a proton to the 5’-OH leaving group. 
Lastly, we propose residue T185 is involved in substrate binding. This threonine is found 
mid-way through an α-helix with its sidechain exposed to the periphery. When we changed 
this threonine to an isoleucine we saw a decrease in tRNase activity. Considering this is in 
close proximity to the proposed active site, we postulate that tRNA makes contact with this 
threonine and the bulky side chain of isoleucine, or lack of ability to H-bond, hinders tRNA 
docking. This is of course all completely speculative and a resolved structure of tRNA bound 
to the complex will be required to determine the precise mechanism of cleavage. 
Unfortunately, we were unable to concretely identify the role of CysK in the complex. 
Genetic selection, making forced mutations, and examining alleles from distant species failed 
to find mutations in CysK that affected toxin activation without reducing its ability to bind 
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the CT. Thus, we postulate that CysK acts to stabilize the toxin which allows it to properly 
bind and cleave tRNA.   
We also looked at a distant homolog of CdiA-CT for some insights on the role of CysK 
in the complex. We established CT
R.lactaris 
does not require CysK for activity both in vivo and 
in vitro. Furthermore, we found it has a slightly altered activity than CdiA-CT in that it acts 
as a specific tRNase, although still cutting in the anti-codon loop. We credit this specificity to 
residues N139-D143 in CT
R.lactaris
 because when we grafted these residues onto CdiA-CT, it 
became a specific tRNase. Reasonably, this insertion is located distal from the active site, 
suggesting its role in substrate binding and not enzymatic activity. Perhaps then, the role of 
CysK is to stabilize CdiA-CT in a way that allows the complex to bind tRNAs non-
discriminately. The implications of being able to cut a broad range of tRNAs versus a narrow 
range is unknown. Finally, we demonstrated that a toxin from a competition system used by 
Gram-positive species could be delivered via the CDI pathway into Gram-negative target 
cells. This demonstrates the adaptability of CDI systems, and their potential to deliver a vast 
repertoire of toxins. 
Lastly, does delivered CdiA-CT affect cysteine metabolism? Cysteine metabolism is 
under strict regulation in the cell where increased amounts of OAS will upregulate CysK 
expression
275
. With CdiA-CT
 
binding in the active site of CysK, it could potentially displace 
CysE or prevent OAS from entry. This would decrease cysteine production and ultimately 
alter the expression of the metabolic enzymes. Furthermore, since the toxin can bind to CysK 
in the presence of immunity protein, even sibling cells can be affected. With the recent 
finding that CDI systems have an extremely narrow target range and are mostly limited to 
intra-species and even intra-strain delivery, this could possibly be a way to regulate CysK 
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activity amongst kin
118
. Extensive efforts were put into trying to try to find an effect on 
cysteine biosynthesis in cells upon delivery of CdiA-CT, but none seemed to be relevant 
under natural conditions. For example, we could block CysK activity in vivo by 
overexpressing CdiA-CT inside cells, but when we tried to block the enzyme by delivering 
CdiA-CT via the CDI pathway, we no longer saw a loss of CysK activity (data not shown). 
However, perhaps under certain environmental conditions, there could be enough CdiA-CT 
delivery into cells, or scarce enough amounts of CysK, where CDI would in fact affect 
cysteine metabolism. In addition, the 9 residue insertion that presumably makes CT
R.lactaris 
CysK-independent is only found in Gram-positive species which do not contain CDI 
systems. This further supports the idea that CDI systems are involved in communication 
rather than competition.  
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Figure 1. Stucture of CysK/CdiA-CT/CdiI ternary complex. A) CdiA-CT is depicted in 
pink, CysK in purple, and CdiI in green, each in ribbon form. The model presented shows 
CysK in its dimer form, with hydrophobic interactions faciliating binding at the described 
interface. PLP is not shown. B) CysK in purple and CdiA-CT in pink with its C-terminal 
GYGI amino acids (yellow) sticking into the active site of CysK. PLP is not shown.  
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Figure 2. Proposed active-site residues of CdiA-CT . A) An overlay of CysK/CdiA-
CT(H178A) in light blue and light pink with CysK/CdiA-CT in purple and pink. PLP is not 
shown. B) CysK in purple and CdiA-CT in pink with the proposed active-site residues in 
white. The molecule is in sphere form to demonstrate electrostatic potential. C) The same 
molecule as B), but in ribbon form with the active-site residues shown as sticks. D) The same 
molecule as C), but CdiI has been added to show it blocks the proposed active-site residues. 
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Figure 3. Homologs of CdiA-CT show conserved active-site residues. A) An alignment of 
CdiA-CT to homolgous toxins found in the species stated below. Black arrows point to 
conserved residues that were mutated for analysis. This is a heat map alignment performed 
by PRALINE Multiple Sequence Alignment. B) The heat map in A) is grafted onto the 
crystal structure of CdiA-CT with CysK in purple. The residues pointed to in A) are shown in 
stick form.  
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Figure 4. Mutational analysis of CdiA-CT active-site residues in vivo. Arbainose-
inducible plasmid, pCH450, with the specified cdiA-CT alleles, was transformed into E. coli 
X90 or X90 cysK cells and selected on LB-glucose or LB-arabinose plates supplemented 
with tetracycline. The last panel is a homolog of CdiA-CT from E. coli EC93. The T185I 
mutation has a greater effect on this toxin.  
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Figure 5. Mutational analysis of CdiA-CT active-site residues in vitro. A) Purified CdiA-
CT mutants were mixed with equimolar CysK-his6 and put over a Ni
2+ 
column (In). The 
unbound (Un) and bound (Bnd) fractions were collected and analyzed by SDS-PAGE. B) 
1uM of CdiA-CT, CdiI, and CysK were added to 8ug of total RNA where indicated. RNA 
was analyzed by ethidium bromide stain and Northern blot using a probe to tRNA
Ile1
.  
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Figure 6. Mutational analysis of CysK in vivo. A) CdiA-CT in pink and CysK in purple 
with each mutated CysK residue shown in stick form in white. B) E. coli X90 cysK was co-
transformed with the specified pTrc99a::cysK construct and either pCH450::CdiA-CT or 
CdiA-CT(H178A) and selected on LB-glucose plates supplemented with tetracycline and 
ampicilin. C) The annotated target cells were co-cultured with CDI
EC93
, CDI
UPEC536
, or CDI
- 
inhibitors at a 1:1 ratio in liquid broth for 3 hours. Growth inhibition was assessed by 
quantifying the number of viable target cells as colony-forming units per milliliter (CFU/mL) 
and data are reported as the mean ± SEM for two independent experiments. 
  
 
 
 
 
 
 
 
183 
 
Figure 7. Distant CysK alleles activate and bind CdiA-CT. A) A heat map alignment of 
CysK from the species designated using PRALINE Multiple Sequence Alignment B) E. coli 
X90 cysK was co-transformed with the specified pTrc99a::cysK construct and either 
pCH450::CdiA-CT or CdiA-CT(H178A) and selected on LB-glucose plates supplemented 
with tetracycline and ampicilin. The last panels shows pTrc99a::CysK
N.lactamica 
required 
arabinose induction to acticate CdiA-CT. C) Purified CdiA-CT was mixed with the annotated 
CysK-his6 at equimolar ratio and put over a Ni
2+ 
column (In). The unbound (Un) and bound 
(Bnd) fractions were collected and analyzed by SDS-PAGE. 
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Figure 8. Distant CysK alleles activate CdiA-CT in vitro. Purified CdiA-CT was incubated 
with increasing amounts of the indicated CysK and 8ug of total RNA. The reactions were 
analyzed by ethidium bromide stain and Northern blot to tRNA
Arg2
.    
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Figure 9. Distant CysK alleles support CDI. The indicated target cells were co-cultured 
with CDI
EC93
, CDI
UPEC536
, or CDI
- 
inhibitors at a 1:1 ratio in liquid broth for 3 hours. Growth 
inhibition was assessed by quantifying the number of viable target cells as colony-forming 
units per milliliter (CFU/mL) and data are reported as the mean ± SEM for two independent 
experiments. Western blot analysis of CysK-his6 expression levels in target cells using anti-
his6 antibody.  
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Figure 10. CT
R.lactaris 
does not require CysK in vivo. A) An alignment of distant homologs 
to CdiA-CT using PRALINE Multiple Sequence Alignment and shown as a heat map with 
conserved residues in red and divergent residues in cool colors. The 9 residue insertion found 
in Gram-postive species is highlighted with a black bar. The insertion is between residues 
K197 and N198 in CdiA-CT. B) Strucure of CysK in purple and CdiA-CT in pink to show 
the insertion site between two α-helices in CdiA-CT. C) The two arabinose-inducible 
constructs were transformed into E. coli X90 or X90 cysK cells and selected on LB-glucose 
or LB-arabinose plates supplemented with tetracycline.   
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Figure 11. CT
R.lactaris 
does not require or bind CysK in vitro. A) 1uM of toxin was 
incubated with 8ug of total RNA and equimolar CysK and/or Immunity where indicated. 
Reactions were examined via ethidium bromide stain and Northern blot analysis to 
tRNA
Ala1B
.
 
 B) Equimolar ratios of toxin and CysK-his6 were incubated with Ni
2+
 beads (In). 
The fractions that did (Bnd) and did not bind (Un) the Ni
2+
 beads were analyzed by SDS-
Page. C) 1uM of toxin was incubated with 8ug of total RNA with or without S30 extract. 
1uM of Immunity protein was added where indicated. RNA in the reactions was oberserved 
via ethidium bromide stain.  
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Figure 12. Analysis of CdiI
UPEC536 
and Immunity
R.lactaris
. A) PRALINE Multiple Sequence 
Alignment of CdiI
UPEC536 
and Immunity
R.lactaris
 and shown as a heat map. B) E. coli X90 
cysK
+
 cells carrying the annotated toxin and immunity constructs were induced for both toxin 
and immunity expression for 3 hours. RNA was collected and analyzed via Northern blot to 
tRNA
Ala1B
. C) Equimolar ratios of the indicated purified toxin and immunity-his6 proteins 
were mixed with Ni
2+ 
beads and assayed for their abilty to bind one another. “In” represents 
what was added to the beads, “Un” denotes what did not bind, and “Bnd” is what eluted off 
the Ni
2+
 beads. 
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Figure 13. Chimeric CdiA-CT
UPEC536
/CT
R.lactaris 
shows specific tRNase activity. A) 
PRALINE Multiple Sequence Alignment of CdiA-CT, CT
R.lactaris
, and the 3 chimeric toxins 
generated. They are shown as a heat map with unconserved residues in cool colors. B) E. coli 
X90 cysK
+
 cells carrying the indicated arabinose-inducible toxin construct were induced after 
30 minutes of growth. C) At 3 hours, RNA was collected and analyzed via Northern blot to 
tRNA
Thr2
. 
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Figure 14. CT
R.lactaris 
is delivered into target cells via the CDI pathway. A) Chimeric 
CdiA proteins present in the designated inhibitor cells. CdiA-CT is composed of an N- and 
C-terminal domain. Figure is not drawn to scale. B) E. coi JCM158 target cells with the 
indicated immunity constructs were co-cultured with each inhibitor cell at a 1:1 ratio for 3 
hours in liquid broth. Growth inhibition was assessed by quantifying the number of viable 
target cells as colony-forming units per milliliter (CFU/mL) and data are reported as the 
mean ± SEM for two independent experiments. 
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Chapter 6. Characterizing Type VI secretion in Enterobacter 
cloacae 
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Note: Other members of the Hayes lab participated on this project. Fellow graduate student 
Sonya Donato contributed to the work presented in Figures 6, 9, and 12 and will be finishing 
the remaining pieces of the project. Undergraduate students David Cunningham, Jeff Kim, 
Donghoon (Alex) Kang, and Ian Singleton and incoming Master’s student Kelsy Siegel 
helped with competition experiments. David also played a significant role in starting this 
project.  
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Abstract 
The type VI secretion system (T6SS) is the most recently identified secretion system 
found in one-fourth of sequenced Gram-negative bacteria. It forms a dynamic syringe-like 
structure that delivers toxic effector proteins into neighboring cells. Its role in bacterial 
competition and virulence has been demonstrated in a limited number of species. Here we 
show Enterobacter cloacae ATCC13047 is a great model organism to study T6S. It contains 
a functional T6SS that is constitutively expressed under laboratory conditions and is involved 
in inter- and intra-species competition. There are at least 13 components required to build the 
T6S organelle, including a PAAR domain-containing protein. We find at least one of the 
PAAR-containing rearrangement hot spot (Rhs) proteins found in E. cloacae is required for 
T6 assembly and function.  Furthermore, we demonstrate that full-length Rhs, not just its 
PAAR domain, is required for T6S. Our work raises questions about the function of PAAR-
containing proteins and suggests Rhs proteins have a vital structural role in T6 assembly in E. 
cloacae.   
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Introduction 
The type VI secretion system (T6SS) is a membrane-spanning apparatus that injects toxic 
effector molecules into neighboring prokaryotic or eukaryotic cells
127
. It is found in 25% of 
sequenced proteobacteria where strains can have up to six type VI loci present in their 
genome
135
. There are 13 core components required to make a functioning T6 organelle
136,138
. 
With the exception of Hcp, VgrG, ClpV, and VasK, the remaining core components are 
named TssX  for Type six secretion gene X. The organelle is made up of an inner tube 
capped by spike proteins that gets encapsulated by a sheath and attached to the cell 
envelope
151
.  The inner tube is made up of hemolysin-containing protein (Hcp) that form 
monohexameric rings that stack on top of one another
149,150
. Valine-glycine repeat protein G 
(VgrG) trimers cap this tube and a PAAR (proline, alanine, alanine, arginine) motif-
containing protein binds to the C-terminus of VgrG to further sharpen the tube spike
153
. The 
sheath is made up of alternating TssB/C units
151
. This entire tubule assembles onto a 
baseplate and is anchored to a membrane-associated complex made up of three proteins, 
including VasK
151
. The capped tubule and baseplate are structurally and functional 
homologous to the tail-spike of T4 phage
140
. Similar to this contractile phage, upon 
contraction of the sheath, the inner tube is propelled forward out of the cell where the tube 
spike is thought to help penetrate target cells
152
.  
There are numerous toxins that can be deployed by the type VI secretion system. Small 
effector molecules (10-20kDa) have been demonstrated to bind inside the Hcp hexameric 
structure, becoming part of the inner tube upon assembly
164
. The C-terminus of some VgrG 
proteins contain a toxic domain, thus receiving the name “evolved” or “extended” VgrGs133. 
Likewise, PAAR proteins can have toxins on the N- or C-terminal end of the PAAR domain 
that interacts with VgrG
153
. PAAR domains are also found in the N-terminus of 
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rearrangement hotspot (Rhs) proteins.  Rhs proteins have a core of YD-repeats with a C-
terminal toxin domain that is demarcated by conserved DPXGL motifs
121
. However, the 
reported PAAR-containing proteins that are required to support T6 activity are only ~95 
residues while Rhs proteins are ~1400 residues
153
. Nevertheless, Rhs proteins are deployed 
by the T6SS, presumably by their PAAR domain interacting with a VgrG protein. There are 
also medium sized effectors that are too big to fit inside an Hcp tube, thus their mechanism of 
delivery is unknown.  The small and medium sized effectors typically act in the periplasm 
where they target the cell wall or other membrane components
128
. Rhs proteins almost always 
encode nucleases that act in the cytoplasm, and PAAR proteins contain a mix of periplasmic- 
and cytoplasmic-acting toxins
153
. Ultimately, there are numerous diverse toxins deployed by 
the T6SS.  
Despite the large variety of bacteria that contain T6SSs, functional T6S has only been 
experimentally shown in a handful of species. The field is still trying to understand the 
mechanism of T6 assembly, firing, and delivery of effectors into their proper compartments 
in target cells.  Here we demonstrate that Enterobacter cloacae ATCC13047 (ECL) is a great 
model organism to study T6 secretion. We show it contains a functional T6S locus that is 
involved in inter- and intra-species competition. We establish that the two Rhs proteins found 
in ECL are functional and utilize specific VgrG proteins to deploy into target cells. We 
demonstrate that at least one Rhs protein is required for a functional T6 apparatus. 
Surprisingly, we find that full-length Rhs protein, and not just its PAAR domain, is required 
for functional T6 secretion in ECL. Furthermore, we demonstrate the assembly of the T6 
organelle, and not just function is dependent on full-length Rhs. This suggests Rhs proteins 
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are more involved in the T6 assembly process than previously believed, and do more than 
just sharpen the tip of VgrG proteins.  
 
Materials and Methods 
Bacterial strains and plasmids used in this study 
Strains or plasmids Description
a
 Reference 
Strain   
X90 
F´ lacI
q
 lac´ pro´/ara∆(lac-pro) nal1 argE(amb) 
rif
r
 thi-1, Rif
R
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CH6733 
Salmonella enterica serovar typhimurium with 
genomically-encoded chloramphenicol 
resistance cassette flanked by Roth universal 
primers, Cm
R 
David 
Low 
CH8160 Alcaligenes faecalis Rif
R
 ATCC 35655 This study 
CH8161 Citrobacter freundii Rif
R
 ATCC 8090 
118
 
CH8162 Enterobacter aerogenes Rif
R
 ATCC 13048 
118
 
CH7839 Enterobacter cloacae ATCC 13047 ATCC 
CH8163 Enterobacter cloacae Rif
R
 ATCC 13047 
118
 
CH11641
 
Serratia marcescens Rif
R
 ATCC 8100 
118
 
CH8330 Proteus mirabilis Rif
R Dylan 
Peterson 
CH11196 ECL vasK1::kan This study 
CH11396 ECL vasK1 This study 
CH11615 ECL vasK1 RifR This study 
CH12037 ECL vasK2::kan This study 
CH12038 ECL vasK1 vasK2::kan This study 
CH12384 ECL vgrG1::kan This study 
CH11436 ECL vgrG2::kan This study 
CH12414 ECL vgrG2 vgrG1::kan This study 
CH11199 ECL hcp3::spec This study 
CH11191 ECL clpV1::kan This study 
CH11202 ECL tae4::spec This study 
CH11204 ECL tae4 tai4::kan This study 
CH11205 ECL tae4 tai4 This study 
CH11685 ECL tae4 tai4 RifR This study 
CH11876 ECL 01553::kan This study 
CH11895 ECL 01553 01554::spec This study 
CH11904 ECL 01553 01554::spec RifR This study 
CH11178 ECL rhs1::kan This study 
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CH11179 ECL rhs1 This study 
CH11530 ECL rhs1 rhs2 1-206::kan This study 
CH11645 ECL rhs1 rhs2 1-857::kan This study 
CH11531 ECL rhs1 rhs2 1-1161::kan This study 
CH12486 ECL rhs1 rhs2 1-1277::kan This study 
CH11181 ECL rhs1rhsI1::kan This study 
CH11182 ECL rhs1rhsI1 This study 
CH11185 ECL rhs1rhsI1 RifR This study 
CH12415 ECL rhs1vgrG1::kan This study 
CH12416 ECL rhs1vgrG2::kan This study 
CH11186 ECL rhs2::kan This study 
CH11733 ECL rhs2 This study 
CH12497 ECL rhs2 rhs1 1-250::kan This study 
CH12226 ECL rhs2 rhs1 1-966::kan This study 
CH11749
 
ECL rhs2 rhs1 1-1323::kan This study 
CH12492 ECL rhs2 rhs2 1-1330::kan This study 
CH11188 ECL rhs2rhsI2::spec This study 
CH11223 ECL rhs2rhsI2::spec RifR This study 
CH11748
 
ECL rhs2rhs1::kan This study 
CH11903
 
ECL rhs2rhs1 This study 
CH12385 ECL rhs2vgrG1::kan This study 
CH12386 ECL rhsvgrG2::kan This study 
CH11221 ECL rhs1rhsI1 Drhs2 DrhsI2::spec This study 
CH11472
 
ECL hcp1::kan This study 
CH11652 ECL hcp2::kan This study 
CH11653 ECL hcp4::kan This study 
CH11654 ECL hcp5::kan This study 
CH12482
 
ECL tssC-GFP::kan This study 
CH12549
 
ECL rhs2rhs1 tssC-GFP::kan This study 
CH12031 ECL spec_araC_pBAD_T6SS-2 This study 
CH12039 ECL vasK1 spec_araC_pBAD_T6SS-2 This study 
CH11498
 
ECL tep1 This study 
CH11500
 
ECL tep1tep1::kan This study 
CH11670 ECL tep2 This study 
CH11659 ECL tep2tep2::kan This study 
CH11209 ECL tep4 This study 
CH11211
 
ECL tep4tep4::kan This study 
CH11675
 
ECL tep5 This study 
CH11660 ECL tep5tep5::kan This study 
CH11807 ECL 01556  
CH11830
 
ECL 01556 01557::kan This study 
CH1347 ECL 03144 This study 
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CH11902 ECL 0314403145::kan This study 
CH11922 ECL 0221702217imm. 04194 This study 
CH11943
 ECL 0221702217imm. 
0419404194imm.::kan 
This study 
Plasmids 
pTrc99a IPTG-inducible expression plasmid, Amp
R
 
GE 
Healthcare 
pTrc99aCm 
Cm
R 
IPTG-inducible expression plasmid, 
Amp
R
 
This study 
pCP20 
Heat-inducible expression of FLP 
recombinase, Cm
R
 Amp
R 
225
 
pKOBEG 
L-arabinose inducible expression phage l red 
genes, temperature-sensitive replication origin, 
Cm
R
 
250
 
pKAN 
pBluescript with kanamycin-resistance 
cassette ligated to SmaI site, Amp
R
 Kan
R
 
251
 
pSPM 
pBluescript with spectinomycin-resistance 
cassette ligated between BamHI and EcoRI sites, 
Amp
R
 Spc
R
 
252
 
pCH450 
pACYC184 derivative with E. coli araBAD 
promoter for arabinose-inducible expression, Tet
R
 
249
 
pCH450K 
pACYC184 derivative with E. coli araBAD 
promoter for arabinose-inducible expression with 
KpnI site, Tet
R
 
This study 
pZS21kan 
pZS31 derivative carrying an ampicillin-
resistance cassette, Kan
R
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pET21P::rhs1(82-
467) 
Overproduces Rhs1(82-467)-His6 under 
control of phage T7 promoter, Amp
R
 
This study 
pZS21kan::tai4 Constitutive expression of Tai4, Kan
R 
This study 
pZS21kan::rhsI1 Constitutive expression of RhsI1, Kan
R 
This study 
pTrc99aCm::0155
4 
Constitutive expression of 01554, Cm
R
 This study 
pTrc99aCm::rhsI2 Constitutive expression of RhsI2, Cm
R
 This study 
pCH450::vasK1 
Arabinose-inducible expression of VasK1, 
Tet
R This study 
pCH450::hcp3 Arabinose-inducible expression of Hcp3, Tet
R 
This study 
pCH450K::clpV1 
Arabinose-inducible expression of ClpV1, 
Tet
R This study 
pCH450K::hcp1 Arabinose-inducible expression of Hcp1, Tet
R 
This study 
pCH450K::hcp2 Arabinose-inducible expression of Hcp2, Tet
R 
This study 
pCH450K::hcp4 Arabinose-inducible expression of Hcp4, Tet
R 
This study 
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pCH450::hcp5 Arabinose-inducible expression of Hcp5, Tet
R 
This study 
pCH450K::rhs1(1-
230) 
Arabinose-inducible expression of Rhs1(1-
230), Tet
R
 
This study 
pCH450K::rhs1(9
4-230) 
Arabinose-inducible expression of Rhs1(94-
230), Tet
R This study 
pCH450K::rhs1(1-
467) 
Arabinose-inducible expression of Rhs1(1-
467), Tet
R This study 
pCH450::rhs1(82-
467) 
Arabinose-inducible expression of Rhs1(82-
467), Tet
R This study 
pCH450K::rhs2(8
0-163) 
Arabinose-inducible expression of Rhs2(80-
163), Tet
R This study 
pCH450K::02217 
02217imm. 
Arabinose-inducible expression of 02217-
02217Imm., Tet
R This study 
pCH450K::03143-
03145 
Arabinose-inducible expression of 03143-
03145, Tet
R This study 
pCH450K::tep1-
tip1-hcp1 
Arabinose-inducible expression of Tep1-
Tip1-Hcp1, Tet
R This study 
pCH450K::hcp2-
tep2-tip2 
Arabinose-inducible expression of Hcp2-
Tep2-Tip2, Tet
R This study 
pCH450::hcp3-
tae4-tai4 
Arabinose-inducible expression of Hcp3-
Tae4-Tai4, Tet
R This study 
pCH450::hcp4-
tep4-tip4 
Arabinose-inducible expression of Hcp4-
Tep4-Tip4, Tet
R This study 
pCH450::tep5-
tip5-hcp5 
Arabinose-inducible expression of Tep5-
Tip5-Hcp5, Tet
R This study 
a
Abbreviations: Amp
R
, ampicillin resistant; Cm
R
, chloramphenicol resistant; Kan
R
, 
kanamycin resistant; Rif
R
, rifampicin resistant; Str
R
, streptomycin resistant; Tet
R
, tetracycline 
resistant 
 
Oligonucleotides used in this study 
tae4-up 5' - GGG GAG CTC CCC AGC CAG GTA ATA TG - 3'  
5' - CCA CTA GTT CTA GAG CGG CTT GTT TCT 
CCT TGA AAA G - 3' 
This study 
tae4-ds 5' - GCT TAT CGA TAC CGT CGA CAC CTT CTG 
GAG CCT GAA ATG - 3' 
5' - TCT GAT AAT GAC CAG GCT CGG TAC C - 3'  
This study 
tai4-ds 5' - GCT TAT CGA TAC CGT CGA CTA GTA AAG 
ATG AAA TCG GC - 3' 
5' - ATA GGT ACC GTC ACT TCG ATG CGG - 3' 
This study 
01553-up 5' - CAA GAG CTC CGG GAT GGT TGC C -3'  
5' - ATT GGA TCC GTC CTG TTA CCA GTC - 3'  
This study 
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01553-ds 5' - AGG CTC GAG ACA TT CAA TTA TTA GG - 3' 
(XhoI) 
5' - AAC GGT ACC TGG CGA TAA ACC CGC - 3'  
This study 
01554-ds 5' - CCA ACT CGA GTT AAA TAG GAA ACG - 3' 
(XhoI) 
5' - CCA GGT ACC AAA GTG CTG TGT GC - 3'  
This study 
clpV1-up 5' - TTT GAG CTC GGT CAA ACT GAT CGC CAA C 
- 3'  
5' - TTT GGA TCC GTT TCC ATT AAC AAT GAT 
TCG G - 3'  
This study 
clpV1-ds 5' - TTT GAA TTC CAA GAG AAC TGT AAA AGA 
TGA C - 3'  
5' - TTT GGT ACC GCC TCG TTA ATC AGC TCC - 3'  
This study 
vasK1-up 5'- TTT GAG CTC GAA ATC GAC GCC GGT CTG -3' 
5'- TTT GGA TCC TTT CCT TGC GGC AAT CCG -3' 
This study 
vasK1-ds 5'- TTT GAA TTC CAA  GGA CAG CCG TAT GAC -
3' 
5'- TTT GGT ACC GAA TCG ACA TCA GCA TCT C -
3' 
This study 
vasK2-up 5' - TTT GAG CTC GGC AAC CGC CTG ACA C - 3' 
5' - CCA CTA GTT CTA GAG CGG CTT CCG TAG 
TCT TCG GTG C - 3'  
This study 
vasK2-ds 5' - GCT TAT CGA TAC CGT CGA CGG ACA GTA 
CGG AAA GCA G - 3' 
5' - TTT GGT ACC GCC GAG CCA TTC - 3' 
This study 
vgrG1-up 5' – GTT GAG CTC GTT ATG GAT GTC ATT TTG 
TCA ATC 
5' – AAT GGA TCC GAG CAT AAT CGT TAT TCC 
GTA ATG 
This study 
vgrG1-ds 5' – AAG GAA TTC AAT AAG TAA ACG TAA TTA 
GAA AC 
5' – CTT GGT ACC AGC AAA AGT TCG ATT TAT 
TCA AC 
This study 
vgrG2-up 5' - TTT GAG CTC CCC TTG CTA CGG CCA AAC -3'  
5' - TTT GGA TCC TCG TTA TTC CAC TAT GGG C -
3'  
This study 
vgrG2-ds 5' - TTT CTC GAG GCT GGA GCG GTG CTT G - 
3'(XhoI)  
5' - TTT GGT ACC CGA GTC CAG ACA ATC AGG - 
3'  
This study 
hcp1-up 5' – cagGAGCTCtagcgatagcatggacg  
5' – ccactagttctagagcggcggatttgacatacaaactcc  
 
This study 
hcp1-ds 5' - atgGAATTCcaacatactaaaacgtgatccc 
5' - agcGGTACCacccgctccctgc 
 
This study 
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hcp2-up 5' - catGAGCTCcctcttccctcgcctc 
5' - gggGGATCCcattctgaaagctccttttcag 
 
This study 
hcp2-ds 5' - attGAATTCcagacagatgatccgttgc 
5' - agaGGTACCctgagtgaacgggtttcatc 
 
This study 
hcp3-up 5' - TTT GAG CTC CCA GGT GCA GGA GAT TC - 3'  
5' - CCA CTA GTT CTA GAG CGG CTA CTC TTC 
GTC GAT GAA C - 3' 
This study 
hcp3-ds 5' - GCT TAT CGA TAC CGT CGA CGT AGT GGG 
TCC GAA AGG G - 3'  
5' - AAA GGT ACC TTC CAG AGT GTT ACA TGC - 
3'  
This study 
hcp4-up 5' - cacGAGCTCttcctgatttccgctgc 
5' - aggGGATCCcatagtctactcatcatccatgt 
 
This study 
hcp4-ds 5' - tagGAATTCagagcgttaattatgcgtactc 
5' - catGGTACCctgcaggttttcatacacg 
 
This study 
rhs1-up 5' - TTT GAG CTC ATA CAC CCT CCA GGA AGG - 
3' 
5' - TTT GGA TCC GCC TTA CAC ATT CCG GTT G - 
3' 
This study 
rhs1-ds 5' - GAA GAA TTC TGG CAA GAG GAT TAC TTA 
ATG - 3' 
5' - TTT GGT ACC CAT CAT TAG TAA TGC AAA G 
- 3' 
This study 
rhsI1-ds 5' - TTT GAA TTC GTT AAT GTT CGA CCA CAA 
TTG - 3' 
5' - TTT GGT ACC CAT GCC GAT GTC GAT TAA 
AG - 3' 
This study 
rhs2-up 5'- TTT GAG CTC ACC CGC TCA ATG TCA GAA C -
3' 
5'- TTT GAA TCC CCC TGG TGT TAA TGG TGG -3' 
This study 
rhs2-ds 5'- TTT GAA TTC CAA TGA ATA TGC TGA ATG 
TGA G -3' 
5'- TTT GGT ACC ACT TCG TCA TTA TCA TCT GC 
-3' 
This study 
rhsI2-ds 5'- TTT CTC GAG ATC CCG GAA ACC ATT AAG -3' 
(XhoI) 
5'- TTT GGT ACC CAT CCT CTG CAT GAA GAT G -
3' 
This study 
rhs2(206)-up 5' - GCC GAG CTC GGC GCA TCC TGC CTT GGC - 
3'  
5' - CAG GGA TCC TGC CCA GCT ACT TAG AGA 
GCG C - 3'  
This study 
202 
 
rhs2(857)-up 5' - TTT GAG CTC TGC TGA GTG CCG TGA TC - 3'  
5' - TTT GGA TCC ACT AGC TTT CGA TAC CCA 
GCG C - 3'  
This study 
rhs2(1161)-up 5' - TAC GAG CTC GAA GGG CGT CTG CTG AAG C 
- 3'  
5' - TGT GGA TCC AGT AAA TCT AAC CGC TGC 
TCT GG - 3' 
This study 
rhs2(1277)-up 5' - TAC GAG CTC GAA GGG CGT CTG CTG AAG C 
- 3'  
5' - AAC GCG GCC GCT TAC GCG GAG AGT CCC 
CAC (NotI) 
This study 
rhs1(250)-up 5' - GCG GAG CTC CTA ACC TGG CGG GTG 
5' - GAG GGA TCC TTA CCC CAG TGC CAG C 
This study 
rhs1(966)-up 5' - GGT GAG CTC CCG CTG GGA CAG C 
5' - GCT GGA TCC TTA CCC GCT GCC GTA G 
This study 
rhs1(1323)-up 5' - TTT GAG CTC ACA GAA GTG ATC AGC CAG - 
3'  
5' - TTT GGA TCC CTA TAT TCG GGT TAG ACT 
ATT AGC - 3'  
This study 
rhs1(1330)-up 5' - TAA GAG CTC GCG GGA AGA ACG GG - 3' 
5' - CCT GCG GCC GCG AGT CCC CAC GGA TCA 
ATC - 3' (NotI) 
This study 
tep1-up 5' - gttGAGCTCctgacggcaccacc 
5' - agaGGATCCcataacgtatccatactgtttttatgg 
 
This study 
tep1-ds 5' - gatGAATTCgctatctataacgacttaaaggataaatag 
5' - aaaGGTACCagggatcacgttttagtatgttg 
 
This study 
tip1-ds 5' - attGAATTCgctttgataagtacgattgagtttta 
5' - aaaGGTACCagggatcacgttttagtatgttg 
 
This study 
tep2-up 5' - acaGAGCTCtcaaactcactgaaaaggagc 
5' - gcaGGATCCcatctgtctgcccaagaatc 
 
This study 
tep2-ds 5' - gcaGAATTCaggtctactgatgaaaccc 
5' - atcCTCGAGtgcaaaaaataacgttgactcatc (XhoI) 
This study 
tip2-ds 5' - aacGAATTCatattgattagcgcattgtgaaag 
5' - atcCTCGAGtgcaaaaaataacgttgactcatc 
 
This study 
tep4-up 5' - CAC GAG CTC GGT AGA TGT TCA TGA TC - 3' 
5' - CCA CTA GTT CTA GAG CGG AAT TAA CGC 
TCT GCC CAG C - 3'  
This study 
tep4-ds 5' - GCT TAT CGA TAC CGT CGA CGG TTT TTA 
ACT GGC GAG TC - 3' 
5' - CCC GGT ACC TAG CGT TGA TGA TCA G – 3' 
This study 
tip4-ds 5' - GCT TAT CGA TAC CGT CGA CTC ATA AAC This study 
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GCT ATT TAC CG -3' 
5' - CCA CCG GTA CCG ACA GCG CAA GG - 3' 
tep5-up 5' - ttaGAGCTCgtcatatgacagtttccattaagtg 
5' - gacGGATCCcatacacaccttcatagccatt 
 
This study 
tep5-ds 5' - catGAATTCgaccggatatggtaactgaac 
5' - cacCTCGAGccgtagctcgctcattc (XhoI) 
 
This study 
tip5-ds 5' - tggGAATTCgattaataaggaggaaaatgatggc 
5' - cacCTCGAGccgtagctcgctcattc 
 
This study 
02217-up 5' - CAA GAG CTC GCG TGA GCA TGC GAC - 3'  
5' - TTA GGA TCC GGT AAT TAG TAA ATT G - 3'  
 
This study 
02217-ds 5' - TAA CTC GAG AAG CGG GGC TGT ACA AAT 
G - 3'  (XhoI) 
5' - TTG AGA ATG GTA CCA GAA AAG CCC - 3'  
This study 
02217imm.-ds 5' - CTT CTC GAG TAT AAT TCT CAA TTC TC - 3' 
(XhoI) 
5' - GGT CGG TAC CGC ACT CTG AAG CGC - 3'  
This study 
04194-up 5' - GCC GAG CTC CCG CCG CAA CTG C 
5' - GTT GGA TCC CAG CGG GTG AAC AAC AAC 
This study 
04194-ds 5' - TAC GAA TTC TGA CAG TGA ATG TTG AAG 
CG 
5' - TAT GGT ACC CTG CAA AAA GCC CCT ACC 
This study 
04194imm.-ds 5' - GCA GAA TTG GTA GTG TTC AAT ATA AGC 
CCC G 
5' - TCC GGT ACC CTG GAA CTG AAG CAG GC 
This study 
03144-up 5' - GGT GAG CTC CGC ATA TGT GTT TAA GG - 3'  
5' - CAT GGA TCC CTC TAC TTT ATA TGG - 3'  
This study 
03144-ds 5' - AGA GAA TTC ATG AGG TTG TTA AAT AA - 3'  
5' - TCC GGT ACC TTT GCT TAA AGG G - 3' 
This study 
03145-ds 5' - CAA GAA TTC AGG AAA AAA TTG ATT TTA - 
3' 
5' - TTA GGT ACC TCG ATC CTT GCC G - 3'  
This study 
01556-up 5' - ACC GAG CTC TGG CTA ATC AGC GAA TG - 3'  
5' - ACT GGA TCC CTC ATT TAA TCG ATT CG - 3' 
This study 
01556-ds 5' - GAA GAA TTC CCT GAC GAG TTT TGA G - 3'  
5' - CAA GGT ACC GTC TGC TTA ATT TCG - 3'  
This study 
01557-ds 5' - ATC GAA TTC AAG CAG ACG GTG AC - 3'  
5' - TGC GGT ACC GTC TGC CCC TGG - 3'  
This study 
Tai4-EcoRI-
for 
5' - TTT GAA TTC TTC TGG AGC CTG AAA TGA 
AAA AG - 3'  
This study 
Tai4-BamHI-
rev 
5' - TTT GGA TCC CTA CTT TGA GGA TTT GAG 
TGG - 3'  
This study 
01554-KpnI- 5' - GAG GGT ACC ATG AAA TCG TTC TTA TCA This study 
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for GGC - 3’ 
01554-XhoI-
rev 
5' - ATA CTC GAG CTA TTT AAC CGG AGT TGG 
TG - 3’ 
This study 
VasK1-NcoI-
for 
5' - TTT CCA TGG TGA CGA CTC TTC TTT C - 3'  
 
This study 
VasK1-XhoI-
rev 
5' - TTT CTC GAG TTA TGG GCA TGA GAA ACG - 
3' 
This study 
Hcp1-KpnI-
for 
5' - TTT GGT ACC ATG TCA AAT CCG GCT TAT 
TTG - 3'  
This study 
Hcp1-XhoI-
rev 
5' - TTT CTC GAG TTT AGT ATG TTG CTC GCT C - 
3'  
This study 
Hcp2-KpnI-
for 
5' - TTT GGT ACC ATG GCT ATA CCC GCA TAT C 
- 3'  
This study 
Hcp2-XhoI-
rev 
5' - TTT CTC GAG ATC ATC TGT CTG CCC AAG - 3'  
 
This study 
Hcp3-NcoI-
for 
5' - ATA CCA TGG CTA TTG ATA TGT TTC - 3'  
 
This study 
Hcp3-XhoI-
rev 
5' - TTT CTC GAG CAC TAC TAT TAT GCT TCT 
TTG - 3' 
This study 
Hcp4-KpnI-
for 
5' - GAG GGT ACC ATG GCA ATT CCT GTA TAT 
CTT TTC - 3' 
This study 
Hcp4-XhoI-
rev 
5' - TTT CTC GAG AAT TAA CGC TCT GCC CAG - 
3'  
 
Hcp5-NcoI-
for 
5' - TTT CCA TGG CTG TAC CGG TCC - 3'  
 
This study 
Hcp5-XhoI-
rev 
5' - TTT CTC GAG GCA CTT CAA ACC GTA GC - 3'  
 
This study 
RhsI1-EcoRI-
for 
5' - TTT GAA TTC GGC AAG AGG ATT ACT TAA 
TG - 3'  
This study 
RhsI1-
BamHI-rev 
5' - TTT GGA TCC CGA ACA TTA ACA TAT TAA 
ATC G - 3'  
This study 
RhsI2-KpnI-
for 
5' - TTT GGT ACC ATG AGT GAA ATT GAA GAG 
TC - 3'  
This study 
RhsI2-XhoI-
rev 
5' - TTT CTC GAG GTA TCC TAG CCA TAA AAA 
TAA TC - 3'  
This study 
02217-KpnI-
for 
5' - GCG GGT ACC ATG GGT TAC CGT ACC G 
 
This study 
02217Imm.-
XhoI-for 
5' - TGT CTC GAG CAT TAC CAG CGA AGC TC 
 
This study 
03143-KpnI-
for 
5' - CTC GGT ACC ATG CAG CAA TAC ACC AAC 
 
This study 
03145-XhoI-
for 
5' - CTT CTC GAG ATG CTA TCG AAA ATA CAA C 
 
This study 
Rhs1-KpnI-
for 
5' - GTG GGT ACC ATG AGC GAT AAC AAC GCG 
GCC - 3' 
This study 
Rhs1(94)- 5' - GCG GGT ACC ATG GGT GAT GCG CTG TTC C This study 
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KpnI-for  
Rhs1(82)-
NcoI-for 
5' - TGG CCA TGG TTA CTG ACG ATA TCA G - 3' 
 
This study 
Rhs1(230)-
XhoI-rev 
5' - CAG CTC GAG TTA GCC GAT GAT CAC ATT 
CG 
This study 
Rhs1(467)-
XhoI-rev 
5' - AAA CTC GAG TTA GGC AGC GGT TAC GCG 
 
This study 
Rhs2(80)-
KpnI-for 
5' - CG GGT ACC ATG GCC GAT GCC GGG G 
 
This study 
Rhs2(163)-
XhoI-rev 
5' - CTG CTC GAG TTA GCC GAT GAA GAC GTT 
GTG 
This study 
 
Bacterial strains, plasmids, and growth conditions  
All bacterial strains and plasmids used in this study are listed in the table above. Bacteria 
were grown in LB media or LB-agar with antibiotics at the following concentrations: 
ampicillin (Amp) 150 μg/mL; kanamycin (Kan) 50 μg/mL; rifampicin (Rif) 200 µg/mL; 
spectinomycin (Spc) 100 μg/mL; and tetracycline (Tet) 10 μg/mL. The listed primer pairs 
were used to amplify ~400bp up or downstream of the designated gene. The upstream 
product was digested with SacI/BamHI, downstream product with EcoRI/KpnI (unless noted 
otherwise) and ligated into pKAN or pSPM to flank kanamycin- or spectinomycin-resistance 
cassettes, respectively. tae4, tai4, vasK2, hcp3, tep4, and tip4 constructs were produced by 
OE-PCR. The resulting plasmids were linearized by restriction endonuclease digestion and 
electroporated into E. cloacae cells expressing the phage λ Red proteins from plasmid 
pKOBEG 
250,253
. Kan cassettes were removed using pCP20
225
. For construction of the 
plasmids listed in the first table above, the primer pairs listed in the second table were used 
for PCR off E. cloacae gDNA. The PCR products were digested with the annotated enzymes 
and ligated into their respective plasmids.  
 
Growth competitions  
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 Donor and inhibitor cells were grown to late-log phase with aeration in liquid LB. 
Cells were spun down, concentrated with M9 salts, and mixed at a 1:1 ratio at OD600 17:17. 
100uL of the mixture was plated onto LB-agar plates and incubated at 37ºC for 4 hours. Cells 
were harvested with 1.5mLs of M9 salts, serial diluted, and plated on selective agar plates for 
colony counts.   
 
Western blots analysis 
Cells were grown in 2mLs of liquid LB supplemented with 0.2% arabinose where 
indicated to mid-log with aeration. Cells were lysed in urea lysis buffer or RIPA buffer. 
Supernatants were ethanol precipitated for at least 2 hours at -20ºC. Equal amounts of protein 
were subjected to 10% acrylamide SDS-PAGE and transferred onto nitrocellulose or PVDF 
membrane and incubated with 1:10,000 anti-Rhs1 or 1:25,000 anti-Hcp3. 
 
Results 
T6SS-1
 
mediates inter-species competition 
ECL contains 2 T6SS loci that we have named T6SS-1 and –2 based on their 
chronological location in the genome (Fig. 1A & 1B). To determine if either of these loci is 
functional in bacterial competition, WT, vasK1
-
 and vasK2
-
 donor cells were assayed for their 
ability to inhibit the growth of Escherichia coli recipients. Competition data will be 
represented as the competitive index of donor over recipient cells unless noted otherwise. We 
found that WT and vasK2
-
 cells kill E. coli 3-4 logs while vasK1
-
 cells minimally hindered E. 
coli growth (Fig. 2A). We note this may be due to the slightly slower growth rate of E. coli 
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compared to ECL under the conditions tested (data not shown). These experiments 
demonstrate that T6SS-1, but not T6SS-2 is on and functional under laboratory conditions.  
Next we wanted to see if T6SS-1 gave ECL a competitive advantage against other species 
of bacteria. ECL, vasK1
-
 or vasK2
-
 cells were competed against various proteobacteria. Only 
Proteus mirabilis was able to hinder the growth of ECL during co-culture, while ECL 
dominated all other species tested (Fig. 2A). We note that P. mirabilis has its own T6SS that 
may be facilitating this competitive advantage. Furthermore, it seems ECL fares better 
against P. mirabilis when it has a functional T6SS (Fig. 2A). These experiments further 
demonstrate that T6SS-1 mediates inter-species competition and is efficient to outcompete a 
variety of proteobacteria under laboratory conditions. 
  
Tae4
ECL
 and ECL01553 are deployed by T6SS-1  
Next we examined what toxins could be deployed by T6SS-1 to facilitate this competitive 
advantage. Tae4-Tai4 is a T6 effector-immunity (E-I) pair that has previously been described 
to function as an amidase, acting in the periplasm to cause cell lysis. ECL contains this E-I 
pair in T6SS-1, immediately downstream of the only Hcp in the locus (Hcp3) (Fig. 1A). 
Therefore, we assumed this effector is deployed by T6SS-1. To test this, we made 
tae4tai4 recipient cells and asked how they fared in competition against various donor 
cells. Consistent with Tae4 serving as a functional amidase, tae4tai4 cells were less fit 
than WT donors, and this decrease in fitness was dependent on tae4, vask1, hcp3, clpV1 and 
at least one vgrG in donor cells (Fig. 3). Furthermore, expression of Tai4 restored their 
fitness defect (Fig. 3A), suggesting Tae4-Tai4 serves as a functional T6SS E-I pair that is 
deployed by T6SS-1.  
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Further examination of the T6SS-1 locus reveals ECL01553 has predicted lipase 
function. Mougous identified and characterized 5 classes of lipase proteins that act as 
effectors. ECL01553 has the characteristic GXSXG motif that is present in classes 1-4
165
. 
Consistent with other T6 effectors, which are found in bicistrons with cognate immunity 
genes, ECL10554 is found immediately downstream and has a predicted signal sequence that 
would direct it to the periplasm (Fig. 1A). Based on these observations, we hypothesized that 
ECL01553 encodes an effector that targets the phospholipid bilayer while ECL01554 
encodes for an immunity protein capable of inactivating ECL01553. To test this, we used the 
same approach as described above and competed 10553 10554 recipients against various 
T6SS
+
 and T6SS
-
 donors. WT donors have a 3-log competitive advantage over these 
recipients, and this is abolished when donors lack 01553 or when recipients express 01554 
(Fig. 4A). The fitness advantage was also dependent on donors expressing T6SS-1 genes 
(Fig. 4B & 4C). Thus, 01553-01554 also act as an effective T6SS-1 E-I pair that is able to 
severely inhibit the growth of recipient cells. 
 
Rhs1 and Rhs2 are functional effectors deployed by T6SS-1  
Of note, at the time of these experiments, it was unclear if Rhs proteins were delivered 
via the T6SS. It had been demonstrated in Dickeya Dadantii that donor cells required both 
Hcp and VgrG to inhibit rhsArhsIA or rhsBrhsIB recipient cells252. However, it was 
thought that Rhs proteins get decorated by Hcp, capped by VgrG, and exported out of donor 
cells independent of the T6SS organelle. Furthermore, the interaction between the C-
terminus of VgrG and PAAR domains was not discovered yet. This section is presented in a 
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manner where it is unclear how Rhs proteins are deployed, because at the time of these 
experiments, this was actually the case.  
Rhs proteins have previously been reported as potent contributors to bacterial 
competition. The genome of ECL contains two Rhs proteins, named Rhs1 and Rhs2, which 
each reside upstream of genes encoding predicted cognate immunity proteins (Fig. 1A & 
1C). To test if Rhs1 or Rhs2 are used in bacterial competition, rhs1rhsI1 or rhs2rhsI2 
cells with or without plasmid-borne copies of cognate immunity proteins were competed 
against WT, and rhs1
-
 or rhs2
-
 donor cells. WT donors inhibited the growth of rhs1rhsI1 
and rhs2rhsI2 recipients by 2 and 3 logs, respectively (Fig. 5A). Moreover, this inhibition 
was abrogated when target cells were expressing their cognate immunity protein, or when the 
cognate Rhs was missing in the donor cell (Fig. 5A). These results demonstrate that both 
Rhs1 and Rhs2 can be used in intra-species bacterial competition.  
As previously mentioned, the toxic activity of Rhs proteins reside in the C-terminus (Rhs-
CT)
121
. RhsI1 and RhsI2 are both predicted cytoplasmic proteins, so we reasoned Rhs1-CT 
and Rhs2-CT both act in the cytoplasm. Furthermore, bioinformatic analysis reveals Rhs1-
CT contains an HNH nuclease domain, while Rhs2 is predicted to have DNase activity, so 
the substrates of each protein are located in the cytoplasm. In accord with these observations, 
expressing Rhs1-CT or Rhs2-CT in the cytoplasm of E. coli cells results in cell death while 
E. coli cells expressing cognate immunity proteins survive (data not shown). These data 
suggest Rhs1 and Rhs2 both mediate bacterial competition by targeting substrates in the 
cytoplasm of recipient cells.  
Rhs1 is located directly downstream of T6SS-1 while Rhs2 resides as a distant site in the 
chromosome, unlinked to any other T6SS gene (Fig. 1A & 1C). We wanted to determine if 
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the entire T6SS-1 is required for Rhs1 or Rhs2 deployment, or if only VgrG and Hcp are 
required, like previously reported in D. dadantii. First, we confirmed that both hcp3
-
 and 
vgrG
-
 donor cells are not able to deliver Rhs1 or Rhs2 (Fig 5B & 7B). Next, we competed 
vasK1
-
 and clpV1
-
 donors against rhs1rhsI1 or rhs2rhsI2 recipient cells (Fig. 5B). 
VasK and ClpV are both essential components needed for proper T6SS assembly and 
disassembly, respectively. Donors lacking either essential component are no longer able to 
inhibit rhs1rhsI1 or rhs2rhsI2 recipient cells, but inhibition can be fully restored when 
vask1
-
 cells are complemented with plasmid-borne VasK1 and partially restored when clpV1
-
 
donors are complemented (Fig. 5B).  Thus, we conclude that Rhs1 and Rhs2 both require the 
entire T6S apparatus, and not just VgrG and Hcp, for proper delivery into target cells. 
ECL contains 5 Hcp alleles scattered throughout its genome, but only Hcp3 is linked to 
other T6 components. We were curious if any other Hcp protein was required for T6SS-1 
function. To test this, we made individual knock outs of each hcp allele in ECL and 
competed these donors against E. coli, rhs1rhsI1, rhs2rhsI2, and 0155301554 
recipients to look for effects on inter-species, Rhs, and T6 effector delivery, respectively. We 
found that only hcp3
-
 donors lost their ability to inhibit any of the recipient cells (Fig. 6A). 
Next we examined if we could complement hcp3
-
 donors with the other 4 hcp alleles. 
However, the inhibitory phenotype of hcp3
-
 donors could only be restored by expressing 
Hcp3, and not any of other hcp allele (Fig. 6B). An alignment of all 5 Hcp proteins shows 
that Hcp3 is the prevalent outlier of the group (Fig. 6C).  Additionally, Hcp3 is the only allele 
present in T6SS-1 (Fig. 1A). These data suggest Hcp3 is not only required for T6S, but also 
the only Hcp in ECL capable of making a functional T6SS-1.  
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When examining Rhs deployment in vgrG
-
 cells, we noticed that vgrG1
-
 donors could 
inhibit rhs1rhsI1 recipients, but were unable to inhibit rhs2rhsI2 recipients (Fig. 7B). 
Conversely, vgrG2
-
donors showed the opposite phenotype where they were unable to inhibit 
rhs1rhsI1 recipients, but could inhibit rhs2rhsI2 recipients (Fig. 7B). These results 
demonstrate that Rhs1 requires VgrG2 for deployment, while Rhs2 requires VgrG1. A closer 
analysis of the two VgrG proteins reveals that the two proteins are 100% identical until their 
C-termini where VgrG1 extends an extra 106 residues (Fig. 7A). Furthermore, Rhs1 and 
Rhs2 proteins are divergent, with only 29% sequence homology. Therefore, we hypothesized 
Rhs1 and Rhs2 were interacting specifically with the C-terminus of VgrG1 and VgrG2, 
respectively. Before any subsequent experiments could be performed to prove our model, the 
laboratory of John Mekalanos (Schneider et al.) revealed the C-terminus of VgrG proteins 
bind to PAAR-containing proteins in Vibrio cholera and E. coli
153
. Rhs1 and Rhs2 each 
contain distinct PAAR domains at their N-termini, consistent with our model of Rhs1 and 
Rhs2 interacting with the divergent C-termini of VgrG1 and VgrG2 in ECL. Taken all 
together, these results demonstrate that Rhs1 and Rhs2 are T6SS-1 effectors that mediate 
intra-species competition via the toxic domains in their C-termini.  
 
Rhs proteins are required for T6S 
Schneider et al. also reported that at least one PAAR-containing protein is required in V. 
cholera and Acinetobacter baylyi for Hcp secretion and the ability to inhibit E. coli cells
153
. 
PAAR motifs coordinate zinc ions and use hydrophobic packing to bring PAAR-containing 
proteins to a sharp point
153
. Therefore, Schneider et al. proposed that PAAR proteins are a 
core component of the T6SS that act by sharpening the tip of the VgrG spike
153
. We had 
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noticed in our experiments that E. coli cells have the same fitness against rhs1
-
rhs2
-
 donor 
cells as they do against vasK1
-
 cells (Fig. 1A & 8A). We found this unusual because this 
suggests Rhs1 and Rhs2 are the only T6 effectors effective against E. coli. We had 
demonstrated Tae4 and 01553 are functional T6 effectors, and other T6 effectors have been 
shown to kill E. coli cells. If Rhs1 and Rhs 2 are the only T6S effectors mediating the 
inhibition of E. coli, then E. coli cells expressing both RhsI1 and RhsI2 should be resistant to 
WT ECL. However, this was not the case. ECL was still able to inhibit the growth of these 
cells, suggesting other T6 effectors are being deployed by T6SS-1 to inhibit the growth of E. 
coli, but in a manner that requires the presence of at least one Rhs protein in ECL (Fig. 8A). 
Of note, the same immunity expression constructs are able to protect rhs1rhsI1 rhs2 
rhsI2 cells from inhibition against WT ECL, indicating the constructs are able to protect 
recipients from Rhs1 and Rhs2 activity (Fig, 8A). Furthermore, we showed that delivery of 
01553 into recipient cells and proper Hcp3 secretions is dependent on at least one cognate 
Rhs/VgrG pair (Fig. 8B & 8C). Therefore, we conclude that the presence of either Rhs1 or 
Rhs2 in ECL is required for functional T6S. 
The above results are not unreasonable considering both Rhs proteins have a PAAR 
domain, and Schneider et al. demonstrated the requirement of at least one PAAR-containing 
protein for proper T6 function
153
. However, ECL contains multiple additional PAAR-
containing proteins encoded in its genome. It seems that in ECL, the PAAR domain required 
for T6SS-1 function is present in its Rhs proteins. It is conceivable that perhaps these other 
PAAR proteins are not expressed and therefore do not have the opportunity to participate in 
T6SS-1 function. To rule this out, we complemented rhs1
-
 rhs2
-
 donor cells with plasmid-
borne PAAR proteins. However, these constructs were unable to restore T6SS-1 function 
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(Fig. 10A), again suggesting the PAAR domains in the Rhs proteins are required for T6 
function in ECL. However, expression of the PAAR domains of Rhs1 or Rhs2 was also not 
sufficient to complement rhs1
-
 rhs2
-
 donor cells (Fig. 10A). Western blot analysis reveals at 
least some of the Rhs1 PAAR constructs are being expressed in donor cells. This led us to 
believe we did not have proper expression levels of the Rhs PAAR domains, and moved on 
to the subsequent experiments. 
Interestingly, the PAAR containing proteins in V. cholera and E. coli are only ~95 
residues and they are able to support T6 function, while Rhs1 and Rhs2 in ECL are ~1400 
residues
153
. If it is only the PAAR motifs that are required for T6 function, then only the 
PAAR domain of Rhs should be required to restore T6 activity. To test this, we inserted stop 
codons in Rhs1 and Rhs2 after the predicted PAAR domains in each protein (Rhs-PAAR) 
(Fig. 9A). Surprisingly, we found these donor cells could not inhibit the growth of E. coli or 
1055310554 recipients (Fig. 9B). We reasoned we might have hindered the fold of the 
PAAR protein by removing its C-terminus, so we inserted a stop codon after the YD-repeat 
motifs of each Rhs (Rhs-YD) (Fig. 9A). Again, surprisingly, these donor cells also failed to 
inhibit the growth of either recipient tested (Fig. 9B). Finally, when we insert a stop codon 
just upstream of the toxin domain (Rhs CT), but downstream of the conserved DPXGL 
motifs (Fig. 9A), are we able to restore full delivery of 01553 into recipients, and full E. coli 
inhibition (Fig. 9B). Interestingly, if we insert the stop codon in Rhs1 just 7 residues 
upstream of the toxin domain (Rhs DDPXL) and therefore remove some of the DPXGL 
motif (Fig. 9A), we lose some inhibitory activity (Fig. 9B). Consistent with the competition 
results, Hcp3 secretion is only fully restored in the mutants that contain stop codon insertions 
immediately upstream of the toxin domain (Fig. 9C).  
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It is still formerly possible that these truncated Rhs proteins are not being expressed, or 
we have disrupted their proper fold, therefore resulting in their destabilization and 
subsequent degradation. To rule this out, we extracted protein from each of the Rhs1 donor 
cells tested, and performed a western blot with antibodies raised to residues 82-467 of Rhs1.  
A prominent band corresponding to the correct size is present in Rhs1-PAAR cells, 
suggesting this protein is expressed and stable in these donor cells (Fig. 9D). No band was 
detected in Rhs-YD cells, but there is a high molecular weight band unique to Rhs2, Rhs1-
DDPXL, and Rhs1-CT samples (Fig. 9D). While this does not correspond to full-length 
protein, it suggests all three cell lines are expressing Rhs1 to the same level. Taken all 
together, these results demonstrate that full-length Rhs protein, and not just its PAAR 
domain, is required for functional T6S in ECL.  
 
Rhs proteins are required for T6 assembly 
We have demonstrated that rhs1
-
 rhs2
-
 donors have abolished T6S activity based on their 
inability to inhibit E. coli cells, deliver 01553, and secrete Hcp3 into the supernatant. Next 
we wanted to know if the T6SS apparatus was still able to assemble, just not fire in the 
absence of Rhs. Previous studies have reported the ability to track T6 firing events in real-
time by fusing fluorescent proteins to TssC, one of the sheath proteins
139
. We took a similar 
approach to look at T6 assembly and firing in ECL. By fusing GFP to the C-terminus of 
TssC, we were able to see both punctate and dynamic green fluorescence (Fig. 11). We 
gather that the punctate spots represent seeding T6SSs and the dynamic fluorescence 
represents assembly and firing events because hcp3
-
 and vgrG
-
 cells only contain diffuse 
green fluorescence (data not shown). Surprisingly, rhs1
- 
rhs2
-
 cells contain neither punctate 
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nor dynamic green spots, indicating there is no assembly of the T6S organelle in rhs
-
 cells 
(Fig. 11).  
 
T6SS-2 in nonfunctional 
We examined the genome of ECL for more T6S E-I pairs. Interestingly, we found that 
immediately up or downstream of the other 4 hcp alleles present in ECL, there are always 
two unannotated open reading frames. Further analysis of these ORFs reveals they encode for 
potential E-I pairs. Each effector was found in other T6SS
+
 bacteria in a bicistron with its 
presumed immunity protein. Furthermore, the Hcp protein that is linked to each effector in 
ECL is also found in these other T6SS
+
 strains, either linked or unlinked to the E-I pair. 
Therefore, we presumed these were E-I pairs that bound to their linked Hcp protein to be 
delivered via the T6SS. We named the E-I pairs Tep-Tip for type VI effector protein and type 
VI immunity protein. To test this, we deleted each Tep-Tip pair and asked if the parental 
strain could inhibit their growth. We found that each Tep-Tip deletion strain has no fitness 
defect against parental donors, thus concluding the effectors are not being deployed into 
recipient cells (Fig. 12A). However, if the Tep-Tip loci are not being expressed then this 
could explain the lack of inhibition seen. To rule this out, we cloned each Hcp-Tep-Tip or 
Tep-Tip-Hcp locus into an arabinose inducible plasmid, the same plasmid we used to 
complement other T6SS components, and asked if donors expressing the loci could inhibit 
the Tep-Tip deleted recipients. We tested all 4 pairs and saw no fitness defect in recipients 
(Fig. 12C and data not shown).    
Next, we looked at the non-Rhs PAAR-containing proteins that we had identified earlier 
for any toxin motifs. We found 4 PAAR proteins that were either fused or linked to predicted 
216 
 
toxic domains. ECL02217 and 04194 share similar toxin domains and likewise have 
homologous immunity proteins located immediately downstream of each gene. To test for 
delivery of either of these toxin domains, we made recipient cells lacking the immunity 
proteins for each of these potential effectors. ECL03144 is located upstream of Rhs2 with 
transcription going in the opposite direction of Rhs2 and encodes for a PAAR-toxin with 
predicted pore-forming activity. Interestingly, ECL03143 also contains PAAR motifs. Lastly, 
although it does not contain a PAAR domain, ECL01556 is found in the T6SS-1 locus and 
homologous to Cas9 and we reasoned its predicted nuclease activity could be used in 
bacterial competition. However, these toxic domains do not seem to be deployed, as recipient 
cells grow to the same levels against WT or toxin
-
 donors (Fig. 12B). Again, we tried to 
express each PAAR-toxin pair in donor cells, but there was still no fitness defect in recipient 
cells (data not shown).  
We hypothesized these Hcp-linked and PAAR-containing toxins are normally deployed 
through T6SS-2, but this locus is not on under laboratory conditions. To test this, we put an 
arabinose inducible promoter in front of T6SS-2 and asked if it could make a functional 
T6SS. To do this, we competed vask1
-
 T6SS-2
+
 cells with E. coli, Salmonella enterica and 
each of the potential E-I recipient strains tested above. We found that T6SS-2, even when 
turned on, could not inhibit the growth of any recipient strain tested (Fig. 13A & 13B and 
data not shown). Even when we forced expression of the potential E-I pairs in the T6SS-2
+
 
donor cells, there was still no inhibition seen (data not shown). Therefore we conclude that 
T6SS-2 is either non-functional, or we have not successfully forced the right levels of 
expression of each component needed to build the T6S apparatus.       
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Upon further analysis of the T6SS-2 locus, we found multiple issues that could contribute 
to its lack of activity. First, the VgrG present in the locus (VgrG3) has a stop codon 603 
residues into the ORF, most likely rendering it non-functional. However, restoring the stop 
codon to a tyrosine and expressing this gene in T6SS-2
+
 cells still does not support T6SS-2 
activity (Fig. 13C). Second, there is a PAAR-containing protein (PAAR-01815) that is 
truncated after residue 63 by a transposon insertion. Bioinformatic analysis shows full-length 
PAAR-01815 is found in other closely related Enterobacter species with a WT VgrG3 allele. 
This suggests the C-terminus of VgrG3 binds to PAAR-01815 to build a functional T6SS. 
Lastly, Enterobacter hormaechei contains a similar T6SS-2 locus; however it contains an 
Hcp protein in the locus while ECL does not. Taken all together, T6SS-2 in ECL is non-
functional due to missing or mutated core components. Further studies will have to be 
performed to test if the Hcp-linked effectors or PAAR-containing toxins in ECL are 
functional T6SS E-I pairs.  
 
Discussion 
The work presented here demonstrates that ECL is a practical model organism to study 
T6S. We established that T6SS-1 plays a prominent role in both inter- and intra-species 
competition while T6SS-2 has some crucial defects that render it inactive. We showed that 
Tae4-Tai4 and 01553-01554 are both effective E-I pairs that likely contribute to the strong 
competitive phenotype of ECL. Furthermore, we demonstrated that Rhs1 and Rhs2 both 
contribute to bacterial competition, most likely by their C-terminal toxin domains targeting 
nucleic acid substrates in the cytoplasm of recipient cells. We determined that Rhs1 and Rhs2 
are specific for VgrG2 and VgrG1, respectively, consistent with the divergent C-termini of 
the VgrG proteins interacting with the distinct PAAR domains present in Rhs1 and Rhs2. 
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Strikingly, we find that the PAAR domains of Rhs proteins are not sufficient to support T6S, 
and that only full-length Rhs protein can restore proper T6S. Most importantly, we 
demonstrate that not only T6 firing, but assembly of the apparatus is dependent on full-length 
Rhs.  
As mentioned previously, T6S has been studied in a limited number of bacterial species. 
Based on the results presented here, it seems different bacterial species may have evolved 
distinct ways to assemble and fire their T6SSs. For example, in V. cholera and A. baylyi, the 
PAAR-containing proteins required to produce a functional T6SS are only ~95 residues 
while Rhs1 and Rhs2 in ECL are ~1400 residues
153
. Furthermore, in Serratia marcescens, 
rhs
- 
donors still exhibit function T6S while D. dadantii rhsA
- 
rhsB
-
 cells have abrogated T6 
activity (data not shown) 
279
. Schneider et al. proposed that the role of PAAR-containing 
proteins is to sharpen the T6SS apparatus by interacting with the C-terminus of the spike 
protein, VgrG
153
. VgrG is also considered a baseplate component because it is necessary for 
Hcp tubule formation, which is in turn required for sheath polymerization
151
. We propose a 
model in which Rhs proteins in ECL and D. dadantii act as a seed for proper VgrG folding 
and subsequent Hcp tubule formation. The YD-repeat regions have the potential to act as a 
scaffold by encasing the spike tip or facilitating interactions with the membrane complex. 
Evidence for this is given by the recent crystal structure of an Rhs-repeat protein forming a 
cocoon around its toxin domain
280
. It seems the DPXGL motifs in Rhs also play some 
unidentified, perhaps structural role for the apparatus. With the presence of T6SSs in 25% of 
sequenced strains, and their prevalence in pathogenic species, it is important to understand 
the mechanism of toxin delivery.  Identifying the differences between T6S in various species 
will lead to an improved understanding of these systems.  
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In addition, understanding the mechanism of effector delivery will help us identify the 
role of T6SSs in nature. It is unclear why so many T6SSs are present in the genome of some 
bacteria and if these systems facilitate a competitive advantage in specific habitats. Carrying 
independent T6S loci to deploy specific effectors comes at a cost, as compared to having one 
locus and regulating expression of E-I pairs based on the environmental conditions 
encountered. Nonetheless, some bacteria carry multiple loci and we still do not understand 
the advantage of this, or what excludes core components from different loci working 
together. We understand that VgrG and PAAR domains must evolve to work together, as do 
TssC/B, but the specificity of the remaining components remains unknown. Are VgrG 
proteins specific to Hcp or do they recognize the tubular structure that Hcp forms? Do 
TssC/B directly interact with Hcp or do they recognize the baseplate components? Can we 
swap components and direct differential assembly of T6SSs and therefore delivery of distinct 
effectors? Can each T6SS deliver into eukaryotic cells? These are all questions that remain to 
be answered, and the answers could give some insight into why some strains have so many 
loci and the contribution of each locus to bacterial competition and/or virulence. Further 
examination of T6SS-2 in ECL could give some insight into which core components interact 
with one another. Ultimately, clarifying the role of T6SSs in nature will help us understand 
how microbial communities are shaped and the potential consequences these communities 
have on an ecosystem. 
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Figure 1. T6S and Rhs loci in Enterobacter cloacae ATCC 13047. A) T6SS-1 locus B) 
T6SS-2 locus C) Rhs2 locus. Open reading frames of T6SS genes are annotated in yellow. 
Red represents genes that contain toxic domains and green are the cognate immunity proteins 
located downstream of each toxin. IS elements are shown in grey.   
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Figure 2. T6SS-1 mediates inter-species competition. A) Various species of bacteria were 
co-cultured with the annotated ECL donor cells at a 1:1 ratio under contact-promoting 
conditions for 4 hours. The results are reported as the mean ± SEM for two independent 
experiments. B) E. coli recipients were co-cultured under the same conditions as A) with the 
specified ECL donor cells. The results are reported as the mean ± SEM for three independent 
experiments. C) Western blot analysis of the supernatant and cytoplasm of the indicated ECL 
donor cells grown to mid-log in liquid LB.  
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Figure 3. Tae4-Tai4 is a functional E-I pair deployed by T6SS-1. A) and B) The 
indicated ECL recipient and donor cells were mixed at a 1:1 ratio under contact-promoting 
conditions for 4 hours. The results are reported as the mean ± SEM for three independent 
experiments. C) ECL donor cells were grown in 0.2% L-arabinose, and then mixed at a 1:1 
ratio under contact-promoting conditions with the indicated ECL recipients on LB-agar 
supplemented with 0.4% L-arabinose for 4 hours. The results are reported as the mean ± 
SEM for three independent experiments. 
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Figure 4. ECL01553-01554 is a functional E-I pair deployed by T6SS-1. A) and B) The 
specified ECL recipient and donor cells were mixed at a 1:1 ratio under contact-promoting 
conditions for 4 hours. The results are reported as the mean ± SEM for three independent 
experiments. C) ECL donor cells were grown in 0.2% L-arabinose, and then mixed at a 1:1 
ratio under contact-promoting conditions with the specified ECL recipients on LB-agar 
supplemented with 0.4% L-arabinose for 4 hours. The results are reported as the mean ± 
SEM for three independent experiments. 
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Figure 5. Rhs 1 and Rhs2 are deployed by T6SS-1. A) Donors and recipients are shown at 
the top and bottom of each graph, respectively. Cells were mixed at a 1:1 ratio under contact-
promoting conditions for 4 hours. Growth inhibition was assessed by quantifying the number 
of viable recipient cells as colony-forming units per milliliter (CFU/mL) and data are 
reported as the mean ± SEM for two independent experiments. B) Recipient and donor cells 
are shown at the top and bottom of each graph, respectively. Donors were grown in 0.2% L-
arabinose, and then mixed at a 1:1 ratio under contact-promoting conditions with the 
annotated recipients on LB-agar supplemented with 0.4% L-arabinose for 4 hours.  Growth 
inhibition was assessed by quantifying the number of viable recipient cells as colony-forming 
units per milliliter (CFU/mL) and data are reported as the mean ± SEM for two independent 
experiments. 
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Figure 6. T6SS-1 requires Hcp3. A) ECL donor cells were mixed at a 1:1 ratio with E. coli 
recipients under contact-promoting conditions for 4 hours. The data are reported as the mean 
± SEM for three independent experiments. B) ECL donor cells were grown in 0.2% L-
arabinose, and then mixed at a 1:1 ratio under contact-promoting conditions with E. coli 
recipients on LB-agar supplemented with 0.4% L-arabinose for 4 hours. The results are 
reported as the mean ± SEM for three independent experiments. C) Alignment of the 5 Hcp 
proteins found in ECL. Shaded areas represent conserved residues between the Hcps. The 
alignment was performed by T-coffee and analysis by Box Shade.  
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Figure 7. Divergent VgrG C-termini direct Rhs deployment. A) PRALINE Multiple 
Sequence Alignment of VgrG1 and VgrG2 in ECL. B) Donors and recipients are shown at 
the bottom and top of each graph, respectively. Cells were mixed at a 1:1 ratio under contact-
promoting conditions for 4 hours. Growth inhibition was assessed by quantifying the number 
of viable recipient cells as colony-forming units per milliliter (CFU/mL) and data are 
reported as the mean ± SEM for two independent experiments.  
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Figure 8. Rhs proteins are required for T6SS-1 function. A) and B) The indicated 
recipient and ECL donor cells were mixed at a 1:1 ratio for 4 hours under contact-promoting 
conditions. The data are reported as the mean ± SEM for three independent experiments. C) 
Western blot analysis of the supernatant and cell lysate of donor cells grown to mid-log in 
liquid LB. 
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Figure 9. Full-length Rhs proteins are required for T6SS-1 function. A) Domains found 
in Rhs1 and Rhs 2. Stop codon insertions tested in B), C) and D) are labelled. Figure is not 
drawn to scale. B) The indicated recipient and ECL donor cells were mixed at a 1:1 ratio for 
4 hours under contact-promoting conditions. The data are reported as the mean ± SEM for 
three independent experiments. C) Western blot analysis of the supernatant and cell lysate of 
donor cells grown to mid-log in liquid LB. D) Western blot analysis of protein harvested 
from the specified donor cells using RIPA buffer.  
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Figure 10. PAAR-containing proteins do not restore T6SS-1 activity. A) ECL donor cells 
were grown in 0.2% L-arabinose, and then mixed at a 1:1 ratio under contact-promoting 
conditions with recipients on LB-agar supplemented with 0.4% L-arabinose for 4 hours. The 
first 7 bars are reported as the mean ± SEM for two independent experiments. B) Western 
blot analysis of the cell lysate of specified donor cells grown to mid-log in liquid LB 
supplemented with 0.2% L-arabinose. Cells were lysed with either urea lysis buffer (ULB) or 
RIPA buffer. 
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Figure 11. Rhs is required for T6SS-1 assembly. The indicated cells were incubated on 
minimal media agar pads for 2 hours. Cells were viewed at 100X and captured every 15 
seconds for 1.5 minutes for live-cell imaging. The images below represent one of the frames 
taken. White arrows are pointing to assembled T6SS-1.  
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Figure 12. Hcp-linked E-I pairs and PAAR-containing toxins are not deployed. A) and 
B) The indicated ECL donor and recipient cells were mixed at a 1:1 ratio for 4 hours under 
contact-promoting conditions. The data are reported as the mean ± SEM for three 
independent experiments. C) ECL donor cells were grown in 0.2% L-arabinose, and then 
mixed at a 1:1 ratio under contact-promoting conditions with recipients on LB-agar 
supplemented with 0.4% L-arabinose for 4 hours. The data are reported as the mean ± SEM 
for three independent experiments. 
 
234 
 
Figure 13. T6SS-2 is not functional. A) and B) ECL donors were mixed at a 1:1 ratio with 
the indicated recipients for 4 hours under contact-promoting conditions. The data are 
reported as the mean ± SEM for two independent experiments. C) ECL donor cells were 
grown in 0.2% L-arabinose, and then mixed at a 1:1 ratio under contact-promoting conditions 
with E. coli recipients on LB-agar supplemented with 0.4% L-arabinose for 4 hours. The data 
are reported as the mean ± SEM for two independent experiments. 
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Chapter 7. Conclusion 
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Conclusion 
Bacteria can be found in almost any ecological niche trying to flourish on limited 
resources. These harsh conditions have driven the evolution of many different competition 
and communication systems. The research presented here examines the mechanism of toxin 
activity and delivery in two such systems. Now we will dissect what we learned in each 
chapter to elucidate how these systems can be used in nature to shape complex microbial 
communities.  
In the introductory chapter we looked at three systems bacteria use to inhibit the growth 
of neighboring bacterial cells. While the overall theme of these systems is similar - kill 
surrounding bacteria to have more space and nutrients for your own kin - they each have 
dramatically different mechanisms to perform their task. For example colicin-producing cells 
must lyse to deliver their effectors into the environment, and only target other E. coli 
strains
51
. Therefore, this competition system only seems to be effective under conditions 
where colicin-producing strains are fighting for resources that are specific to E. coli. In 
contrast, type VI secretion systems (T6SS) deliver across species barriers and require 
physical contact with neighboring cells to deploy toxic effectors
127
. Contact-dependent 
growth inhibition (CDI) systems share similarities with colicins and T6S. CDI requires direct 
physical contact, but the target range is limited to specific species, or even strains within a 
species of bacteria
112,118
.  
CDI and colicin toxin delivery through the cell envelope seems to have more finesse than 
T6S. It is intriguing that the delivery process of the T6S tube spike into cells is not 
detrimental to a recipient cell. As long as recipient cells contain cognate immunity proteins 
for each effector delivered, they show no growth defect or changes in morphology
281
. 
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Interestingly, the small T6S effectors that get packaged into Hcp or elsewhere on the 
apparatus are almost exclusively periplasmic acting while Rhs, PAAR, CDI and colicin 
toxins contain nuclease activity
121,153,164
. This may highlight the differences in the delivery 
processes amongst these systems. Perhaps the smaller T6 effectors that target the cell wall 
and membrane only get delivered as far as the periplasm while Rhs and PAAR toxins are 
capable of crossing the inner membrane to reach their substrate in the cytoplasm. The 
location of Rhs and PAAR toxins on the tube spike certainly gives them first access to the 
inner membrane or may even facilitate direct injection into the cytoplasm
139,153
.  
In chapter 2, we identified a novel mechanism of CDI toxin entry into E. coli cells. 
We demonstrated the N-terminal domain of CdiA-CT from UPEC536 (CdiA-CT
NT
) can 
interact with the F pilus subunit, TraA, to bypass the outer membrane upon retraction of the 
pilus. R17 bacteriophage use a similar mechanism for entry into cells. It is unclear if this 
mechanism of entry is exploited in nature or if this was a property of early CDI systems 
before they evolved to more efficiently deliver CdiA-CT.  Alternatively, CdiA-CT
NT 
could be 
an evolved phage protein that got fused to a CDI system, but still held onto its phage-like 
properties including the ability to bind TraA. Regardless, this work demonstrates the 
adaptability of CDI systems, particularly CdiA-CTs, and possibly illustrates how early CDI 
systems delivered cargo to the cytoplasm.  
Chapter 3 reveals that CDI systems have a narrower target range than previously 
reported. We identified OmpC and OmpF as the receptor proteins for CdiA
UPEC536
. 
CDI
UPEC536 
exploits the highly variable loops of both proteins, limiting its target range to a 
sub-population of E. coli strains. We sequenced 98 ompC alleles from uropathogenic E. coli 
(UPEC) strains isolated from the urinary tract of humans, dogs, or cats, and found that ~50% 
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of these alleles are resistant to CDI
UPEC536
.   Given UPEC536 likely interacts with these 
UPEC strains in the environment; this raises questions about the use of CDI as a competition 
system in nature. With this work and work done by Ruhe et al. demonstrating CDI
EC93
 also 
has a narrow target range, we propose CDI systems are involved in kin selection. Kin 
selection is important in microbial communities as it can potentiate homogeneous gene 
expression and thus give a bacterial population the advantage of behaving like a uniform 
multicellular organism
235
.  
In chapter 4, we identified novel 16S rRNase activity in CDI toxins. CdiA-CT from 
E. cloacae (CdiA-CT
ECL
) was shown to have a similar fold as the toxin domain of colicin E3 
(ColE3-CT) and likewise cut 16S rRNA at the same nucleotide position in the A-site of 
ribosomes. This work highlights the conservation of toxic activities found in colicins and 
CDI systems. The mechanism of delivery is different for each system; however the toxin 
domains seem to be conserved and restricted to targeting essential substrates. Colicins have 
been shown to act as pore-formers, or nucleases towards rRNA, tRNA, and DNA. Likewise, 
we have identified CdiA-CTs that can perform these same activities, CdiA-CT
ECL 
being the 
first 16S rRNase identified.  Furthermore, it seems CdiA-CT
ECL 
and ColE3-CT are products 
of convergent evolution as the primary sequences of the two proteins, active-site residues, 
and immunity proteins are unique.  Taken all together, this suggests targeting central dogma, 
and in this case the A-site of ribosomes, is the most efficient way to kill cells. Identifying the 
toxic activities and plasticity of CdiA-CTs will help us understand the potential of CDI 
systems to deliver a repertoire of diverse cargo. The ability of CdiA-CT/CdiI pairs to easily 
evolve and become distinct can play a drastic role in microbial competition. For example, if a 
daughter cell mutates its CdiA-CT/CdiI pair enough to still block parental CdiA-CT but 
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parental CdiI cannot block the new CdiA-CT activity; this could lead to subsequent 
proliferation of the mutated population. Events like this have the potential to drive speciation 
and thus have an impact on the composition of microbes in a given niche. 
Chapter 5 tries to elucidate the role of CysK in the tRNase activity exhibited by 
CdiA-CT
UPEC536
.  The crystal structure of CysK/CdiA-CT/CdiI confirms that CdiA-CT binds 
in the active site of CysK. With the recent proclamation that CDI
UPEC536 
is utilized in kin 
selection, we reasoned CdiA-CT could influence cysteine metabolism amongst kin via self-
delivery of CdiA-CT. We were able to demonstrate that CdiA-CT can block CysK activity 
inside cells, however only when over-expressing the CT. It is unclear if enough CT could be 
delivered during CDI to have an effect on cysteine metabolism in nature. There could 
however be certain environmental conditions where delivery of CdiA-CT can influence 
CysK activity, and therefore CDI would serve as a communication rather than a competition 
system.  In support of this, homologs of CdiA-CT in Gram-positive species, which do not 
contain CDI systems, do not require CysK for activity. This suggests the role of the tRNase 
toxin in Gram-positive species is for competition, while in CDI systems it acts as a 
communication signal. As previously mentioned, communication within kin is an advantage 
for bacteria, especially in crowded habitats as it allows for nutrient scavenging and biofilm 
formation
235
.  
Contrary to the restricted target range of colicins and CDI systems, chapter 6 covered 
the more versatile T6SS of E. cloacae (ECL). We showed that T6SS-1 deploys at least four 
different toxic effectors to inhibit the growth of a wide range of Gram-negative bacteria, 
giving ECL a clear competitive advantage in a laboratory setting. The fact that T6SSs are 
found in 25% of sequenced Gram-negative bacteria, and especially in enteric strains, 
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suggests having a T6SS provides an advantage in nature too
135
. Unique to ECL, compared to 
other T6SS
+ 
bacteria that have been studied, is the requirement of at least one Rhs protein for 
T6 function and assembly. Again, this illustrates the importance of studying these systems, as 
ECL seems to have evolved a different mechanism of toxin delivery. With enough changes 
this could lead to a distinct delivery system. In fact the T6SS is homologous to T4 contractile 
bacteriophage. Presumably theT6SS evolved to be able to inject cargo out rather than into a 
cell
150
.  Understanding the mechanism of effector delivery in T6S will help establish the 
efficiency and role of these systems in nature.  
In this thesis we covered three examples of competition systems used by Gram-negative 
bacteria and highlighted some of the similarities and differences amongst the systems. ECL 
harbors all three of these competition systems, suggesting they each provide a distinct 
advantage for ECL in its respective niche. Moreover, colicins, CDI systems, and T6Ss are 
commonly found in pathogenic species and often in the same strain. T6S has been shown to 
be a virulence determinant in many species including Burkholderia pseudomallei, Vibrio 
cholera, and Burkholderia mallei
282-284
. One of the barriers of invading a host is getting past 
the commensal layer of bacteria present
285
. Perhaps T6S allows pathogens to kill commensal 
bacteria to more efficiently invade a host. Ultimately, identifying the mechanism of toxin 
activity and delivery into targets will help elucidate the function of competition systems in 
nature and their distinct roles in shaping microbial communities.   
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